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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable 
and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisers; professionals 
and researchers working in the field of drugs; and, more broadly, 
the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug 
phenomenon in the EU and is an essential reference book for those seeking 
the latest findings on drugs in Europe. 
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How to obtain EU publications
Our priced publications are available from EU Bookshop (http://bookshop.europa.eu), 
where you can place an order with the sales agent of your choice.
The Publications Offi ce has a worldwide network of sales agents. You can obtain their 
contact details by sending a fax to (352) 29 29-42758.
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5Foreword
This is the 12th annual report of the European Monitoring 
Centre for Drugs and Drug Addiction. Like previous reports, 
it provides a comprehensive update on the current situation 
regarding drug use in Europe. It also demonstrates Europe’s 
achievement in implementing a methodologically sound, 
sustainable and comprehensive information system to monitor 
drug use.
The report addresses two fundamental questions. What 
is known about drug use in Europe and the problems it 
causes? And what has been learned about responding 
effectively to drug-related problems? These questions are 
important because, regardless of political persuasion or 
ideological position, policymakers across Europe have come 
to recognise that the drugs problem presents a complex set 
of issues for which there is no simple solution. They recognise 
that the way forward lies in analysing the available evidence 
regarding both the size and nature of the problem and the 
costs and benefits of different intervention approaches. In this 
respect, the report also demonstrates Europe’s commitment to 
balanced and evidence-based policymaking and to sustained 
effort over time rather than relying on ‘quick-fix’ solutions. As 
a result, Europe can be proud that its response to this difficult 
and often emotive issue is both rational and humane. 
In this report we also reflect on the progress that has been 
made in responding to the drugs problem in Europe. This 
is particularly pertinent this year, as both in Europe and 
internationally we will soon be reflecting on achievements 
in this area. In 2008, the European Commission will begin 
its task of assessing the impact of the current European 
action plan on drugs and the United Nations Commission 
on Narcotic Drugs (CND) will debate the progress made 
in meeting the goals set at the United Nations General 
Assembly Special Session in 1998. 
In Europe, the drugs situation still represents a serious 
challenge for health and social policy and for law 
enforcement. It is not hard to find areas that arouse special 
concern. Nonetheless, we feel strongly that it is also 
important to acknowledge progress where it has been 
made. In Europe, more and more Member States are 
adopting strategic and planned approaches to tackling the 
drugs problem. There has also been a dramatic increase 
in investment in prevention, treatment and harm-reduction 
activities and improved cooperation and increased focus in 
supply reduction. Drug use in general remains at historically 
high levels, but it has stabilised in most areas, and in some 
areas there are even signs that merit cautious optimism. The 
European Union and its Member States give considerable 
support to international programmes and, in a global context, 
it is satisfying to observe that, in a number of important 
areas, the European situation looks relatively positive.
As a monitoring agency, we deal in facts and figures; we 
are committed to being scientifically rigorous and impartial, 
interpreting the information available without prejudice 
or prior position. This is our role, and as Chairman of the 
Management Board and Director we accept no compromise 
on this position and take pride in the high standards we 
maintain. But while scientific rigour is essential to our work, 
we must never forget that behind the figures we report 
are real human beings whose lives have been affected 
and sometimes ruined by drug problems. Behind the dry 
statistics on treatment demand, drug-related deaths and 
criminal behaviour are the grieving families, lost potential 
and children growing up in unsafe communities. To develop 
effective responses to the drugs problem requires us to be 
dispassionate about our data, but we must never become 
dispassionate about the topic.
Marcel Reimen
Chairman, EMCDDA Management Board
Wolfgang Götz
Director, EMCDDA
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9Introductory note
This annual report is based on information provided to the EMCDDA by the EU Member States and candidate countries and 
Norway (participating in the work of the EMCDDA since 2001) in the form of a national report. The statistical data reported 
here relate to the year 2005 (or the last year available). Graphics and tables in this report may reflect a subset of EU countries: 
the selection is made on the basis of those countries from which data are available for the period of interest.
An online version of the annual report is available in 23 languages and may be found at http://annualreport.emcdda.europa.eu
The 2007 statistical bulletin (http://stats07.emcdda.europa.eu) presents the full set of source tables on which the statistical 
analysis in the annual report is based. It also provides further detail on the methodology used and over 100 additional 
statistical graphs. 
Country data profiles (http://dataprofiles07.emcdda.europa.eu) provide a top-level, graphical summary of key aspects of the 
drug situation for each country.
Three in-depth reviews accompany this report and explore the following issues: 
• Drugs and driving; 
• Drug use among minors;
• Cocaine and crack cocaine: a growing public health issue.
The selected issues are available in print and online (http://issues07.emcdda.europa.eu) in English only.
The national reports of the Reitox focal points give a detailed description and analysis of the drugs problem in each country 
and are available on the EMCDDA website (http://www.emcdda.europa.eu/?nnodeid=435).
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Commentary — the drug situation in Europe
Europe plays an increasingly important role in supporting 
global actions to reduce drug problems
Neither trends in the use of drugs nor those who are 
involved in drug production and trafficking respect national 
or geographic boundaries. It is therefore important to 
recognise that the European drug problem is part of a 
broader global phenomenon, with patterns of drug use 
in Europe both affected by and affecting the problem 
elsewhere. This is recognised in the current EU action plan 
on drugs, which addresses the need for greater European 
coordination on international affairs and the need to 
support programmes to reduce drug demand and supply in 
neighbouring and producer countries. European investment 
in support of international actions is now considerable, 
with a recent European Commission audit suggesting that 
the European Union is now funding demand and supply 
reduction measures in third countries to the tune of at 
least EUR 750 million. Moreover, the EU is now the major 
international donor supporting the work of the United Nations 
Office on Drugs and Crime (UNODC). 
In addition to financial support, there is also evidence that 
European countries have taken seriously the commitments 
made at international level to develop appropriate responses 
to drug problems. In 2008, the international community will 
evaluate the global progress made in respect of the goals 
set in the 1998 special session of the United Nations on 
combating the world drug problem. To complement the data 
available at international level, the EMCDDA will support the 
review process by providing a more detailed assessment of 
the European situation. As can be seen in the data presented 
in this report, over the last 10 years EU Member States have 
developed increasingly comprehensive national and EU-level 
coordination mechanisms, usually based around strategies 
and action plans. In addition, they have dramatically 
improved the information available on the drug situation and 
increased investment in both supply-side and demand-side 
interventions. While acknowledging that the use of drugs 
remains a major challenge for public health and social policy 
within Europe, it is also important to recognise these positive 
developments. 
Putting Europe in a global context
Drug use is a global problem, and a useful insight into the 
relative size of the drug problem in Europe can be gained 
by comparing European data with information from other 
countries. The difficulty here is that only in a few other 
parts of the world is relatively comprehensive and robust 
information available. The USA, Canada and Australia can 
provide meaningful comparison points on estimates for last 
year drug prevalence. UNODC estimates show that the 
prevalence of opioid use in these countries is broadly similar 
to that in the European Union, ranging between 0.4 % and 
0.6 % of the adult population, with Canada slightly lower 
and the USA slightly higher. Estimated cannabis use is, on 
average, considerably lower in the European Union than in 
the USA, Canada or Australia. As regards stimulant drugs, 
levels of ecstasy use are broadly similar worldwide, although 
Australia reports high prevalence levels, and, in the case of 
amphetamine, prevalence is higher in Australia and the USA 
than in Europe and Canada. The prevalence of cocaine use 
is higher in the USA and Canada than in the European Union 
and Australia. A lack of comparable data makes it difficult 
to assess the health impact of drug use across countries, 
although a cautious comparison of estimated rates of newly 
diagnosed HIV infections related to drug injecting in 2005 
suggests rates in Australia, Canada and the European Union 
at below 10 cases per million population, and around 
36 cases per million in the USA.
Quantifying complexity: setting meaningful targets 
and developing useful summary measures
The objective of all European drug strategies is to reduce 
drug use and the damage that drugs can cause, both to 
those who use them and the communities in which they live. 
This policy objective can be simply stated, but it is important 
to recognise that drug use is a multifaceted and complex 
phenomenon and any attempt to evaluate the impact of 
policies in this area has to reflect this underlying reality. 
A positive conclusion of this report is that European drug 
policies are becoming more sensitive to the need to focus 
on specific activities and develop meaningful targets. This 
is reflected in the general shift in Europe towards national 
drug strategies being accompanied by more specific and 
time-limited action plans, and, at the level of European 
coordination, in the annual review of the current EU action 
plan on drugs, with indicators being dropped or modified 
following review of their performance. 
For evaluating actions, moving to a more focused approach 
is clearly helpful. However, it is also useful to be able to 
have some summary measures that allow complex issues to 
be more easily described. Although constructing such scales 
and measures is difficult, a number of recent developments 
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in this area show promise. In this report, we provide a new 
analysis of data on European public expenditure on drugs. 
While the data are partial, they do illustrate the considerable 
sums of money spent each year in Europe on reducing drug 
demand and supply: somewhere between EUR 13 billion and 
EUR 36 billion. Moreover, it should be borne in mind that 
these figures do not reflect the social costs of drug use. 
Among the advances that may be helpful in this direction is 
the development of indexes that try to capture the different 
costs and harms of using illicit drugs, such as the drug harm 
index developed recently in the United Kingdom. Harm 
is also one of the key concepts included in the UNODC’s 
recently proposed illicit drug index (IDI). These sorts of 
approaches may prove useful in the future for policy analysis 
purposes, but they are dependent on the quality of data on 
which the composite measure is based and on the extent to 
which these data can encompass the target concept. 
Harm reduction is now an explicit component 
of the European approach 
There are still considerable differences between European 
countries in the nature and scale of their national drug 
problems and also in the range and configuration of 
response. Despite this, there is considerable agreement on 
more general fundamentals: that drug policies should be 
balanced, comprehensive and evidence based. In the area 
of demand reduction, the need for prevention, treatment 
and social rehabilitation activities is accepted by all. But, 
historically, the topic of harm reduction has been more 
controversial. This is changing, and harm reduction as 
part of a comprehensive package of demand reduction 
measures now appears to have become a more explicit 
part of the European approach. This is evident in the fact 
that both opioid substitution treatment and needle and 
syringe exchange programmes are now found in virtually all 
EU Member States, although the level of service provision 
varies considerably. It is also evident in a recent report 
from the European Commission, which found that the 
Council recommendation of 18 June 2003 had played a 
role in encouraging Member States to develop and expand 
harm-reduction activities. 
Prison: services for drug users remain underdeveloped
An important conclusion drawn from the review of the 
progress made in implementing the Council recommendation 
of 18 June 2003 was that, despite advances made in other 
areas, services of all types were usually poorly developed 
in prison settings. Although some Member States have 
introduced schemes to divert offenders with drug problems 
into treatment as an alternative to criminal sanctions, those 
with drug problems continue to account for a significant 
proportion of the prison population in virtually all countries. 
The EMCDDA is currently collaborating with the World 
Health Organisation (WHO) to establish a database for 
the collection of prison health indicators. The general 
principle that those in prison should have access to the same 
healthcare options as are available in the wider community 
is not achieved in many areas for those with drug problems. 
Not only do many of those entering prison have drug 
problems, but studies show that drug use often continues in 
prison. The lack of services for drug users in prison raises the 
serious concern that not only is an opportunity being lost to 
intervene to reduce future drug use and offending behaviour 
but also that health gains achieved elsewhere may be 
undermined by a lack of services in this setting. 
Identifying and sharing knowledge on what works 
Increasingly, the focus of the debate on demand reduction 
activities of all types is on identifying those interventions 
for which there is evidence of effectiveness and which do 
not deliver unintended negative consequences. As any 
intervention, if badly delivered, is unlikely to be effective or 
may even be counterproductive, a second plank of this work 
is to identify good practice and quality control measures. The 
new regulation of the EMCDDA emphasises the importance 
of identifying and disseminating good practice. A key 
difficulty here is the real world settings in which demand 
reduction interventions are applied. Credible controlled 
studies, the gold standard for most medical interventions, 
are often difficult to design or simply impracticable. The 
complexities of assessing evidence for effectiveness and 
identifying quality control standards are addressed in this 
report.
Cannabis: popularity may have peaked — 
as recognition of public health issues grows
Nearly a quarter of all adults have tried cannabis at some 
time in their lives, and one in 14 will have used it in the last 
year, making it the most commonly consumed illicit drug in 
Europe. But, even more so than among the population in 
general, it is by far the most commonly consumed illicit drug 
by young and very young people. Drug use among those 
who are developing both physically and socially can be a 
particular problem, and this issue is dealt with in detail in 
the accompanying selected issue on drug use in minors. 
The importance of understanding the implications of early 
onset of cannabis use and what might constitute appropriate 
responses is one of the complex set of issues that widespread 
cannabis use is now posing for public health and drug 
control policies in Europe.
A general trend in policy in Europe has been to move away 
from criminal justice responses to the possession and use 
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of small amounts of cannabis and towards approaches 
orientated towards prevention or treatment. Despite this, over 
the period 2000–05, recorded cannabis offences increased 
considerably (36 %) and, in most countries, cannabis is the 
drug most likely to be involved in charges for drug use or 
possession. This situation may be changing as a majority 
of countries now report some fall in reported cannabis 
offences — perhaps indicating that law enforcement bodies 
are shifting away from targeting cannabis use.
Despite considerable public and media debate on the topic, 
it is hard to see any direct or simple relationship between 
law enforcement policies and overall prevalence of cannabis 
use. Although there were differences in timing and scale 
between countries, Europe saw a substantial increase in 
the use of cannabis during the 1990s, followed by a more 
stable but generally still increasing trend after 2000. This 
has produced a more homogeneous European picture now 
than has historically been the case. In addition, the most 
recent data suggest that, particularly in the high-prevalence 
countries, cannabis use is moving into a more stable phase 
or even decreasing. And, although the data are still relatively 
weak, there is some evidence that the popularity of the 
drug among the younger age groups is decreasing in some 
countries. Although national trends vary overall, it is possible 
to be cautiously optimistic that the escalation of cannabis use 
that has been seen in Europe since the 1990s may now have 
reached its peak. 
If Europe is entering a period of more stable cannabis use, 
it is also clear that current levels are by historical standards 
very high; and, although only a relatively small proportion 
of cannabis users are using the drug on a regular and 
intensive basis this still represents a significant number of 
individuals. A growing body of research evidence and 
clinical experience now provides a better understanding of 
the needs of those with cannabis-related problems, although 
the extent to which cannabis users in general develop 
problems with their drug use remains poorly elaborated. 
Treatment data compiled by the EMCDDA show that the 
number of reported new cannabis treatment demands has 
almost trebled since 1999, although this trend now appears 
to be stabilising. Interpretation of this trend is complicated for 
a number of reasons that include an increase in both services 
for, and awareness of, cannabis-related problems, and 
because a significant proportion of referrals are directive, 
from either criminal justice or social services. It also appears 
that the needs of cannabis users coming into contact with 
treatment services are varied, as indeed are the responses 
that are being provided — which range from brief and 
prevention-orientated interventions to more formal treatment 
approaches.
The European cannabis situation is also complicated by 
market factors, and this problem is confounded by the lack of 
good data on the relative share and availability of different 
cannabis products in the EU. Europe remains the main global 
market for cannabis resin, most of which is produced in 
North Africa. Herbal cannabis is also available in Europe, 
At a glance — estimates of drug use in Europe 
(Note that these estimates relate to the adult population 
and are the most recent estimates available. For complete 
data and full methodological notes see the 2007 statistical 
bulletin.)
Cannabis
Lifetime prevalence: at least 70 million, or one in fi ve 
European adults
Last year use: about 23 million European adults or one third 
of lifetime users
Use in the past 30 days: over 13 million Europeans
Country variation in last year use: 1.0 % to 11.2 % 
Cocaine
Lifetime prevalence: at least 12 million, or around 4 % of 
European adults
Last year use: 4.5 million European adults or one third of 
lifetime users
Use in the past 30 days: around 2 million
Country variation in last year use: 0.1 % to 3 %
Ecstasy 
Lifetime prevalence: about 9.5 million European adults (3 % of 
European adults)
Last year use: 3 million or one third of lifetime users 
Use in the past 30 days: more than 1 million
Country variation in last year use: 0.2 % to 3.5 %
Amphetamines 
Lifetime prevalence: almost 11 million or around 3.5 % of 
European adults
Last year use: 2 million, one fi fth of lifetime users
Use in the past 30 days: less than 1 million
Country variation in last year use: 0.0 % to 1.3 %
Opioids
Problem opioids use: between one and eight cases per 
1 000 adult population (aged 15–64)
Over 7 500 acute drug deaths, with opioids being found in 
around 70 % of them (2004 data)
Principal drug in about 50 % of all drug treatment requests
More than 585 000 opioid users received substitution 
treatment in 2005
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although the volume of resin seized is over 10 times that of 
herbal cannabis. This picture may be changing however: 
cannabis resin seizures fell slightly in 2005, while herbal 
seizures continue to increase, as did seizures of cannabis 
plants. Half of European countries reported some domestic 
cannabis production in 2005. Some forms of home-produced 
cannabis can be of relatively high potency, and domestic 
production also has implications for drug control activities. 
Cannabis use raises a complex set of issues for drug, public 
health and social policy in Europe. One positive development 
is that Member States now appear to be beginning to 
develop a better understanding of the implications of the 
widespread use of this drug and the debate is becoming 
more focused and less prone to either under- or overstatement 
of the problem.
Cocaine: estimates of use rise again
The EMCDDA has revised its estimate of cocaine use in this 
report to 4.5 million Europeans having used the drug in the 
last year, up from 3.5 million in the 2006 annual report. The 
general picture reported last year of a stabilising situation 
is also called into question by the new data, which point to 
an overall increase in use. The new data confirm cocaine’s 
place in Europe as overall the second most commonly used 
illicit drug, after cannabis and ahead of both ecstasy and 
amphetamine on all measures, and estimates of last month 
use of cocaine are now more than double those for ecstasy. 
Although recent increases mean that more countries now 
report a significant cocaine-using population, inter-country 
variation remains high, with low rates of cocaine use 
reported in most countries in eastern Europe. 
Increased prevalence rates are also reported in the new data 
available from both Spain and the United Kingdom, the two 
countries with the highest prevalence in Europe — although 
in neither case are the increases dramatic. In both countries, 
last year prevalence rates among young adults are similar to 
or greater than those found in the USA. Worryingly, in both 
countries, cocaine use among the young is relatively high 
(4–6 % in 15- to 16-year-olds). In Spain, analysis suggests 
that the recent increase has been driven by use in the 
15–24 age group. It is important to note that estimates of those 
experiencing serious problems with cocaine are far lower. 
Although estimates of problem cocaine use are available 
for only three countries (Spain, Italy, the United Kingdom), 
the figure ranges between 0.3 % and 0.6 % of the adult 
population. Crack cocaine use remains rare across Europe, 
but does cause severe localised problems where it occurs. 
Other indicators also demonstrate an upward trend, 
confirming the growing importance of cocaine in Europe’s 
drug problem. Both quantities and numbers of seizures 
have increased, perhaps reflecting increased targeting of 
the European market but possibly increased interdiction 
activities. Coordinated actions against cocaine trafficking are 
growing in Europe, and a new intergovernmental task force 
is to be located in Portugal, which appears appropriate given 
the country’s growing importance in cocaine interdiction. 
Although record seizures do not appear to have affected 
price trends, which are still downwards, they may have had 
an influence on purity levels. 
To date, increased levels of cocaine consumption 
have had only a modest impact on health-related 
indicators, but this may be changing. Each year, around 
400 cocaine-related deaths are reported in Europe, 
and there is a suspicion that cardiovascular deaths in 
which cocaine has been an aggravating factor may go 
largely undetected. Requests for drug treatment for those 
with cocaine problems are rising. In 2005, cocaine was 
the primary drug of about 13 % of clients demanding 
treatment, and in an even higher proportion of those new 
to treatment (22 %). The number of new treatment demands 
reported has roughly tripled over the last five years, and 
now stands at over 33 000. Cocaine was also reported 
as a secondary drug in around 15 % of cases, and there 
is a growing awareness that concurrent cocaine use is 
complicating the treatment of opioid problems in some 
countries. However, overall cocaine treatment requests 
are lower than those related to cannabis and considerably 
lower than for opioid problems. 
HIV: overall assessment positive, but new infections 
underline the need for continued efforts
During the 1990s, the experience, or potential threat, of 
a widespread HIV epidemic among drug injectors was a 
catalyst for the development of services for this group. With 
the expansion of services, the HIV epidemics seen earlier 
in Europe have largely been avoided, although localised 
problems have been observed in some countries, notably 
the Baltic States, and in some countries affected by earlier 
epidemics, HIV prevalence rates among injectors have 
remained quite high. Overall, while injecting drug use 
has declined as a route of HIV transmission, the EMCDDA 
estimates that, in 2005, it accounted for around 3 500 newly 
diagnosed cases of HIV in the European Union. This figure 
may be low by historical standards, but it still represents a 
considerable public health problem.
Analysis of the most recent data suggests that, in most 
countries, rates of new infection related to injecting are low 
and that, in most EU regions, HIV prevalence among injectors 
fell between 2001 and 2005. As a result, especially in areas 
where prevalence has been high, the burden of infection 
resulting from injecting drug use is likely to be decreasing. 
The situation in Estonia, Latvia and Lithuania remains a 
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concern, but here again most of the recent data point to a 
relative decrease in new infections. 
Important caveats to this assessment are that data in 
some important areas are weak and that studies of time 
trends over the last five years have reported increases in 
some areas or samples in about one third of countries. 
In addition, there is cause for concern in a few countries 
either because of relatively high levels of new infections 
or because there has been some small recent increase in 
prevalence even though overall rates remain low. Given 
that recent history demonstrates how quickly HIV problems 
can spread in vulnerable populations, this underlines the 
need to continue to target and develop services to engage 
with those who are at risk. 
Hepatitis C remains Europe’s hidden epidemic
The EMCDDA estimates that there could be as many as 
200 000 Europeans living with HIV infection who are 
current or past drug injectors. While there is good public 
awareness of the HIV risks posed by injecting, it is important 
to remember that there are also an estimated 1 million 
some-time injectors who are infected with hepatitis C virus 
(HCV) — including a significant proportion who are no 
longer using drugs. 
Hepatitis C can have serious health consequences, including 
cancer and death, and meeting the needs of people infected 
with HCV is likely to put an increasing strain on health 
budgets. Across Europe, HCV rates are high among injecting 
populations, and studies show that young injectors continue 
to acquire this disease early in their drug-using careers, 
limiting the opportunities for intervention. Unlike hepatitis B, 
where interventions appear to be delivering benefits, no 
clear trend is evident in the HCV data, although differences 
between countries may provide some clues as to what might 
constitute effective actions in this area.
Heroin use is stable but there are concerns about 
increasing problems with synthetic opioids 
It is estimated that potential global heroin production, 
mostly in Afghanistan, increased again in 2006, to 
over 600 tonnes. This raises the question for Europe: 
what effect will this increase have on the drug problem? 
Increasing heroin production has not thus far become 
evident in most indicators of heroin use — which overall 
have been stable for some time. Evidence from the analysis 
Afghanistan — can alternative development 
measures have an impact?
The sustainability of the general stable or improving situation 
seen in heroin use in Europe is called into question by increasing 
opium production in Afghanistan. Estimates for 2006 suggest that 
production increased by 43 % as a result of a substantial increase 
in the area under cultivation. 
Opioid seizures and laboratories dismantled seem to indicate 
that opium produced in Afghanistan is increasingly being 
transformed into morphine or heroin in the country itself, before 
being exported (CND, 2007). Heroin then enters Europe by two 
major traffi c routes: the old Balkan route, which is still the most 
important in terms of heroin smuggling, and the more recent ‘silk’ 
route (see Chapter 6). 
Regional differences inside Afghanistan point to the potential for 
economic growth to reduce poppy cultivation but also show how 
it can be undermined by the lack of political security, corruption 
and infrastructure problems. Reductions in cultivation can be 
achieved quickly but are reversed equally quickly. For example, 
in Nangarhar province, in the east of the country, the level of 
opium poppy cultivation fell by 96 % in 2004/05, but there, as 
in many other districts, it has since returned to previous levels, 
in part driven by the economic needs of densely populated 
areas that have been unable to diversify to other high-value 
crops and non-farm income opportunities (Mansfi eld, personal 
communication and 2007).
In contrast, in other parts of the eastern region, levels of 
cultivation are likely to remain negligible, and even in the 
southern provinces of Kandahar and Helmand reductions in 
cultivation can be expected in areas close to the provincial 
centre. The supporting factors here appear to be greater 
governmental control and more diversifi cation in agricultural 
production, factors which have allowed relatively high-value 
crops to be established together with the introduction of a 
transportation and marketing infrastructure. In the north and 
north-east of the country, not only have increasing wage rates 
and falling opium prices deterred poppy planting, but also 
some high-value vegetables actually generate greater returns 
than poppies. In these areas, crop diversifi cation has been 
supported by counter-narcotics efforts and greater governmental 
involvement — leading to a general perception that opium 
prohibition measures will be enforced.
Rising labour costs and falling prices now mean that returns on 
opium poppy are not unassailable and, in some areas, higher 
incomes can be generated from alternative products, particularly 
where other non-farm income opportunities also exist. These 
legal income opportunities are, however, not open to all and, in 
many areas, farmers’ options are limited by high transport costs, 
poor roads and problems arising from lack of security. In these 
areas, corruption and insecurity are reducing the opportunities 
for trading in legal goods and impeding economic growth and 
efforts to encourage crop diversifi cation, even in areas relatively 
close to the provincial centres.
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of drug treatment data and drug overdoses suggests 
that the heroin-using population in Europe continues to 
age, although the picture in eastern European countries 
is less clear. Overall estimates of problem drug use also 
generally point to a stable situation. Nonetheless, the 
falling price of the drug and the increase in the number 
of young heroin users in treatment in some countries 
underlines the need for continued vigilance. 
Although there is currently no clear-cut evidence that heroin 
use is gaining popularity with young people, there are 
indications from a variety of reports that the use of synthetic 
opioids may be a growing problem in some parts of Europe, 
and that synthetic opioids may even be replacing heroin in 
some countries. In Austria, a growing proportion of treatment 
demand clients are under 25 and are seeking help for 
problems due to the use of opioids diverted from legitimate 
uses. Similarly, Belgium reports some increase in the illicit 
use of methadone; and in Denmark, methadone is commonly 
mentioned in reports on drug-related deaths. Buprenorphine, 
a drug regarded by some as having a low appeal on 
the illicit market, is also reported to be increasingly used 
and injected in the Czech Republic; it may have replaced 
heroin in Finland; and monitoring in France raises concerns 
about the illicit use of this drug, including injecting use by 
young people, who have initiated their opioid use with 
buprenorphine rather than heroin. 
Downward trend in drug overdose deaths tails off 
The EMCDDA reports regularly on acute drug-related deaths 
in Europe — these are principally overdose deaths, usually 
involving heroin or other opioids, although in most cases a 
range of substances will have been consumed. Overdose 
deaths constitute a significant cause of avoidable mortality 
among young adults. 
Since 2000, many EU countries have reported decreases 
in the numbers of drug-related deaths, possibly reflecting 
increased service provision or changes in the numbers of 
injecting heroin users. However, this trend has not continued 
in 2004 and 2005. Particularly of concern is the fact that 
in a few countries the proportion of younger people among 
those dying has been growing. Reducing drug-related deaths 
is an important public health target and the reasons for the 
faltering in the downward trend needs to be identified. 
Death by overdose is not the only health risk facing those 
with drug problems. Studies reveal that excess mortality from 
all causes is considerable among problem drug users: as 
much as 10 times what would be expected in the general 
population. There is therefore a need to develop a more 
comprehensive approach to addressing both the physical 
and mental health needs of this group if the morbidity 
and mortality associated with chronic drug use is to be 
significantly reduced.
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Chapter 1
Policies and laws
In this chapter, drug policies in the EU as a whole and 
in individual Member States, as well as the relationship 
between these two levels of policymaking, are described. A 
data collection exercise brought forward by the EMCDDA 
in the reporting period permits an overview of current 
national drug strategies and institutional frameworks across 
Europe. Estimating the cost of drugs to society is discussed 
in a section on drug-related public expenditure. Based on 
data on national public expenditure reported by Member 
States, a first approximation is made of the total amount 
spent by European governments on the drugs phenomenon. 
Legislative changes focusing on supply reduction and on 
legal approaches to drug testing are described in a section 
on recent changes in national laws. An overview of the 
latest statistics on drug law offences and trends in offences 
involving opioids and cannabis are presented in a section on 
drug-related crime. The chapter concludes with a section on 
drug-related research in Europe.
National drug strategies
General situation and new developments
In early 2007, all EU Member States, except Italy, Malta 
and Austria, had a national drug strategy, sometimes 
accompanied by an action plan. At that time, a total of more 
than 35 different national drug planning documents were 
in force in Europe, covering a time period ranging from as 
little as two years (Czech action plan) to more than 10 years 
(Dutch national drug strategy). 
A noticeable trend in recent years has been the shift from 
a single national planning document to the adoption of 
two complementary instruments: a strategic framework 
and an action plan. This approach, which allows a better 
conceptualisation of short-, mid- and long-term objectives, is 
now used in almost half of EU Member States, and is even 
more common in those that joined the EU in 2004 and 2007: 
eight of these 12 countries have both a drug strategy and an 
action plan. 
The policy of combining a drug strategy with action plans 
facilitates more detailed definitions of objectives, actions, 
responsibilities and deadlines. Some countries, for example 
Cyprus, Latvia and Romania, have incorporated detailed 
implementation processes in their drug strategies and action 
plans. This approach, which has been in place in other 
Member States (e.g. Spain, Ireland, the United Kingdom) for 
some time, is becoming more widespread and has also been 
implemented in the current EU action plan on drugs.
In 2006, new drug strategies or action plans were 
adopted by four Member States (Greece, Poland, Portugal, 
Sweden) and Turkey, as well as Northern Ireland in the 
United Kingdom. In none of these cases was this the first 
such exercise, and in each of these cases the national 
reports mentioned that the new drug policy documents had 
benefited from the experience of earlier ones. In 2007, two 
Member States, Malta and Austria, as well as Norway, 
are due to adopt new drug strategies, while the Czech 
Republic, Estonia, France and Hungary will implement new 
action plans.
Content
Reducing drug use in general and problem drug use in 
particular is a key objective of the national drug strategies 
and action plans of all EU Member States, candidate 
countries and Norway. The objective of preventing and 
reducing the individual and collective harm resulting from 
the use of drugs is also shared by all countries. Another 
common feature is the ‘comprehensive’ approach, whereby 
interventions aimed at drug supply reduction and those 
aimed at drug demand reduction are linked. The ‘balanced’ 
approach, which aims to give priority both to supply 
reduction and to demand reduction, is also very widespread. 
All these elements are also part of the EU drugs strategy.
The range of psychoactive substances included in national 
drug strategies is an area in which notable differences 
are found among European countries. This can be seen 
in the new documents adopted in 2006. Of these, two 
mainly address illicit drugs (Poland, Portugal), albeit with 
some links between the drug and the alcohol/tobacco 
strategies, two address both illicit drugs and alcohol (Greece, 
Northern Ireland in the United Kingdom) and one (Turkey) 
addresses all addictive substances. In addition, Sweden 
has simultaneously adopted two interlinked action plans, 
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one for alcohol and one for illicit drugs. Moves towards 
the integration of licit and illicit drugs policies have been 
evident in some countries for several years (e.g. Germany, 
France) (1). The scope of future drug strategies and their 
possible integration with other public health strategies is 
likely to remain an important theme during the coming years.
National drug strategies and action plans generally include 
interventions in the areas of prevention, treatment and 
rehabilitation, harm reduction and supply reduction. The 
extent of the different interventions and the importance given 
to each of them varies, however, between countries (2). This 
can be explained by differences regarding the size and 
characteristics of the drug problem but also by the diversity 
of social and health policies in Europe. Financial resources, 
public opinion and political culture are also important factors, 
and it can be shown that countries having certain common 
features adopt similar drug policies (Kouvonen et al., 2006).
Evaluation
Having in the EU a diversity of national drug strategies 
with common objectives can be viewed as a strength 
because it allows comparative analysis of different types of 
approach. The evaluation of national drug strategies and 
action plans is therefore important not only for assessing the 
efforts at national level but also for improving the overall 
understanding of the effectiveness of drug strategies. The 
EU and its Member States have already invested significant 
resources in this field. 
Almost all European countries mention the objective of 
evaluating their national drug strategy. Governments want 
to know if their policies are implemented and if the expected 
outcomes are achieved. In two Member States (Belgium, 
Slovenia), the scope of the evaluation has been limited to 
a number of selected projects. In most other countries, and 
at EU level, the implementation of the actions set out in the 
national drug strategy is systematically monitored. This 
enables progress reviews to be carried out, the findings 
of which may be used to improve or renew existing drug 
strategies or action plans. 
Global evaluations, covering process, output, outcome 
and impact, are less frequent in Europe. Some countries 
(Estonia, Greece, Spain, Poland, Sweden) report on the 
planning of an internal evaluation based on implementation 
progress reviews and other available epidemiological and 
criminological data. In some cases (Luxembourg, Portugal) 
such an evaluation will be performed by an external body.
In summary, progress reviews on the implementation of 
national drug strategies and action plans are becoming 
standard in Europe. The next step, which is developing 
outcome and impact evaluations, is still in its early stages, 
and the future impact assessment of the EU drug action 
plan 2005–08, for which the European Commission has 
commissioned a study aimed at designing a methodology, 
could become an example. There is also some activity in the 
area of developing indexes designed to assess the impact 
of national drug strategies or the overall drug situation. Both 
the United Kingdom and the United Nations Office on Drugs 
and Crime (UNODC) have invested considerable effort in this 
field.
(1) See the 2006 selected issue ‘European drug policies: extended beyond illicit drugs?’.
(2) See Chapter 2.
New regulation of the EMCDDA
On 12 December 2006, the European Parliament and the 
Council of the European Union signed the recasted regulation of 
the EMCDDA, which came into force in January 2007.
The new regulation underlines the importance of the key 
indicators, and notes that their implementation is a prerequisite 
for the Centre to perform its duties. Emphasis is also given to the 
need to develop an information system that is sensitive to new 
and emerging trends.
The new document broadens the scope of the EMCDDA’s remit. 
Particular reference is now made to providing information on 
the combined use of licit and illicit psychoactive substances 
and on best practice in Member States. The EMCDDA can also 
develop tools and instruments to help Member States monitor 
and evaluate national drug policies and to help the European 
Commission do the same at EU level. All these new elements will 
enable the agency to provide a more complete picture of the drug 
phenomenon. 
The new regulation places stronger emphasis on collaboration 
with partner agencies, particularly Europol in the case of 
monitoring new psychoactive substances, and other partners such 
as the WHO, the UN or relevant statistical authorities to attain 
maximum effi ciency. The new regulation clarifi es the countries 
to which the EMCDDA can transfer its know-how, at the request 
of the European Commission and with the approval of the 
Management Board. 
The role of the Reitox network of national focal points is more 
clearly defi ned in the new document. The recast also modifi es the 
regulation regarding the Scientifi c Committee. This will provide 
the agency with a cohesive, independent body of eminent 
scientists. In addition to helping to ensure the quality of the 
work of the EMCDDA, it will also provide a bridge to the wider 
scientifi c and research community.
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Drug policy indexes
The United Kingdom’s drug harm index (DHI) is designed 
to capture the social costs of harms generated by the 
problematic use of any illegal drug. It covers four types 
of harms: health impacts, community harms, domestic 
drug-related crime and commercial drug-related crime. 
However, it is not intended to be a full summary of the 
country’s drug situation, as the indicators are limited to those 
for which robust data already exist, and the outcome figures 
and trends are being used as a baseline against which 
to assess future progress (MacDonald et al., 2005). The 
UNODC’s illicit drug index (IDI) combines three dimensions 
of the drug phenomenon: drug production, drug trafficking 
and drug abuse. The outcome is an overall score, based 
on a ‘harm/risk factor per capita’, which should reflect 
the magnitude of all drug problems which arise in a given 
country (UNODC, 2005).
The conceptualisation of both instruments has involved 
interesting methodological developments and has allowed 
a first insight into the use of overall indexes to evaluate 
drug strategies and monitor overall drug situations. A first 
observation is that such instruments can be useful for a 
longitudinal follow-up of the national situation but that, to 
understand what is really going on, the result should be 
contextualised with the analysis of individual indicators within 
the indexes. The use of an overall index for inter-country 
comparison could be more difficult given the limitations of 
existing data sets and the absence of contextual variables 
(e.g. geographical situation) from the analysis. 
Coordination mechanisms
While formal drug coordination mechanisms now exist 
in almost all EU Member States and Norway, there is 
considerable diversity in the existing systems, reflecting 
differences in the political structures between countries. 
Nevertheless, some general features can be described.
Most countries have drug coordination mechanisms at both 
national level and regional or local level. At the national 
level, there is usually an interministerial committee on drugs, 
which is often supplemented by a national drug coordination 
agency and/or a national drug coordinator who is 
responsible for the day-to-day coordination activities. At the 
regional or local level, drug coordination agencies and/or 
drug coordinators exist in most countries.
European countries differ in how coordination mechanisms 
at the national level are linked to those at regional or local 
level. In some countries, in particular those with a federal 
structure (e.g. Belgium, Germany), vertical coordination 
systems are used to allow cooperation between the different 
coordination bodies that are acting independently. In other 
countries (e.g. Finland, Portugal), coordination at regional or 
local level is directly supervised by the national coordination 
bodies.
Comparative analysis of drug coordination mechanisms in 
the EU is made difficult by the diversity of existing systems. 
However, a study commissioned by the EMCDDA has shown 
that it is possible to assess coordination systems by focusing 
on their ‘implementation quality’, a concept for studying their 
capacity to produce coordination outcomes (Kenis, 2006). 
This approach will be further developed to enable it to be 
used in the evaluation of national drug coordination systems.
Drug-related public expenditure
Public expenditure on the drug problem reported by 
the European countries ranges from EUR 200 000 to 
EUR 2 290 million (3). The high variability is partly 
explained by the different sizes of the Member States and 
partly by differences between countries in the types of 
expenditure reported and the completeness of the data. 
Most countries reported only expenditures incurred in 
connection with the implementation of national drug policy 
programmes, and did not detail other expenditures in the 
field of supply and demand reduction. Furthermore, not all 
the main areas of State spending on the drug phenomenon 
were always included, with only 15 out of 23 countries 
providing detailed information on expenditure on ‘health 
and social care’ activities (treatment, harm reduction, health 
research, educational, prevention and social activities) 
and only 14 countries reporting on ‘law enforcement’ 
expenditure (police, army, law courts, prisons, customs and 
finance guard activities). Information about expenditure in 
other areas (e.g. administration, coordination, monitoring 
and international cooperation) was even more scarce 
(seven countries), as was information on regional and 
municipal budgets (six countries). 
Six countries provided detailed information of expenditure 
associated with tackling drugs (Table 1). In these countries, 
drug-related public expenditure represented between 0.11 % 
and 0.96 % of the total general government expenditure in 
the year (median 0.32 %) or between 0.05 % and 0.46 % of 
the national gross domestic product (GDP) (median 0.15 %). 
‘Law enforcement’ activities accounted for 24–77 % of the 
total expenditure, while the remainder was spent on ‘health 
and social care’ activities. 
European countries together reported a total drug-related 
public expenditure of EUR 8.1 billion. This figure is likely 
to underestimate the full extent of drug-related public 
expenditure, given the high level of under-reporting. The 
six countries included in Table 1 account for 76 % of the 
total public expenditure reported by EU Member States 
(3) Overall figures on drug-related public expenditures in 2005 in the EU Member States and Norway were identified by the corresponding national focal points. 
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and Norway. Based on the data supplied by these six 
countries, the total drug-related public expenditure by 
European countries is calculated to lie somewhere between 
EUR 13 billion and EUR 36 billion (4). These figures 
represent between 0.12 % and 0.33 % of the GDP of the 
EU (25 countries) in 2005.
At EU level, considerable funding will be provided by 
the European Commission to tackle the drugs issue under 
the new 2007–13 budget. A new funding instrument for 
drugs prevention and information of EUR 21 million is 
under negotiation and may be adopted by the end of 
2007, making EUR 3 million available for transnational 
projects this year. Other new financial instruments, such 
as the prevention of and fight against crime programme, 
the public health programme 2007–13 and the seventh 
RTD framework programme 2007–13, also provide 
funding opportunities for organisations working in different 
aspects of the drugs field. In addition, as of 2005, the 
EC and the Member States had co-financed drug-related 
assistance projects in third countries to the value of over 
EUR 750 million. 
In response to the EU drugs action plan 2005–08, the 
EMCDDA is currently working towards developing a 
methodology that will enable the Member States, candidate 
countries and Norway to compile standardised data on 
drug-related expenditure. This will help the EMCDDA to 
estimate both the total public expenditure allocated to drugs 
and how this is divided between different activities.
(4) Of the six countries, four (Hungary, the Netherlands, Finland and Sweden) provided detailed modelled approaches of their figures. Applying to the remaining 
countries the value of the first and third quartiles of the distribution of the percentage of total general government expenditure (0.18 % and 0.69 % respectively), 
and of the percentage of GDP (0.08 % and 0.37 % respectively) publicly spent by the six selected countries, provides an interval of the overall total 
accumulated expenditure.
The costs of drug use
Studies on the costs of drug use can be an important source 
of information for the development and management of drug 
policies. 
Drug-related costs can be divided into two major categories: 
direct and indirect. Direct costs are those for which payments 
are made, and typically include expenditure in the areas of 
prevention, treatment, harm reduction and law enforcement. 
Indirect costs are the value of productive services not performed 
because of drug use, and typically consist of lost productivity due 
to drug-related morbidity and mortality. Drug-related costs may 
also include the intangible costs of pain and suffering, usually in 
the form of quality of life measures, but this category of costs is 
often omitted because of the diffi culty in accurately quantifying it 
in monetary terms.
A cost study may be conducted from several different perspectives, 
each of which might include different costs, for example costs 
to society as a whole, the government, the healthcare system, 
third-party payers, and drug users and their families. 
The societal perspective
Drug-related social costs are the total of all the costs to society, 
direct and indirect, caused by drug use. The output, expressed in 
monetary terms, is an estimate of the total burden that drug use 
places on society (Single et al., 2001).
Determining the social cost of drug use has several benefi ts. 
First, it reveals how much society is spending on drug-related 
issues and, implicitly, the amount that would be saved if drug 
use were completely abolished. Second, it identifi es the different 
components of cost and the size of the contribution of each 
sector in society. Such information can help to determine funding 
priorities by highlighting areas where ineffi ciencies may exist and 
savings can be made. 
The public expenditure perspective
The term ‘public expenditure’ refers to the value of goods and 
services bought by the government of the State (i.e. central, 
regional, local) in order to execute each of its functions (i.e. 
healthcare, justice, public order, education, social services). 
The analysis of a State’s public expenditure provides useful 
information regarding the ability of its government to spend 
effectively and effi ciently. 
The estimation of drug-related public expenditure is a different 
exercise from that of estimating social costs. Public expenditure 
represents only a proportion of social costs, mainly in the 
form of direct costs; indirect costs are explicitly excluded, as 
there are costs from private stakeholders (e.g. private health 
insurance companies). Direct public expenditures explicitly 
labelled as ‘drug-related’ can be initially traced back by 
exhaustively reviewing offi cial fi nancial reporting documents 
(e.g. budgets or year-end reports). Estimations are complicated 
when drug-related expenditures are not labelled as such but 
embedded in programmes with broader goals (e.g. overall 
police operations budget). In this case, direct non-labelled 
drug-related expenses must be calculated through modelling 
approaches. 
The primary aim of social cost calculations is to weigh the 
burden that drug problems pose on society against the cost 
to society of addressing these problems (including possible 
indirect effects). Ultimately, this leads to the question of 
effectiveness and effi ciency: do governments spend their 
money wisely on the right problems? However, some authors 
(Reuter, 2006) have proposed that, for policy purposes, public 
expenditures are more relevant than social costs. The drugs 
budget helps to describe what policies a government is using 
to reduce drug use and related problems, which is the fi rst 
step towards deciding whether the level and content of such 
policies is adequate.
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EU legal and policy developments
At the end of 2006, the European Commission presented its 
first progress review (5) on the implementation of the EU drugs 
action plan (2005–08). This assessed the extent to which the 
activities planned for 2006 were achieved and whether the 
plan’s objectives for 2006 have been fulfilled. The EMCDDA 
contributed to this exercise by producing a set of reports. 
A similar exercise will take place in 2007, prior to the final 
impact assessment of the EU drug action plan that will be 
presented by the European Commission in 2008.
In June 2006, the European Commission issued a Green 
Paper on the role of civil society in drugs policy in the 
European Union (6), as laid down in the drugs action 
plan. The aim of the Green Paper is to explore how 
best to organise a continuous dialogue with civil society 
organisations active in the drugs field. Stakeholders were 
invited to comment on two options for a structured dialogue: 
a civil society forum on drugs as a platform for regular 
informal consultations or a thematic linking of existing 
networks. 
The involvement of civil society in drug policy in the EU is 
also one of the main objectives of the specific programme 
for drugs prevention and information 2007–13 (7), which 
has been proposed by the European Commission within the 
general programme for fundamental rights and justice. The 
general objectives of the drug programme are to help make 
Europe a free, secure and just area by improving information 
on the effects of drug use and by preventing and reducing 
drug use, dependence and drug-related harm. For the 
period 2007–13 this programme has an overall budget of 
EUR 21 million. The drug programme is still being discussed 
in the European Parliament and in the Council, in view of its 
adoption under the co-decision procedure.
(5) http://ec.europa.eu/justice_home/doc_centre/drugs/strategy/doc/sec_2006_1803_en.pdf
(6) http://eur-lex.europa.eu/LexUriServ/site/en/com/2006/com2006_0316en01.pdf
(7) COM (2006) 230 final.
Table 1: Comparison of selected countries with complete data and further details on the composition 
of their drug-related public expenditure
Country Overall expenditure reported Proportion of overall expenditure 
devoted to
amount 
(EUR million) 
as a proportion 
of total public 
expenditure (1) (%)
as a proportion 
of GDP (2) (%)
health and social 
care (3) (%)
law 
enforcement (4) (%)
Belgium (5) 185.9 0.14 0.07 43 54
Hungary 43.5 0.11 0.05 23 77
Netherlands 2 185.5 0.96 0.43 25 75
Finland 272.0 0.36 0.18 76 24
Sweden (2002) 1 200.0 0.80 0.46 60 40
United Kingdom 2 290.0 0.29 0.13 51 49
(1)  Total general government expenditure in the year (source: Eurostat).
(2)  Gross domestic product in the year (source: Eurostat).
(3)   Health and social care expenditures include treatment, harm reduction, health research and education, prevention and social affairs interventions. For 
Finland, in addition to ‘substance abuse prevention’, the amount given also includes property damage, monitoring and research.
(4)  Law enforcement expenditures include expenditure on police, army, law courts, prisons, customs and fi nance guards. 
(5)  Belgium also allocated 3 % of the overall expenditure reported to ‘policy management activities’.
Sources: National focal points and Eurostat.
Reports on the social cost of drug use
Data on the social cost of drug use are reported by only 
a small number of countries. In Finland (data from 2004), 
the indirect cost related to the use of drugs, including 
misuse of pharmaceuticals, was calculated to be in the 
region of EUR 400 to 800 million, of which EUR 306 to 
701 million was attributed to the cost of life lost due to 
premature death while production losses amounted to 
EUR 61 to 102 million. The social cost of illicit drug use 
was estimated at EUR 907 million in France in 2003 and 
at EUR 29.7 million in Luxembourg in 2004.
kg707374insideEN.indd   22 12/10/07   11:38:16
23
Chapter 1: Policies and laws
New national laws
Supply reduction
In the past year, Member States have made numerous 
legislative changes in the field of demand reduction, but 
2006 also saw a number of countries undertake measures to 
improve the legal frameworks that address drug trafficking 
and issues related to supply reduction. 
In Ireland, substantive changes included the introduction 
of the Criminal Justice Act 2006, which sets out new 
offences of supplying drugs to prisoners, provisions to 
deal with antisocial behaviour and proposals to strengthen 
imposition of the 10-year mandatory minimum sentence 
for trafficking drugs with a street value of EUR 13 000 
or more. Membership or facilitation of a ‘criminal 
organisation’ (as defined in the law) is penalised, and 
a drug offenders register has been established, which 
requires those convicted of drug trafficking to inform the 
police of their address upon their release from prison. 
Procedural changes, by contrast, were introduced in 
Hungary, where the national police headquarters’ 
provision aimed to codify all police activities related to 
drugs and precursors in one single, comprehensive law, to 
help fight drug-related crime.
Procedures regarding the use of certain tools to combat drug 
trafficking were also established or improved. In Estonia, 
the Narcotic Drugs and Psychotropic Substances Act and 
Associated Acts was amended in May 2005 to widen the 
scope of surveillance. In Romania, a law implemented in 
June 2006 introduced the European arrest warrant and set 
out procedures for its use, as well as measures to improve 
judicial cooperation, surveillance and cross-border pursuit 
and transfer of legal procedures. In Bulgaria, the new Penal 
Procedure Code introduced in October 2005 regulates 
controlled delivery, confidential transactions and undercover 
investigations. There are also provisions for the temporary 
protection of witnesses in drugs cases and, in some 
circumstances, for protecting the identity of witnesses, as well 
as special rules for the questioning of such witnesses and use 
of undercover officers. 
Similar tools are available to prosecutors in other 
countries. In the Czech Republic, the prosecution of drug 
offences often invokes the provisions of the Code of 
Criminal Procedure, which enables protection of witnesses’ 
identity and surveillance of persons. The Law for the 
Protection of Witnesses has also been widely applied in 
drugs cases in Cyprus. 
The recent increase in cocaine trafficking has focused 
attention on the Caribbean area. In the Netherlands, since 
early 2003, a special law court with prison facilities has 
been operational at Schiphol airport. Since the beginning 
of 2005, there has been 100 % control of all flights from 
key countries in the Caribbean. In 2004, an average 
290 drug couriers per month were arrested, decreasing 
to 80 per month by early 2006. In France, a law enacted 
in October 2005 strengthens cooperation with the 
Caribbean region, with the aim of intercepting illicit drug 
trafficking by air and sea.
Drug testing regulation
A number of countries have reported the introduction of 
legislation that permits, defines or regulates drug testing 
of drivers, arrestees, prisoners or employees in different 
situations.
Random roadside checks on drivers, using on-site rapid 
testing devices, are now allowed for in Lithuania, according 
to the resolution approving the national programme on safe 
road traffic 2005–10, and in Luxembourg under a draft law 
of 2004 modifying the law on traffic control. In Latvia, the 
amended criminal law now penalises drivers believed to be 
operating a vehicle while intoxicated and who refuse to take 
a test, with the option of imposing a prison sentence in the 
event of repeated refusal within a year. Also in Latvia, the 
modified law ‘on police’ now states that a person may be 
transferred to a medical establishment to determine whether 
he or she has used alcohol or narcotic, psychotropic or toxic 
substances, and refers to the cabinet regulations that detail 
the procedure. Procedures regarding the drug testing of 
drivers are further described in the 2007 selected issue on 
drugs and driving.
Particular groups of arrestees may be now drug tested in 
Scotland, in line with the position in England and Wales, 
and new draft prison rules published in Ireland in June 
2005 by the Department for Justice, Equality and Law 
Reform introduce the possibility of mandatory drug testing of 
prisoners. This is stated to be in the interest of good order, 
safety, health and security, and would be carried out on 
samples of urine, oral fluids and/or hair. 
In Norway, it is no longer the case that drug testing in the 
workplace can be carried out provided an employee or job 
applicant gives consent. Since section 9-4 of the Working 
Environment Act 2005 came into force, an employer can 
require an employee or job applicant to undergo a drugs test 
only in the circumstances set out in statutes and regulations, 
or if performing the job while intoxicated carries particularly 
high risks, or if the employer deems that testing is necessary 
to protect the life and health of employees or a third party. 
The new Finnish government decree on drug testing at work 
lays down a comprehensive list of provisions addressing 
consent, as well as the quality requirements of the test 
laboratories, samples and test results.
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In the Czech Republic, rules covering drug testing by the 
police, prison staff or employers are now defined by Act 
379/2005 Coll. on ‘Measures for protection from harm 
caused by tobacco products, alcohol, and other addictive 
substances’. A professional examination is mandatory when 
it is reasonable to assume that the use of substances puts 
the person in a condition in which they or others could be 
harmed. It also specifies when the police, prison staff or 
employers are entitled to carry out a breath test or take a 
saliva sample. Medical examinations, by breath test and 
samples of biological material, can be carried only out 
in healthcare facilities with adequate professional and 
operational competence.
Drug-related crime
The need to prevent drug-related crime is high on the 
European policy agenda, as illustrated by the fact that the 
current EU drug strategy identifies this objective as a key 
area of action for achieving its aim of ensuring a high level of 
security for the general public. 
Among the tasks scheduled for 2007 in the EU drug action 
plan 2005–08 is the adoption of a common definition of 
‘drug-related crime’, on the basis of a European Commission 
proposal based on studies brought forward by the EMCDDA. 
What is meant by ‘drug-related crime’ varies across 
disciplines and professionals, but it can be considered to 
include four broad categories: psychopharmacological 
crimes (those committed under the influence of a 
psychoactive substance), economic compulsive crimes (those 
committed in order to obtain money/goods/drugs to support 
a drug habit), systemic crimes (those committed within the 
functioning of illicit drug markets) and drug law offences 
(including use, possession, dealing, trafficking, etc.) (see also 
EMCDDA, 2007a).
Definitions of the first three of these aspects of drug-related 
crime are sometimes difficult to apply in practice, and 
data are rare and patchy. Data on ‘reports’ (8) of drug 
law offences are routinely available in all the European 
countries analysed in this report. However, these data also 
reflect differences in national legislation and the different 
ways in which the laws are applied and enforced as well 
as differences in priorities set and resources allocated by 
criminal justice agencies to specific offences. In addition, 
there are variations between national information systems 
on drug law offences, especially in relation to reporting and 
recording practices, i.e. what is recorded, when and how. 
As a result, it can be difficult to make comparisons between 
countries; therefore, it is more appropriate to compare trends 
rather than absolute numbers, and to take into account 
national population sizes when analysing European average 
trends. Overall, at EU level, the number of ‘reports’ of drug 
law offences increased by an average of 47 % between 
2000 and 2005 (Figure 1). The data reveal increasing 
trends in all reporting countries except Latvia, Portugal and 
Slovenia, which reported an overall decline over the five-year 
period (9). 
The balance between offences related to use and those 
related to trafficking varies, with most European countries 
reporting that the majority of offences are related to drug use 
or possession for use, figures in 2005 ranging up to 91 % 
in Spain (10). However, in the Czech Republic, Luxembourg, 
the Netherlands, Turkey and Norway, drug law offences 
related to dealing and trafficking are predominant, with these 
offences accounting for up to 92 % (the Czech Republic) of all 
drug law offences reported in 2005. 
In most European countries, cannabis is the illicit drug most 
often involved in reported drug law offences (11). In the 
countries where this is the case, cannabis-related offences 
in 2005 accounted for 42–74 % of all drug law offences. 
In the Czech Republic, methamphetamine-related offences 
predominated, accounting for 53 % of all drug law offences, 
while in Luxembourg cocaine was the most reported 
substance (implicated in 35 % of drug law offences). 
In the five-year period 2000–05, the number of ‘reports’ of 
drug law offences involving cannabis remained stable or 
increased in the majority of reporting countries, resulting in 
an overall average increase of 36 % at EU level (Figure 1). 
Downward trends were, however, reported by the 
Czech Republic (2002–05) and Slovenia (2001–05). 
In all reporting countries except Luxembourg and the 
Netherlands, cannabis is the drug most often involved in 
offences for use/possession for use. However, the proportion 
of use-related offences involving cannabis has been 
decreasing since 2000 in several countries (Greece, Italy, 
Cyprus, Austria, Slovenia and Turkey) and in the most recent 
year for which data are available (2004–05) in a majority of 
reporting countries, possibly indicating that in these countries 
(8) The term ‘reports’ for drug law offences is given in quotation marks because it describes different concepts in different countries (police reports of suspected 
drug law offenders, charges for drug law offences, etc.). For an exact definition for each country, refer to the methodological notes on drug law offences in the 
2007 statistical bulletin.
(9) See Table DLO-1 in the 2007 statistical bulletin.
(10) See Table DLO-2 in the 2007 statistical bulletin.
(11) See Table DLO-3 in the 2007 statistical bulletin.
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law enforcement agencies may target cannabis to a lesser 
extent than other drugs (12).
Cocaine-related offences increased over the period 2000–05 
in all European countries except Germany, where the number 
remained relatively stable. The EU average increased by 
62 % over the same period (Figure 1).
‘Reports’ of drug law offences related to heroin between 
2000 and 2005 show a different picture to those related to 
cannabis or cocaine, dropping on the whole by an averaged 
15 % in the European Union, mainly between 2001 and 
2003. However, national trends in heroin offences have 
been diverging over the period with a third of the countries 
reporting upward trends (13). 
Research on the drugs problem
Funding
Drug-related research in Europe, as reported by national 
focal points, is financed through national and European 
public funds. Several Member States report that research 
on drugs is financed by general national research funds 
(Germany, the Netherlands, Finland, the United Kingdom), 
Ministry of Health research funds (Italy) or by funds controlled 
by the national drug coordinating body (France, Sweden). 
In Romania, research is funded through international 
organisations, such as the Global Fund.
Research activity 
Taking peer-reviewed scientific publications as an indicator 
of scientific activity, an analysis of such publications during 
2005 and 2006 and quoted in the national reports reveals 
a pattern of thematic research priorities that varies between 
countries.
Addiction treatment appears to be an important subject of 
research, with the majority of studies examining different 
aspects of substitution treatment. Research on prevention 
accounts for a much smaller proportion of the scientific 
literature cited in the national reports. Of the EMCDDA’s five 
key indicators, publications on infectious diseases are the 
most numerous, followed by publications on the prevalence 
of drug use among young people.
The scientific publications quoted in the national reports vary 
between countries. Treatment research, particularly treatment 
of hepatitis C-positive drug users, is quoted particularly often 
in the German report, whereas the Dutch report focuses on 
new treatment methodologies. Research studies quoted from 
the United Kingdom deal mainly with problem drug use, 
crime and market issues. The few references to neuroscientific 
research are primarily Dutch; however, the French MILDT has 
also financed a series of research projects in this area.
Recently launched research programmes provide evidence 
of similar national research priorities among Member States. 
Current national research funding in Germany is allocated 
to optimising treatment services to meet treatment demand, 
including basic research. In 2006, the Netherlands launched 
the research programme ‘Risk behaviour and dependence’. 
In the United Kingdom, studies on the quality of treatment 
systems and on very young problem drug users have 
recently been initiated. The new Member States are mainly 
concentrating on building up the scientific base for their 
monitoring systems, for example through youth surveys.
(12) In some of the countries where the proportion of use-related offences involving cannabis has been decreasing, it is worth noting that absolute numbers of 
use-related offences involving cannabis are on the increase.
(13) The fact that the European average does not reflect the increase in heroin offences found in half of the reporting countries is mainly because countries for which 
data are missing for two consecutive years are not included in the European average but also because the European average takes into account national 
population sizes (thus giving more weight to figures from some countries than to others). 
Figure 1: Indexed trends in reports for drug law offences in EU 
Member States, 2000–05
NB:   The trends represent the available information on national number of 
reports for drug law offences (criminal and non-criminal) reported by all law 
enforcement agencies in the EU Member States; all series are indexed to a 
base of 100 in 2000 and weighted by country population sizes to form an 
overall EU trend.
   Because definitions and study units differ widely between countries, the 
general term ‘reports for drug law offences’ is used; for more information, 
see ‘Drug law offences: methods and definitions’ in the 2007 statistical 
bulletin.
   Countries lacking data for two or more consecutive years are not included in 
the trend calculations: the overall trend is based on 24 countries; the trend 
for heroin is based on 14 countries, cocaine on 14, and cannabis on 15.
   See Figure DLO-6 in the statistical bulletin for further information. 
Sources:  Reitox national focal points and, for population data, http://epp.eurostat.
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EU research
EU funding for drug-related research is provided through 
research framework programmes, the most recent of 
which, the seventh framework programme (2007–13), was 
launched at the end of 2006. Research projects reporting 
on their results in 2005/06 emerged from the ‘Life quality’ 
theme in the fifth EU research framework programme 
(1998–2002). Among these are ‘quasi-compulsory treatment 
of drug dependent offenders in Europe’ (QCT), ‘Support 
needs for cocaine and crack users in Europe’ (Cocineu) and 
‘integrated services aimed at dual diagnosis and optimal 
recovery from addiction’ (Isadora).
Drugs and driving — EMCDDA 2007 selected issue
Psychoactive substances can impair a person’s ability to drive 
a car to the extent that the risk of accidents and injuries is 
increased. A selected issue on drugs and driving gives an 
overview on the outcomes of different types of studies on this 
topic, focusing on cannabis and benzodiazepines, as well 
as on preventive and legal approaches towards this problem 
behaviour.
This selected issue is available in print and on the Internet in 
English only (http://issues07.emcdda.europa.eu).
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Responding to drug problems in Europe — an overview
The EU drugs action plan 2005–08 specifically calls on 
Member States to increase the provision of effective and 
diversified methods of prevention, treatment, harm reduction 
and social reintegration that are easily accessible. These 
facets of the drug problem in Europe will be discussed in 
more detail in this chapter.
Prevention strategies can be targeted at different 
groups — ranging from total populations to specific risk 
groups — and the methods applied vary accordingly. 
Treatment and harm-reduction measures are also available 
to drug users and drug addicts, and in a considerable 
number of countries their effectiveness has been evaluated 
through outcome studies. Harm-reduction measures aim to 
prevent drug-related deaths and to reduce health-related 
harm, for example HIV or hepatitis C infections. Heroin 
dependence is usually treated with substitution therapy, 
and special programmes have been developed for 
cannabis, amphetamine and cocaine dependence. 
And, in the event of successful treatment, the next step 
is social reintegration. As will be described below, 
the living conditions of many drug users are poor and 
social reintegration strategies often have to overcome 
considerable problems. 
For each type of intervention, examples are given from 
different countries and research results in support of their 
effectiveness, or otherwise, are discussed.
Prevention
The effects of individual prevention strategies cannot, 
in general, be measured by changes in population-level 
prevalences of drug use. However, every prevention 
strategy can be compared against the accumulated 
body of evidence, to determine whether or not it is an 
evidence-based intervention. This requires good information 
on the content, coverage and number of prevention 
interventions. 
Improving the available information: monitoring, 
quality control and evaluation
Member States are increasingly monitoring prevention 
interventions and, as a result, are delivering data on the 
content and availability of interventions. Germany, the 
Netherlands and Norway have extended information 
coverage. Greece, Cyprus, Lithuania and Italy monitor 
school-based prevention, while in Greece, Poland, Sweden 
and Finland, community-based prevention services are 
under study, and France has set up a centralised system 
to monitor drug prevention. Some countries (the Czech 
Republic, the autonomous region of Galicia in Spain, 
Hungary and Norway) are already focusing on the 
evidence base when funding for interventions is applied 
for, and are considering introducing accreditation systems. 
Portugal, Finland and Romania have minimum quality 
criteria for prevention programmes.
Information from Hungary and the Netherlands would 
suggest that the existence of prevention monitoring systems 
and quality criteria leads to better reporting on projects and 
evaluations and a higher quality of interventions. 
Most prevention programmes are not evaluated. Those that 
are evaluated are usually assessed in terms of the ‘scope 
and the acceptance of the intervention’ rather than ‘the 
extent to which the objectives have been achieved’ (Greek 
national report). 
In the past few years, reviews on the effectiveness of 
prevention have been carried out in Germany (Bühler and 
Kröger, 2006) and the United Kingdom (Canning et al., 
2004; Jones et al., 2006), and by the World Health 
Organisation (WHO) (Hawks et al., 2002). These are 
helpful in defining good practice in prevention strategies. 
The most recent and comprehensive study (Bühler and 
Kröger, 2006) evaluated 49 high-quality overviews, 
such as reviews and meta-analyses, on the prevention 
of substance abuse and drew conclusions regarding 
efficient strategies of drug prevention. In the sections 
below, the effectiveness of different types of prevention 
strategy is discussed, based on the results of this study 
and others.
Mass media campaigns
Hawks et al. (2002), in line with the HDA (2004), conclude 
that ‘the use of the mass media on its own, particularly in the 
presence of other countervailing influences, has not been 
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found to be an effective way of reducing different types of 
psychoactive substance use. It has, however, been found 
to raise information levels and to lend support to policy 
initiatives’. However, other evidence suggests that mass 
media campaigns can have positive effects if used as a 
supporting measure to reinforce other strategies (Bühler and 
Kröger, 2006).
In an evaluation of Scotland’s ‘Know the score’ cocaine 
campaign, Binnie et al. (2006) found that 30 % of users 
were less likely to take cocaine after seeing advertisements, 
although 56 % reported that the campaign did not alter 
their intentions to use cocaine and 11 % claimed that they 
were more likely to use. In addition, the recent re-evaluation 
of the US government’s cannabis campaign confirmed 
previous findings that while the campaign (despite positive 
recall rates and differentiation by target groups) had no 
effect on the attitudes of young non-users towards cannabis 
use, exposure to the campaign was associated with 
unfavourable effects on youths’ perceptions of others’ use of 
marijuana (GAO, 2006).
In a few isolated cases, however, there has been a shift in 
emphasis from knowledge enhancement (the aim of most 
mass media campaigns) to the provision of social–emotional 
information (trying to change perceptions about, for 
example, cannabis use). For example, in the Netherlands a 
campaign put across the message ‘You are not mad if you 
are not smoking cannabis, because 80 % of all young people 
do not smoke either’ (14). In addition, some elements of the 
national drug prevention campaign in Ireland seek to dispel 
some of the myths that surround cannabis, such as claims that 
it is ‘organic’ and ‘natural’. 
Environmental strategies on licit substances
Increasing the price of a substance and/or the legal age 
limit for its consumption have been shown to have a positive 
effect in reducing use, but are available only in the case 
of licit substances such as alcohol and tobacco (Bühler 
and Kröger, 2006). Such environmental strategies have 
until now been something of a Nordic or US phenomenon, 
focusing predominantly on alcohol, and with promising 
results (Lohrmann et al., 2005; Stafström et al., 2006). 
Increasingly, however, comprehensive community 
approaches that treat alcohol and tobacco similarly 
to illicit substances are emerging. Belgium, Bulgaria, 
Denmark, Lithuania, Luxembourg, the Netherlands, Poland, 
(14) See http://www.drugsinfo.nl
Evidence-based practice
Evidence-based practices are interventions (e.g. drug treatment) 
that have been consistently proven, based on scientifi c 
investigations (e.g. research studies), to result in preferred client 
outcomes (e.g. reduction in drug use). Criteria commonly used 
to determine whether an intervention can be considered an 
evidence-based practice are effi cacy and effectiveness (Brown 
et al., 2000; Flay et al., 2005). 
Effi cacy is a measure of how well an intervention works under 
ideal research conditions. Effi cacy is ideally determined by 
carrying out a controlled trial, in which some participants receive 
the intervention under test while a control group receives another 
intervention or no intervention, or, better still, in a randomised 
controlled trial, in which participants are randomly allocated to 
receive one of the two interventions (Cochrane Collaboration, 
2007). It is generally believed that only randomised controlled 
trials or controlled trials, preferably combined with process 
evaluation, can establish the effi cacy of an intervention and so 
provide a basis for future practice and policy. 
Unfortunately, however, the random allocation of participants to 
either an intervention or control group is not always feasible.
Effectiveness is a measure of how well an intervention works in 
ordinary circumstances. Frequently, interventions that have shown 
promise in controlled trials are implemented in the community 
to investigate how well they work under routine conditions. 
Effectiveness studies, e.g. national treatment outcome studies, are 
primarily concerned with the impact of the intervention on health 
or other relevant outcomes as a means to establish evidence for 
what works.
The process of establishing evidence is, however, complicated by 
the fact that there are divergent views on how to judge the quality 
of the research studies investigating effi cacy or effectiveness 
and on which type of research method (e.g. quantitative or 
qualitative) is the most appropriate to establish evidence of what 
works. As a consequence, conclusions about what works can 
differ. It remains a challenge to determine how to evaluate and 
weigh the different sources of evidence in the decision-making 
process. This will be even more diffi cult in the case of 
interventions for which a comprehensive evidence base has not 
yet been established but the experience of which would suggest 
may be effective. 
Despite these diffi culties, the guiding assumption remains that 
evidence can help to improve healthcare practice and policy, 
and that discussion of evidence-based practices needs to be 
fostered, accompanied by clear criteria for evaluating evidence. 
To contribute to this exchange and further the dissemination 
of evidence-based practices, the EMCDDA is developing an 
online portal that will provide an overview of the latest available 
evidence regarding the effectiveness of different interventions as 
well as tools available to improve the quality of interventions and 
concrete best-practice examples implemented in Member States 
of the EU. The Cochrane Collaboration will be an important 
source of information to the portal.
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Slovakia and Norway all now report the existence of 
community-based strategies or discussions about additional 
taxes or laws regulating alcohol and tobacco availability. 
Such strategies are aimed at reducing consumption among 
young people, creating alcohol-free zones or increasing 
security in nightlife settings. As far as schools are concerned, 
recent studies from Europe (Kuntsche and Jordan, 2006) 
and elsewhere (Aveyard et al., 2004) confirm that the 
normative climate and informal networks strongly influence 
consumption behaviour of legal drugs and cannabis. The 
introduction of school norms is now receiving greater 
consideration in Germany, Ireland and Italy (15). 
Universal prevention
Interactive programmes based on the model of social 
influence or life skill competence have been shown to be 
effective in schools, but individual measures carried out in 
isolation (for example, only communication of information, 
affective education or other non-interactive measures) have 
been negatively evaluated (Bühler and Kröger, 2006). For 
organisational reasons, school-based prevention is usually 
the responsibility of local authorities, especially in the Nordic 
countries, France and Poland. 
Some commentators have suggested that complementary 
general health/life skills programmes produce greater 
change than skills-based education programmes alone, 
suggesting that interventions are best integrated within a 
well-founded health curriculum (Hawks et al., 2002). This 
seems to have been achieved in almost all Member States. 
Furthermore, several Member States (e.g. Italy, Lithuania, 
the Netherlands, Slovakia, the United Kingdom) address 
drugs prevention together with health and social aspects 
such as violence, mental health problems, social exclusion, 
academic underachievement and tobacco and alcohol use 
under the umbrella of public health prevention, which also 
gives greater focus on responding specifically to the needs of 
vulnerable groups.
A reason frequently given for not implementing model 
programmes is that they would not be adaptable to local 
conditions and would not address individual communities’ 
needs (Ives, 2006). However, a counter argument is that the 
advantages of standardised prevention programmes are that 
protocols provide clear guidelines to enable stable delivery 
infrastructures and teacher training systems to be created; 
and this facilitates common implementation standards, even 
where schools and community conditions are very disparate. 
In many Member States (Bulgaria, Italy, Latvia, Lithuania, 
Luxembourg, Austria, Romania) the content of prevention 
programmes focuses on raising awareness, providing 
information and organising isolated events (such as expert 
visits) (16), despite evidence which suggests that other 
methods may be more effective. 
Social influence programmes in schools are widespread, 
particularly in the United Kingdom and in countries offering 
standardised programmes, such as Germany, Ireland, 
Greece, Spain, Norway and, soon, Denmark. 
As regards universal community-based prevention, 
12 Member States report that drug plans are available in 
most or all municipalities, and in 10 countries they are a 
political priority. Such schemes principally take the form 
of information events and, to a lesser extent, the provision 
of alternative leisure-time pursuits. Universal family-based 
prevention mostly consists of parents’ evenings or information 
approaches, and infrequently in intensive training for 
parents. 
Selective prevention
Member States are increasingly devoting attention 
to prevention strategies targeted at entire vulnerable 
communities (17). This means that such communities need to 
be identified, for example using standardised assessment 
tools, such as the United Kingdom’s Index of Multiple 
Deprivation, or by socio-economic indicators, such as 
standards of accommodation or education (number of pupils 
behind in their schooling or number of subsidised pupils).
Once target communities have been identified (e.g. France 
recognises ‘sensitive urban zones’ or, in the case of schools, 
‘educational priority zones’), supplementary funds can be 
directed towards these underprivileged groups. In Ireland, 
Cyprus and the United Kingdom, selective prevention projects 
are already delivered to most of these areas, and Portugal 
is in the process of implementing such a strategy. Types of 
provision range from counselling services in Estonia, Greece, 
France and Slovakia to outreach projects in Luxembourg 
and Austria, sometimes aimed specifically at ethnic 
groups. Furthermore, some new Member States (Bulgaria, 
Hungary, Lithuania, Poland and Romania) report much on 
interventions aimed at vulnerable families. The focus in most 
Member States is on substance use in the family, although 
a few countries (Greece, Lithuania, Hungary, the United 
Kingdom) have adopted a broader focus aimed at all socially 
disadvantaged families. 
While also used in universal prevention, peer-based 
approaches are increasingly being reported for the delivery 
of selective prevention (Ireland, the Netherlands, Austria, 
Poland and Norway). Parkin and McKeganey (2000), in 
(15) See also http://www.emcdda.europa.eu/?nnodeid=19197
(16) Data from SQ 22 and 25.
(17) For more information on selective prevention, especially risk groups and factors, see previous annual reports and the 2007 selected issue on drug use among minors.
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their review of peer-based approaches, concluded that 
the greatest impact of such schemes is on peer educators 
themselves, rather than the target group. It seems that such 
approaches may be more effective at changing knowledge 
and attitudes than in changing behaviour. Peer projects are 
rarely evaluated at all, but when they are (e.g. Free Style 
in Norway) they typically assess only success in recruiting 
young leaders in schools and whether the peer leaders’ 
knowledge or attitudes were strengthened.
Although selective prevention is gaining in popularity, 
caution is required, especially when involving young people 
at risk in peer-to-peer programmes (Cho et al., 2005; Dishion 
and Dodge, 2005), because negative ‘contagion effects’ 
can occur among vulnerable groups. These unintended 
effects, which are caused by the intervention itself, can lead 
to increased substance use or risk behaviour. However, such 
undesirable outcomes are not unique to selective prevention 
but are also observed in the case of mass media information 
provision as well as individual prevention events (see above).
Treatment and harm-reduction responses
Recent developments in treatment systems
Most treatment of drug users takes place in outpatient 
settings, including general practice. The enlargement of 
outpatient treatment networks has continued in recent years, 
and a further geographical expansion took place in several 
countries, including Bulgaria, Estonia, Greece, Lithuania, 
Romania and Finland; in contrast, the number of inpatient 
facilities has remained stable in most countries. 
Countries in which national geographical coverage of 
specialised drug treatment facilities is very patchy include 
Latvia, Hungary, Slovakia and Romania. Despite recent 
expansions of the network of service providers, waiting lists 
for substitution treatment continue to exist in Greece as well 
as in Hungary and Poland. 
Treatment in residential facilities, formerly the 
predominant approach to the treatment of heroin use 
in many European countries, is relatively less common 
nowadays, and the majority of opioid users are treated in 
outpatient settings. Residential services are, however, of 
growing importance in the care of elderly and long-term 
drug users with complex treatment needs because of 
the coexistence of serious somatic and psychological 
co-morbidity. The philosophy of inpatient facilities and 
the way they work have changed considerably over the 
years, in response to changing needs. The co-location 
of treatment and medical care, including psychiatric 
treatments, highly active antiretroviral treatment and 
treatment of liver disease, has become more common, 
and the use of drug maintenance treatment to stabilise 
clients has increased.
Characteristics of drug users attending 
outpatient treatment
Data from the treatment demand indicator can be used to 
characterise the socio-economic status of patients attending 
treatment centres and, to some extent, all drug users (18). As 
access to outpatient treatment is easier and less selective 
in most countries, it is appropriate to extrapolate from this 
group of clients to drug users as a whole.
In 2005, 20 out of 29 European countries reported 
information on 315 000 drug clients attending outpatient 
treatment centres. The data came from about 4 000 treatment 
units. Approximately half (53 %) of the outpatient clients are 
treated for primary opioid use and the other half for primary 
use of other drugs, in particular cannabis (22 %) and cocaine 
(16 %). The drug that is most commonly the primary drug of 
consumption varies between countries.
About 80 % of outpatient treatment clients are male, with a 
mean age of around 30 years (28 years among those new 
to treatment), and their living conditions are generally poor 
compared with the general population of the same age. 
Around 60 % of outpatient clients have not achieved a level 
of education beyond primary, and about one tenth of those 
clients have not even completed primary education. Around 
half of the clients were in regular employment before entering 
outpatient treatment and the other half were unemployed; 
most outpatient clients are in stable accommodation (85 %), 
of whom 40 % live with their parents and 19 % live alone. 
A significant minority of drug outpatient clients (15 %) live 
with children, either alone or with their partner, representing 
a complicating aspect in the drug user’s life and representing 
a risk factor for the children. 
Information on the socio-economic situation of drug clients 
in treatment is complemented by national information from 
some countries broken down by main substance used. For 
example, in Germany, 67 % of heroin users are unemployed 
or economically inactive, compared with 53 % of cocaine 
clients and 35 % of cannabis clients, and 74 % of opioid 
clients have limited school education, compared with 63 % of 
cocaine clients (Sonntag et al., 2006).
New developments
Specialised facilities targeting specific groups of drug 
users, e.g. female drug users, homeless street injectors, 
sex workers, or young and very young drug users (see the 
2007 selected issue on drug use among minors), have been 
newly established in several countries. In other countries, 
(18) See the TDI tables and graphs in the 2007 statistical bulletin for more details on the figures quoted in this section.
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pharmacological treatment options have been expanded 
to meet the needs of specific user groups with the aim of 
increasing treatment coverage. For example, buprenorphine 
maintenance treatment is now licensed in Malta (19).
Treatment of different groups of drug users
Member States are increasingly acknowledging the 
importance of providing adequate treatment services for 
problematic cannabis and cocaine users. In the case of 
cannabis, treatment, counselling and prevention programmes 
in Europe are often intertwined in order to reach a large 
number of users. New communication strategies, for 
example making use of the Internet, are being implemented 
in an attempt to reach cannabis users whose drug use falls 
somewhere between experimental and problematic. Specific 
cannabis treatment services and programmes, which to 
date have not been widely provided in Europe, are under 
development at the moment (see Chapter 3).
Moreover, Member States facing a high level of demand 
for cocaine treatment are starting to commission research in 
this field, the issue being complicated by the fact that users 
of powder cocaine and crack cocaine are usually members 
of quite distinct social groups (see Chapter 5). At present, 
however, because of the current lack of specific services, 
the large majority of psychostimulant users, including 
amphetamine users, are being treated within traditional, 
opioid-orientated treatment services, with an identified 
training need for treatment staff and clinicians across Europe.
Treatment of heroin dependence
After political endorsement as a response to heroin use in the 
second half of the 1980s, substitution treatment has gone on 
to become the predominant option for the treatment of opioid 
dependence in most countries (Figure 2). 
The main substitution drugs used are methadone and 
buprenorphine. Ideally, pharmacological treatment should be 
combined with psychological counselling and social support. 
Substitution treatment is usually delivered in outpatient 
settings at specialised drug treatment units but increasingly 
also by doctors in private practice. In some countries, 
e.g. Germany, France and the United Kingdom, general 
practitioners are heavily involved in treating drug users. In 
others, the level of involvement of community-based medical 
doctors is still limited, either for legal reasons or because of 
a lack of interest in addiction treatment (20). Quality control 
has also been on the agenda in several countries, resulting in 
regulations being tightened, training requirements increased 
or higher levels of supervision and monitoring introduced (21). 
The treatment of opioid addiction is explored in more detail 
in Chapter 6.
(19) See ‘Prescribing practice for substitution treatment in Europe’, p. 66.
(20) See ‘Legal frameworks of substitution treatment’ and http://eldd.emcdda.europa.eu/?nnodeid=5036
(21) See also p. 67. 
Legal frameworks of substitution treatment
In 2006, a survey was carried out among the specialised 
network of legal correspondents to obtain further information 
about laws and offi cial regulations regarding admission 
criteria for substitution treatment as well as about prescribing 
and dispensing practice. Results were obtained from 
17 countries and complemented a 2003 report from the 
European legal database on drugs (1).
The scope of the legal framework varies considerably 
between Member States. In some countries, e.g. Belgium, 
substitution treatment is covered by a specifi c parliamentary 
law, while in others, e.g. Cyprus, its implementation is subject 
to interpretation of the laws on controlled substances. There is 
a trade-off between strength of the framework and fl exibility. 
The substances that can be used for substitution treatment are 
normally designated by law. In most cases, only methadone 
and buprenorphine or only methadone can be prescribed, 
although in a few countries other drugs such as morphine 
or codeine are permitted. Similarly, in almost all countries 
national admission criteria are laid down either in laws or in 
ministerial decrees or guidelines. The most common criteria 
are diagnosis of addiction and minimum age, although 
the need for previous unsuccessful drug-free treatment also 
features. In some countries, sanctions for violating treatment 
rules are set out in national laws while in others the issue is at 
the discretion of each individual treatment centre.
The laws usually also defi ne who is permitted to prescribe. 
This is primarily doctors in treatment centres, though 
in some countries any doctor or certain trained or 
accredited doctors may prescribe. In practice, it is rare 
for doctors outside treatment centres to initiate substitution 
treatment (2). Maximum doses are rarely defi ned in law. 
To prevent duplicate prescriptions, most countries use 
special prescription forms, though a central register is 
found in several countries and a few issue special ID cards. 
Authorised dispensaries are usually also specifi ed in the 
legislation, mostly pharmacies or treatment centres, though 
some countries also allow doctors to dispense. Finally, in 
most countries, a system for taking doses home has been 
established by law, guidelines or simply tolerance, but 
occasionally this is specifi cally forbidden. 
(1) Further details are available at http://eldd.emcdda.europa.eu/
?nnodeid=5036
(2) See Table HSR-6 in the 2007 statistical bulletin.
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Harm-reduction responses
Prevention of infectious diseases and a reduction in 
drug-related deaths are central targets of the EU response 
to drugs, and the current action plan sets the objective of 
increasing the availability and accessibility of services and 
facilities to prevent and reduce health-related harm.
In April 2007, the European Commission submitted a report 
to the Council and the European Parliament regarding 
the implementation of the Council recommendation 
of 18 June 2003 on the prevention and reduction of 
health-related harm associated with drug dependence (22). 
This report documents that harm reduction is a defined 
public health objective at national level in all Member 
States. The background document commissioned to support 
the report of the Commission provides a comprehensive 
European picture of harm-reduction policies and 
interventions. It is based on information provided mainly by 
policymakers, Reitox experts and grass-root organisations. 
Extensive country-by-country inventories are included in this 
background document (23). 
The Council recommendation has led to more countries 
aligning their national policies with the European strategy, 
placing more emphasis on expanding the provision of 
harm-reduction services. It appears to be particularly 
influential among the countries that joined the EU in 2004.
Social reintegration
Precarious housing, irregular employment and a history 
of imprisonment are indicators of social exclusion that 
characterise the life of numerous drug users. In many 
European countries the number of problem drug users 
being reached, retained in treatment and undergoing drug 
substitution treatment is greater than ever, with the result 
that demand for housing, education, employment and 
legal assistance has significantly increased. Care systems 
are therefore challenged to find novel responses to new 
client profiles, often characterised by multiple needs. Social 
reintegration is now established as an important determinant 
of long-term treatment success.
In some countries, the reintegration sector is receiving 
increasing political attention and investment, and in 
several countries standards for drug maintenance 
treatment envisage that social care and reintegration 
services should be made available to clients. For 
example, the mid-term review of the Irish drugs strategy 
recommended the inclusion of rehabilitation as the fifth 
pillar of the strategy, while in Denmark new programmes 
for vulnerable groups (‘shared responsibility’) were 
launched by the Ministries of Employment and of Social 
Affairs. Another example is the Norwegian government’s 
strategy for preventing and combating homelessness, 
which sets measurable targets, such as reducing evictions 
and increasing access to permanent housing so that 
temporary accommodation becomes the exception. Also 
in Norway, an action plan to combat poverty includes a 
grant scheme that in 2006 distributed EUR 6.5 million for 
the provision of residential follow-up services for homeless 
people and alcohol and drug users. In addition, Greece, 
France, Italy, Lithuania, Austria, Portugal and Slovakia 
participate in the Commission’s EQUAL initiative in the 
area of employment and social inclusion (24).
The EU also encouraged the creation of a framework called 
‘Open method of coordination’ (OMC), in which Member 
States coordinate their policies for combating poverty and 
social exclusion through a process of policy exchanges and 
mutual learning. 
Reintegration measures reflect different national sociocultural 
and economic realities in Europe, but they also show some 
diversity with regard to objectives, target groups and 
conditions. For example, Bulgaria and Romania are the only 
(22) Council recommendation of 18 June 2003 on the prevention and reduction of health-related harm associated with drug dependence (OJ L 165, 3.7.2003, p.31).
(23) Both documents are available at: http://ec.europa.eu/health/ph_determinants/life_style/drug/drug_rec_en.htm#1 
(24) http://ec.europa.eu/employment_social/equal/index_en.cfm
Figure 2: Estimated availability of opioid substitution treatment 
in the EU-15 Member States, 1993–2005
NB:   For further information see Tables HSR-7 and HSR-8 and Figures HSR-1 and 
HSR-5 in the 2007 statistical bulletin.
Sources:  National focal points and reports; see Figure HSR-5 in the 2007 statistical 
bulletin for a detailed list of sources.
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countries that mention specific social reintegration projects 
for street children.
Programmes and actions in many countries are not 
specifically aimed at drug users but address vulnerable 
social groups in general and are typically implemented at 
local or regional level. Thus, the ‘plans de prévention de 
proximité’ (PPP) established by the Walloon government 
in 2003 address locally poverty and addiction as two 
intertwined issues, while in Denmark, the Social Services 
Act obliges municipalities to offer a social action plan to 
all drug users. Similarly, local governments in Poland have 
a legal obligation to socially reintegrate drug users, and in 
the Netherlands most new social reintegration services are 
initiated by municipalities. Finally, in Germany, shelter, 
schooling and housing are taken care of at the Länder 
level or by municipalities, while federal programmes 
for people with disabilities are available to support the 
vocational integration of drug users.
Housing assistance ranges from emergency day shelters, 
hostels and short-term residential facilities to half-way flats, 
assisted accommodation and rent subsidies. To avoid 
‘locking’ clients into longer-term service dependence, 
innovative approaches in the area of supported housing or 
financial management are being explored. For example, 
in Denmark, clients in reintegration flats are offered 
accommodation training to reduce possible future problems 
when they have to manage their own flats, and in the United 
Kingdom clients receive advice about shopping, cooking and 
the management of the household budget. 
While the creation of new opportunities for training and 
access to education is reported as common in many 
countries, paid work is harder to obtain for these groups. 
However, it is of particular importance for the target 
group as it provides not only economic stability but also 
self-esteem, status and a regular rhythm of life. New 
ways of getting clients into paid work include forming 
partnerships with private enterprises, mentoring schemes 
and providing incentives such as subsidising trainees’ 
wages or giving business start-up loans. In several 
countries, drug treatment facilities have started their 
own socio-economic enterprises, gainfully employing 
their clients. Other initiatives focus on improving the 
employment situation through better matching of profiles, 
expectations and skills with the realities of work life. For 
example, the Vienna Job Exchange acts as an intermediary 
between clients, drugs agencies and the public 
employment services, carrying out specific counselling to 
increase success rates on the job. It also helps to identify 
solutions for clients for whom occupational reintegration is 
no longer an option. 
National treatment outcome studies
Three Member States (Ireland, Italy, the United Kingdom) 
have conducted national treatment outcome studies 
aimed at investigating treatment outcome by following 
a cohort of problem drug users over time in different 
treatment modalities and settings. An important feature of 
the studies is that they investigate treatment outcomes in 
existing services under day-to-day clinical circumstances. 
Common treatment modalities examined include methadone 
maintenance, methadone reduction, detoxifi cation and 
drug-free interventions such as therapeutic communities and 
counselling. Drug use, physical and psychological health, 
retention in treatment and criminal behaviour are the main 
outcome variables used. 
In Italy, the Vedette study (1998–2001) aimed to evaluate the 
effectiveness of treatment offered in public treatment centres 
across the country. Retention in treatment and mortality 
among heroin users were the main outcome variables. To 
date, three treatment outcome studies have been instituted 
in the United Kingdom. The fi rst was the National Treatment 
Outcome Research Study (NTORS), carried out by the 
National Addiction Centre in England and Wales between 
1995 and 2000. It investigated treatment outcomes in 
residential or community treatment programmes. There were 
some positive fi ndings, such as increased rates of abstinence 
from illicit drug use, a reduction in the frequency of drug 
use, a reduction in crime and improved health. However, 
some longer-term outcomes over the fi ve-year period were 
less satisfactory, for example early improvement in the use of 
crack was partly reversed after four to fi ve years and many 
drug users continued to drink heavily (Gossop et al., 2001).
An update of the NTORS study will be provided by the Drug 
Treatment Outcomes Research Study (DTORS) being carried 
out at the University of Manchester. The study started in 2006 
and will follow drug users from across England for an initial 
12 months. It aims to evaluate the impact of drug treatment on 
a range of outcome measures and focuses on the analysis of 
which types of treatment pathways produce the best outcomes 
for particular subgroups of drug users. In Scotland, the Drug 
Outcome Research Study (DORIS), being carried out by the 
University of Glasgow, started in 2001. This study examines 
the impact and effectiveness of drug treatment services based 
at treatment agencies, including prison-based services. Drug 
users were followed up for up to 33 months. 
In Ireland, the Research Outcome Study (ROSIE) conducted 
by the National University of Ireland, Maynooth commenced 
in 2003 and evaluates drug treatment effectiveness through 
follow-up of opioid users entering treatment over a period of 
up to three years, documenting the changes observed (Cox 
et al., 2006). At one-year follow-up, the study found marked 
reductions in drug use and criminal activity, a low mortality 
rate and some positive outcomes in terms of participants’ 
physical and mental health complaints.
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The reintegration of marginalised, ageing heroin users with 
high levels of somatic and mental illness poses a particular 
challenge. In Belgium, drug users with psychiatric problems 
may be cared for in specialised substance abuse units at 
psychiatric or general hospitals, or in other psychiatric care 
facilities; Denmark reports that drug users with psychiatric 
problems are taken care of in psychiatric care facilities and 
that alternative care homes accommodate elderly drug users 
who cannot manage alone because of drug use, dementia 
or problem behaviour. In the Netherlands, a new Social 
Support Act was adopted in 2007, including drug addiction 
under the same regulations as (other) chronic psychiatric 
problems. However, a large centralised residential facility 
to accommodate 120 homeless drug users with psychiatric 
problems met with local objections. For those with mental 
health problems, professional help to re-establish a network 
of support and contact persons is identified as an important 
component of the social reintegration process.
In some countries (e.g. Bulgaria, the Czech Republic, 
Greece, Slovenia), structured reintegration programmes are 
provided only as a follow-on from successfully completed 
abstinence-based drug dependence treatment, and specific 
reintegration measures for clients in drug maintenance 
treatment are currently not available. 
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Chapter 3
Cannabis
Introduction: the changing picture 
of cannabis use in Europe
Cannabis is the world’s most commonly used illicit drug 
and a substance that has been at the centre of the drugs 
debate in Europe since the 1960s when its use became 
virtually synonymous with a growing youth counterculture. 
Despite this familiarity, understanding the patterns of 
cannabis use in Europe is a complicated task. One important 
element in this picture is the different cannabis products 
now available on the European market. Historically, three 
main forms of cannabis have been common in Europe: 
cannabis resin; herbal cannabis; and, far less frequently, 
cannabis oil. For many, the smoking of cannabis resin with 
tobacco remains the usual route of administration for the 
drug, though, elsewhere in the world, this pattern of use is 
relatively uncommon. While Europe remains the dominant 
global market for cannabis resin, herbal cannabis products 
appear to be becoming more common and predominate in 
some markets. In recent years, this picture has grown more 
complicated still with the increasing availability of cannabis 
produced within Europe; some of which is grown under 
controlled conditions and can be of relatively high potency. 
This kind of cannabis has become a specific product in its 
own right in many countries and complicates the assessment 
of the public health impact of changing patterns of cannabis 
consumption.
Supply and availability 
Production and trafficking
Because cannabis can be grown in a range of different 
environments and grows wild in many parts of the world, 
it is extremely difficult to produce convincing estimates 
of global production. Following an upward trend over 
several years, taking into account information on the 
diversification of cannabis production, the UNODC has 
reduced its global estimates of herbal cannabis production 
from 45 000 tonnes in 2004 to 42 000 tonnes in 2005, 
mainly due to falling production estimates from North 
America following intensified cannabis eradication efforts. 
It is now estimated that about half of all cannabis is grown 
in the Americas (46 %), followed by Africa (26 %) and then 
Asia (22 %) (UNODC, 2007).
Morocco remains the main international producer of 
cannabis resin, and although recent survey work suggests 
that the area under cannabis cultivation decreased by 
around 40 % between 2004 and 2005, it is still estimated 
that the country produces some 70 % of the cannabis resin 
consumed in Europe. Based on estimates of the total area 
under cultivation, Morocco had a potential production of 
1 066 tonnes in 2005, with most Moroccan cannabis bound 
for the European and North African markets (CND, 2007; 
Interpreting seizures and other market data
Drug seizures in a country are usually considered an indirect 
indicator of the supply and availability of drugs, although 
they also refl ect law enforcement resources, priorities 
and strategies, as well as the vulnerability of traffi ckers to 
national and international supply reduction activities, and 
reporting practices. Quantities seized may fl uctuate widely 
from one year to the next, for example if in one year a few 
of the seizures are very large. For this reason, the number 
of seizures is sometimes a better indicator of trends. In all 
countries, the number of seizures includes a major proportion 
of small seizures at the retail (street) level. Where known, 
origin and destination of drugs seized may indicate traffi cking 
routes and producing areas. The price and purity/potency 
of drugs at retail level are reported by most of the Member 
States. However, data come from a range of different 
sources, which are not always comparable, making accurate 
comparisons between countries diffi cult.
In order to view European drug seizures in a wider context, 
in this report summary information is presented on the 
global situation. The United Nations Offi ce on Drugs and 
Crime produce an annual report on the international drug 
situation and this is the principal source used for the world 
estimates included here. The reader should note that there 
are diffi culties in compiling information of this sort and, in 
many parts of the world, information systems are poorly 
developed. Therefore, these data should be viewed as the 
best approximations possible from the information resources 
currently available.
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UNODC and Government of Morocco, 2007). Cannabis 
resin is smuggled to Europe via the Iberian peninsula. 
Although Morocco is by far the major resin producer for 
the European market, resin from other countries (Moldova 
and India) is reported to be available, particularly in central 
European countries.
If cannabis resin in Europe tends to be a fairly uniform 
product, the same cannot be said of herbal cannabis. The 
origin of seizures reported in 2005 includes Albania, the 
Netherlands, countries of the former Yugoslavia, Angola 
and South Africa. Although domestic production of herbal 
cannabis is difficult to monitor systematically, in 2005, 
it was noted in half of the reporting countries. Some 
cannabis produced in Europe is grown outdoors and can 
be considered virtually indistinguishable from imported 
herbal cannabis. However, relatively high-potency cannabis 
grown under intensive conditions seems to be becoming 
an important and possibly growing part of the market in 
many countries and equipment that allows users to produce 
cannabis at home is now widely available through the 
Internet or, in some countries, from specialist suppliers. The 
fact that this form of the drug is grown inside and often in 
close proximity to the intended market may mean that it is 
less commonly intercepted and, therefore, less visible in the 
available data. 
Seizures
In 2005, global seizures of cannabis resin totalled 
1 302 tonnes as compared to 4 644 tonnes of herbal 
cannabis; both totals were down on the 2004 figures. 
Western and central Europe continued to account for the bulk 
of resin seized (70 %), while quantities of herbal cannabis 
seized remained concentrated in North America (64 %) 
(UNODC, 2007). 
An estimated 303 000 seizures of cannabis resin amounting 
to 909 tonnes were made in Europe in 2005 (25), with Spain 
accounting for about half of all seizures and for around 
three-quarters of the total quantity seized (26). A slight 
increase in the number of reported resin seizures in 2005 
continued the upward trend observed since 2000. However, 
this was not true for the quantity of resin intercepted, which 
fell in 2005, after increasing in the period 2000–04.
The relative position of resin and herbal cannabis can be 
seen by the fact that in 2005 there were only about half as 
many herbal cannabis seizures (152 000) and less than 
one tenth of the volume seized (66 tonnes). The numbers of 
herbal cannabis seizures in Europe have steadily increased 
over the last five years, although the picture for quantities 
seized appears less clear, with a possible increase in 2005 
(25) The data on European drug seizures that this section is based on can be found in Tables SZR-1, SZR-2, SZR-3 and SZR-4 in the 2007 statistical bulletin.
(26) This should be checked against missing 2005 data when available. For estimating purposes, 2005 missing data were replaced by 2004 data. 
Cannabis for personal use: the legal status
Despite the different legal approaches towards cannabis 
across the Member States (1), a general trend in Europe 
can be seen in the development of alternative measures 
to criminal conviction, for cases of use and possession 
of small quantities of cannabis for personal use without 
aggravating circumstances. Cannabis is now frequently 
distinguished from other illicit substances either in the law, 
by prosecutorial directive, or by the judiciary practice. In 
most European countries, the move has been away from 
custodial sentences and towards fi nes, cautions, probation, 
exemption from punishment and counselling. Examples of 
this trend can be found in a number of recent measures, 
including the removal of custodial penalties in Luxembourg 
in 2001 and Belgium in 2003, and reduction of custodial 
penalties in Greece in 2003 and the United Kingdom in 
2004. Directives to police or prosecutors were issued in: 
Belgium in 2003 and 2005, France in 2005, and the United 
Kingdom in 2004 and 2006. In 2006, the Czech Republic 
almost established different classes for non-medicinal drugs, 
but that draft of the Penal Code was rejected for unrelated 
reasons. Despite this, the number of reported cannabis 
offences continues to rise in Europe (see Chapter 1).
The cannabis debate remains contentious and considerable 
disagreement remains over the relative costs and benefi ts 
of different public health and criminal justice responses. 
This is refl ected in the fact that not all measures have gone 
in the direction of easing penalties and, in some countries, 
penalties have been made more severe or the current 
situation is under critical review. In 2004, a directive to 
prosecutors in Denmark called for fi nes to be issued instead 
of warnings and in Italy, in 2006, the legal distinction 
between non-medicinal drugs was removed, discouraging 
the notion of a distinction between ‘soft’ and ‘hard’ drugs. 
Other countries have been reviewing their current response 
to cannabis; for example the Netherlands published a 
specifi c cannabis strategy in 2005 and Germany carried out 
an evaluation of the implementation of penalties for simple 
cannabis possession.
Cannabis policy remains an issue that generates 
considerable public discussion and disagreement. This can 
be seen in the fi ndings of the recent Eurobarometer survey 
(2006), which asked European citizens if they agreed with 
the statement that personal consumption of cannabis should 
be legalised throughout Europe. Just over two thirds (68 %) 
of those asked disagreed and around a quarter (26 %) 
agreed with this proposition. In all countries, although 
the proportion of those sampled that favoured continued 
prohibition varied, it was always the majority view.
(1) For a fuller discussion see the ELDD topic overview: 
http://eldd.emcdda.europa.eu/?nnodeid=5036
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after a period of falling quantities between 2001 and 2004. 
Conclusions here are necessarily preliminary as the United 
Kingdom, a country responsible for most herbal cannabis 
seizures in terms of both numbers and quantities, has not yet 
reported data for 2005.
In 2005, an estimated 13 500 seizures in Europe resulted 
in the interception of about 24 million cannabis plants (most 
of them in Turkey) and 13.6 tonnes of cannabis plants (most 
of it in Spain). Overall, the number of seizures of cannabis 
plants in Europe shows a continuous upward trend since 
2000. If we look at the EU Member States, the number of 
cannabis plants seized peaked in 2001 and increased 
again since 2003, whereas in Turkey after an increase in 
the period 2001–03, the number of cannabis plants seized 
decreased in 2004 and increased again in 2005.
Price and potency
In 2005, the average retail price of both cannabis 
resin and herbal cannabis varied, both between and 
within countries, with the majority of countries reporting 
prices for cannabis products in the range EUR 4–10 per 
gram (27). However, reported average or typical prices 
for both types of cannabis ranged from EUR 2 per gram 
to over EUR 15. Mean prices of cannabis resin, corrected 
for inflation, fell over the period 2000–05 in all reporting 
countries except Poland, where prices remained stable. 
Mean prices of herbal cannabis, corrected for inflation 
also decreased or remained stable over the same period in 
all reporting countries except Slovenia (28). 
The potency of cannabis products is determined by their 
content of delta-9-tetrahydrocannabinol (THC), the primary 
active constituent (EMCDDA, 2004). In 2005, the reported 
average or typical THC content of cannabis resin at retail 
level was reported to vary from less than 1 % to 17 %; such 
a range of variation is difficult to explain given the common 
source of most European resin. Herbal cannabis potency was 
reported to range from less than 1 % to just over 15 %. It is 
not possible to distinguish between domestically produced 
herbal cannabis and imported in the data available; 
however, the Netherlands was able to produce an estimate 
of 17.7 % for locally produced herbal cannabis (29). 
Prevalence and patterns of cannabis use
Among the general population
The more recent survey data confirm the picture of cannabis 
use as the most frequently used illicit substance in Europe. 
During the 1990s, the use of the drug, particularly among 
young people increased in virtually all countries. However, 
some of the more recent data suggest that the upward trend 
is levelling off, albeit at historically high levels. An important 
secondary question is to explore trends among those using 
the drug intensively and for long periods of time. Here, the 
data is less good but concern exists that more young people 
Surveys: an important tool for understanding patterns 
and trends of drug use in Europe
Drug use in the general or school population is assessed 
through surveys, which provide estimates of the proportion of 
people that declare having used drugs over defi ned periods 
of time: lifetime, last year or last month. 
The EMCDDA, in association with national experts, has 
developed a set of common core items (the ‘European Model 
Questionnaire’, EMQ) for use in adult surveys, and this has 
been implemented in most EU Member States. Details of the 
EMQ are included in ‘Handbook for surveys about drug use 
among the general population’ (http://www.emcdda.europa.
eu/?nnodeid=1380). However, there are still differences 
between countries in methodology and year of data 
collection, and small differences between countries should be 
interpreted with caution (1).
As surveys are expensive to conduct, few countries collect 
information annually. In this report, data is presented based 
on the most recent survey available, which in most cases will 
be between 2003 and 2006. 
Three measures of drug use over time are commonly used 
for reporting survey data. Lifetime use or prevalence is the 
broadest. This measure is commonly used for reporting 
on very young groups, for example school children, but is 
of limited value in refl ecting the current situation among 
adults, although it may provide insight into patterns of use 
and incidence. In this report, the focus is on reporting use in 
the last year and in the last month, as these two measures 
better refl ect the present situation, with the latter category 
often serving as a proxy measure for regular use. Clearly, 
identifying those who are using regularly or having problems 
with their use of drugs is important, and some progress has 
been made in this respect with the development of scales to 
assess more intensive forms of use; and these are included 
where they are available (see the box on developing 
psychometric scales, p. 42).
(1) EMCDDA standard age ranges: all adults (15 to 64 years) and 
young adults (15 to 34 years). Data from some countries cover 
slightly different age ranges (e.g. 16–64, 18–64, 16–59 years). For 
more information about methodology of population surveys and the 
methodology used in each national survey, see the 2007 statistical 
bulletin.
(27) See Table PPP-1 in the 2007 statistical bulletin.
(28) Data on price of both cannabis resin and herbal cannabis were analysed for 19 countries (in which data for at least three consecutive years were available).
(29) Data on cannabis potency can be found in Tables PPP-2 and PPP-5 in the 2007 statistical bulletin.
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are using cannabis in this fashion and that this fact may 
in part be reflected in the increases in cannabis treatment 
demands that have been observed in some countries.
It is conservatively estimated that cannabis has been used 
at least once (lifetime prevalence) by more than 70 million 
European adults, that is on average nearly a quarter (22 %) 
of all 15- to 64-year-olds (30). National figures vary from 
2 % to 37 %, with the lowest figures in Bulgaria, Malta and 
Romania, and the highest in Denmark (36.5 %), France 
(30.6 %), the United Kingdom (29.8 %) and Italy (29.3 %) (31). 
Despite this wide overall range, 12 European countries out of 
the 26 that provided information reported lifetime prevalence 
rates in the range 10–25 % (32).
Moving the point of reference from lifetime to last year, 
the levels of reported cannabis use fall but still remain 
considerable. Estimates suggest that more than 23 million 
European adults have used cannabis in the last year, 
producing an average figure of about 7 % of all 15- to 
64-year-olds. National figures range between 1 % and 
11.2 %, with the lowest figures reported by Bulgaria, 
Greece and Malta, and the highest by Italy (11.2 %), Spain 
(11.2 %), the Czech Republic (9.3 %) and the United Kingdom 
(8.7 %). Again, despite the wide overall range, 13 out of 
the 25 countries that provided information reported last year 
prevalence estimates between 4 % and 9 % (Figure 3).
Estimates of last month prevalence will include people using 
cannabis more regularly, although not necessarily in an 
intensive way. It is estimated that 13.4 million Europeans 
adults used the drug in the previous month, on average 
about 4 % of all 15- to 64-year-olds. Country figures range 
between 0.5 % and 8.7 %. The lowest figures were reported 
by Bulgaria, Malta, Lithuania and Sweden, and the highest 
from Spain (8.7 %), Italy (5.8 %), the United Kingdom (5.2 %) 
and France (4.8 %). Of the 26 countries that provided 
information, figures from 13 countries fall within the range 
2 % to 6 % (33).
Cannabis use among young adults
Cannabis use is disproportionately high among young 
people, with, depending on the country surveyed, between 
3 % and 49.5 % of young European adults (15–34 years) 
reporting having ever used cannabis, 3–20 % reporting 
use in the last year, and 1.5–15.5 % reporting use in the 
last month. The highest lifetime figures are reported from 
Denmark, France, the United Kingdom and Spain, with the 
highest reported levels of last year prevalence from Spain, 
the Czech Republic, France and Italy. On average 30 % 
of young adults report lifetime use and 13 % use in the last 
year, and over 7 % report use in the last month. As a point 
of comparison, last year and last month estimates for adults 
aged 35 to 64 years, are 3 % and 1.6 % respectively (34). 
If attention is restricted to young people in the 15- to 
24-year age range, prevalence estimates for lifetime use 
range between 3 % and 44 % (with most countries reporting 
figures in the range 20–40 %). Last-year prevalence rates 
range from 4 % to 28 % (in most countries 10–25 %); and 
last month prevalence rates are between 1 % and 19 % (in 
most countries 5–12 %). Among males in this age group, 
prevalence estimates are higher still. Lifetime use was 
reported by 11–51 % of young males (in most countries 
25–45 %), use in the last year was reported by 5–35 % 
(in most countries 15–30 %), and last month use by 
1.7–23.7 % (in most countries 6–20 %) (35).
Patterns of cannabis use
As noted above, the use of cannabis, as with most other 
illegal drugs, is notably higher among younger people, 
although even here considerable country variation can 
be found. Use is also notably higher among males than 
among females, although this difference tends to be less 
pronounced for young people. In general, the ratio of men 
to women increases in more recent measures of use and, 
again, considerable country variation can be observed, for 
example, gender ratios for reported use of cannabis in the 
last month range from 1.5 in Italy to 1.14 in Lithuania (see 
the 2006 selected issue on gender and drug use). 
For many, cannabis use tends to be discontinued after a 
short experimental period and rates of use generally decline 
as individuals grow older. Tracking the careers of cannabis 
users in the available data and identifying changes over time 
in consumption patterns is, however, difficult. Some insight 
into this issue can be gained by comparing reported lifetime 
use with more recent consumption measures. On average, 
this analysis suggests that 32 % of all adults (15–64 years) 
who have ever used cannabis have done so in the last year 
and 18 % in the last month. These proportions, sometimes 
known as ‘continuation rates’, vary considerably across 
countries, and will be influenced by a number of factors 
(30) The average proportion was computed as the average of national prevalence rates weighted according to the population of the relevant age group in each 
country. Total numbers were computed by multiplying prevalence among the population concerned in each country and, in countries for which no information 
was available, imputing the average prevalence. Figures here are probably a minimum, as there could be some under-reporting.
(31) In this text, the United Kingdom figures are based on the 2006 British Crime Survey (England and Wales), due to practical reasons. There are additional 
estimations for Scotland, Northern Ireland and a combined estimation for the United Kingdom is available (presented in the 2007 statistical bulletin). 
(32) See Table GPS-8 in the 2007 statistical bulletin.
(33) See Table GPS-12 in the 2007 statistical bulletin.
(34) See Table GPS-9, GPS-11 and GPS-13 in the 2007 statistical bulletin.
(35) See Tables GPS-17, GPS-18 and GPS-19 and Figures GPS-1, GPS-3, GPS-7 and GPS-12 in the 2007 statistical bulletin.
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including the historical development of cannabis use within 
a country and the number of new cases. Nonetheless, 
understanding the proportion of cannabis users that go on to 
regular and long term patterns of use is likely to be important 
for understanding the potential public health impact of the 
use of this substance. Despite concerns that there may be 
a growth in the number of those using the drug regularly 
or intensively (36), there is currently very little information 
available to allow this issue to be explored. The EMCDDA is 
currently working closely with a number of Member States on 
the development of a better methodological approach to this 
issue. A crude estimation made by EMCDDA in 2004, based 
on limited data, suggested that around 1 % of European 
adults, or about 3 million people, may be ‘daily or almost 
daily’ cannabis users. It is planned that this estimation can be 
updated in the near future. Several countries have reported 
increases of regular or intensive cannabis use, but only Spain 
reported comparable data on ‘daily use’ (37) which increased 
from 0.7 % in 1997 to 2 % in 2006. 
Another important information need in this area is to better 
understand the factors associated with discontinuing use. As 
noted above, most of those who initiate cannabis use will 
discontinue it after an interval of time. Understanding the 
factors associated with giving up is clearly important for the 
design of interventions in this area. Some information in this 
area is becoming available, for example, the 2005 French 
population survey noted that among those who had ever 
used cannabis, but have not used it in the last year, for most 
(80 %) the main reason for not using the drug was simply 
a lack of interest in a drug; this is despite the fact that most 
adults (almost 60 %) considered that they could easily obtain 
cannabis if they wanted to. 
(36) There is as yet no universally accepted definition of ‘intensive cannabis use’. It is, however, a broad term meaning use of cannabis that exceeds a certain 
threshold of frequency. It does not necessarily imply the existence of ‘dependence/abuse’ or other problems, but it is considered to increase the risk of negative 
consequences, including dependence. In this chapter, figures refer to ‘daily or almost daily use’ (defined as use on 20 or more days out of the last 30 days). 
This benchmark has often been used in studies and can be derived from the European model questionnaire. Ongoing methodological studies (national and 
EMCDDA) will help to understand better relationships between intensive/frequent use and problems (see box on developing psychometric scales, p. 42).
(37) 1997 (0.7 %), 1999 (0.8 %), 2001 (1.5 %), 2003 (1.5 %), 2005/06 (2 %). This measure (use on 30 days during last 30 days) is different from the previously 
used ‘daily or almost daily use’ (use 20 days or more during last 30 days), which will produce a higher estimation. In France, a ‘regular consumer’ is defined 
as using the drug ‘10 times or more in the last 30 days’ (4.3 % of adult males, 1.3 % of adult females). In the United Kingdom, ‘frequent use’ is considered ‘use 
more than once per month in the last year’, and is not comparable with measures used in this section.
Figure 3: Last year prevalence of cannabis use among all adults (aged 15–64) and young adults (aged 15–34 and 15–24)
 (1)   England and Wales.
NB:   Data are from the most recent national surveys available in each country at the time of reporting. Countries are ordered according to the overall (all adults) prevalence. 
See Tables GPS-10, GPS-11 and GPS-18 in the 2007 statistical bulletin for further information.
Sources:  Reitox national reports (2006), taken from population surveys reports or scientific articles.
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Trends in cannabis use among adults
Tracking trends in drug use in Europe is made difficult by 
the absence in many countries of reliable time series data. 
However, an increasing number of countries have launched 
surveys from the 1990s onwards, and these are now 
beginning to provide valuable insight into trends over time.
Time series provided by surveys can shed light on the 
development of cannabis use in Europe. One finding is that 
there are important temporal differences between countries 
and waves of popularity observable in the use of the drug 
since it began to become popular in the 1960s (38). An 
example of this is data from Sweden (2005 Reitox national 
report) where a relatively high level of experimentation was 
reported in the 1970s among conscripts and school students, 
followed by a substantial decrease in the 1980s, and then 
a new rise during the 1990s to levels similar to those of the 
1970s followed by a subsequent decrease in more recent 
years. A similar phenomenon is seen in the Finnish data with 
major drug waves, first in the 1960s and then again in the 
1990s. 
From the survey evidence, it can be concluded that cannabis 
use increased markedly during the 1990s in almost all EU 
countries. This increase has continued until recently in many 
countries, although there are now signs of stabilisation in 
some countries, especially among what can be considered 
the high-prevalence group. An example here is the United 
Kingdom, which in general terms often appears to be a 
‘frontrunner’ in respect to drug-use trends. During the early 
1990s, the United Kingdom stood out as a high-prevalence 
country, reporting on most measures the highest prevalence 
figures in Europe. However, last year prevalence levels 
among young adults (16–34) stabilised from 1998 and 
have fallen between 2003 and 2006 (20.0 % to 16.3 %). 
Interestingly, in the youngest age group (16–24), a steady 
decrease has been observed since 1998, suggesting that 
cannabis use has become less popular among the young (39). 
Levels of cannabis use in France, Spain and Italy have all 
began to approach the United Kingdom prevalence levels in 
recent years (2002, 2003 and 2005 respectively), following 
a period of steady increases. Again, some evidence of 
stabilisation in the situation is becoming apparent: France 
reported a decrease in use in 2005; and although Spain 
reports a slight increase until 2006, overall there are signs 
that the trend may be levelling off in the most recent data. In 
the Czech Republic, a country with high prevalence rates, 
trends are difficult to assess within the data available — 
although the information for young adults suggests that 
prevalence levels may have fallen slightly. 
Among the middle and lower ranking countries in terms of 
last year prevalence among young adults (15–34 years), 
the latest data from Denmark and the Netherlands show 
a slight fall, while levels of use still appear to be increasing 
in Estonia, Germany, Hungary, Slovakia and Norway (40). 
However, most of these increases are small and, in general, 
less pronounced in the more recent estimates. 
Finland and Sweden remain among the countries reporting 
the lowest levels of cannabis use and, although prevalence 
(38) See also Figure 4 in the 2004 annual report.
(39) See Figure GPS-10 in the 2007 statistical bulletin.
(40) See Figure GPS-4 in the 2007 statistical bulletin.
Developing psychometric scales to identify 
intensive, dependent and problematic cannabis use 
in survey data 
Descriptions on drug use from surveys are based on 
self-reported behaviour over different time intervals. 
Historically, daily use has not been monitored systematically, 
in part because in most countries the prevalence of cannabis 
use was low. And, the approach of restricting attention to 
use in the last month does not allow estimates of the number 
of intensive users to be made with any precision. However, 
as cannabis use has increased across Europe and concerns 
about cannabis problems have grown, this approach has 
had to be reconsidered. In fact, nearly all EU countries now 
collect information on how many days the drug has been used 
in the month prior to interview. Based on this information, 
it is estimated that around 3 million people may be using 
cannabis daily or almost daily. 
The EMCDDA is working with national experts to improve 
the reporting of this kind of intensive use in population 
survey data. However, this still provides only a blunt tool for 
identifying those who are suffering problems or dependence 
because of their use of cannabis. This information is crucial 
to understanding the public health impact of cannabis 
consumption and is currently a key issue for the EMCDDA 
expert survey group. 
Current work is under way to develop the methodological and 
conceptual framework necessary for monitoring ‘intensive 
forms of drug use’ that could be used in population surveys 
to better identify those experiencing problems. Some 
countries are now starting to measure ‘dependence’ on or 
‘problematic use’ of cannabis among the general population, 
with pioneering projects under way in Germany, France, the 
Netherlands, Poland, Portugal, the United Kingdom and, most 
recently, Spain.
An example of why this work is important can be found in 
the experience of the 2005 French survey which included the 
experimental CAST scale (cannabis abuse screening test); on 
this measure, a preliminary analysis suggested that as many 
as 16 % of those using cannabis in the last year and 58 % of 
daily users could be at risk of problematic use.
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estimates have increased, there is no suggestion of 
convergence with higher prevalence countries. The increase 
observed in Sweden between 2000 and 2004 in last year 
prevalence among young adults (1.3 % to 5.3 %), although 
large, is difficult to interpret because of methodological 
changes in the way the survey was conducted, and 
prevalence estimates in the 2004, 2005 and 2006 surveys 
suggest a stable situation. 
Among school students
Another useful window on cannabis patterns and trends 
is provided by school survey data, which show levels of 
cannabis use increasing in many EU countries during the late 
1990s and early 2000s. 
Overall, the general picture emerging from the school survey 
data reflects that found in adult surveys. The highest rates of 
lifetime prevalence of cannabis use among school students 
aged 15–16 years in Europe are reported by Belgium, the 
Czech Republic, Ireland, Spain, France and the United 
Kingdom: all report rates between 30 % and 44 % and 
Germany, Italy, the Netherlands, Slovenia and Slovakia 
report rates above 25 %. As a point of contrast, Greece, 
Cyprus, Romania, Sweden, Turkey and Norway all report 
lifetime prevalence estimates lower than 10 %. 
Analysis of data from the first three rounds of the ESPAD 
(European schools project on alcohol and other drugs) 
survey (1996–2003) showed marked geographical 
differences in trends in lifetime prevalence of cannabis use 
among school students aged 15–16 years. Countries can 
be categorised into three geographical groups. In Ireland 
and the United Kingdom, which have long histories of 
cannabis use, lifetime prevalence is high but has remained 
stable during the last decade. In the eastern and central 
European Member States, together with Denmark, Spain, 
France, Italy and Portugal, lifetime prevalence of cannabis 
use increased substantially between 1995 and 2003. In 
the third group of Member States (Finland and Sweden in 
the north and Greece, Cyprus and Malta in the south) plus 
Norway, estimates of lifetime prevalence among school 
students have remained at relatively low levels (around 
10 % and below). Data from the next round of the ESPAD 
study is expected next year.
Only four countries (Italy, Poland, Sweden, the United 
Kingdom) reported new data from national school surveys 
in 2005, and Belgium reported a survey from the Flanders 
region. In Sweden the situation appeared stable and slight 
decreases were noted in the other four surveys.
Cannabis: treatment demand data (41)
Treatment demand patterns overall
Among the total of 326 000 treatment demands reported 
in 2005 (data available from 21 countries), cannabis was 
the primary reason for entering treatment in about 20 % of 
all cases, making it the next most commonly reported drug 
after heroin. The greatest demand for treatment for primary 
cannabis use is usually in outpatient settings (42).
Drug clinic clients are often reported as problematically 
using other drugs along with the primary drug for which 
they seek treatment; this is less often the case for cannabis 
users, who are the clients most often reported as using only 
one substance (cannabis). Some, though, do use cannabis 
in combination with other drugs, most often alcohol (37 %) 
and amphetamines or ecstasy (28 %). After alcohol (38 %), 
cannabis is reported as the second most frequently cited 
secondary substance by those receiving treatment (43).
Increasing treatment demands
Among the approximate 130 000 new demands for 
drug treatment, cannabis clients represent 29 % of all 
new drug clients, following closely the proportion of 
new heroin treatment demands (35 %; data available 
from 22 countries) (44). Although problems concerning 
the availability of data make commenting on trends with 
precision difficult, the main trends in demands for cannabis 
treatment can be identified. Between 1999 and 2005, 
the total numbers of both new and all reported cannabis 
treatment demands have approximately trebled. However, 
the upward trend seems to be stabilising in the most recent 
data. In all countries (except Lithuania), among new clients, 
the proportion reported as seeking treatment for primary 
cannabis use is higher than the corresponding proportion 
among all clients (45). 
Over the period 1999–2005, the proportion of clients 
seeking treatment for primary cannabis use increased in 
all the countries that reported data (Figure 4). However, 
there are interesting variations between countries, with 
cannabis being cited by less than 5 % of all clients reported 
as entering treatment in Bulgaria, Lithuania, Poland and 
Romania and by more than 30 % in Hungary and France. 
For the remaining countries, in 12 the proportion of 
(41) The analysis of the general distribution and the trends is based on the data on clients demanding treatment in all treatment centres; the analysis of the profile of 
clients and the patterns of drug use is mainly based on the data from outpatient treatment centres. 
(42) See Figure TDI-2 in the 2007 statistical bulletin.
(43) See Tables TDI-22 and TDI-23 (part i) and (part iv) in the 2007 statistical bulletin.
(44) See Figure TDI-2 in the 2007 statistical bulletin.
(45) See Tables TDI-3 (part iii) and TDI-5 (part ii) in the 2007 statistical bulletin.
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cannabis clients is between 5 % and 20 % and in seven it is 
between 21 % and 29 %. Similarly, among new treatment 
demands, there are considerable variations between 
countries, with cannabis being cited by less than 10 % of 
new clients in Bulgaria, Lithuania, Luxembourg, Poland and 
Romania and by more than 50 % in Denmark, Germany, 
France and Hungary (46). 
The increase in the demand for cannabis treatment does not 
appear to have a simple explanation. The extent to which 
increased demand for treatment is a result of increases in 
the prevalence of intensive cannabis and related problems 
in the population, and an increased perception of the risks 
remains unclear. Other factors might have also contributed 
to it, including better data coverage of outpatient treatment 
agencies seeing cannabis clients, which are typically the 
centres for cannabis treatment demand, and possibly more 
diagnosis and reporting on problematic cannabis use. 
Contributions from two other possible causes should also 
be considered: the diversification of the treatment offer, for 
example the opening of cannabis treatment centres in France 
in late 2004, and the increase in the number of referrals from 
the criminal justice system. In the first case, in response to 
increasing demand for cannabis treatment, several countries 
have implemented specific programmes for adolescents or 
young people, with a treatment offer more targeted towards 
cannabis users; here, an increase in demand has produced 
an increase in offer which, in turn, may have accentuated 
the demand. In the second case, referrals from the criminal 
justice system are often related to offences associated to 
cannabis use; research findings show that the majority of 
people diverted to treatment from the criminal justice system 
have cannabis as the primary drug of use; in this scenario, 
an increase in the number of referrals from the criminal 
justice system will have contributed to the increased demand 
for cannabis treatment. 
Client profiles
Whatever the explanatory factors that have led to increases 
in demand for cannabis treatment, the characteristics 
of those who end up seeking treatment are of interest, 
although it cannot be suggested that this tiny fraction of the 
cannabis-using population is representative. Looking at the 
profile of people entering outpatient treatment for a primary 
cannabis use, the most common characteristics are being 
young, male, still in education as opposed to employed or 
unemployed, and living with their parents as opposed to 
having their own accommodation (47). Compared to the other 
drug clients, people entering treatment for primary cannabis 
use have the highest proportion of males and the youngest 
age (mean age 24.5 years). Those entering treatment for the 
first time are even younger than all cannabis clients (mean 
age 23.8); correspondingly 67 % and 80 % of those aged 
15–19 or younger than 15 years are new cannabis clients. 
However, in the last three years, indications of an increase 
in the age of new cannabis clients are reported (48). Overall, 
cannabis clients can be divided into three groups: those who 
use it occasionally (34 %), those using it once to several times 
a week (27 %) and those using it daily (39 %). 
It is likely that these differences in reported use of the drug 
among cannabis clients are the result of different referral 
routes into treatment, and speculation might be that the 
increase in referrals from the criminal justice system may 
be associated with some of those with low consumption 
levels reported as entering treatment. There are differences 
between countries in the frequency of cannabis use, with 
half of the countries reporting more than 30 % of clients as 
daily cannabis users and the other half with less than 30 %. 
The Netherlands, Denmark and Spain have the highest 
proportions of regular users among clients in treatment, while 
Hungary, Germany and Italy report the highest proportion 
of occasional users (49). In addition, as discussed below, 
(46) See Tables TDI-5 (part ii) and TDI-4 (part ii) in the 2007 statistical bulletin.
(47) See Tables TDI-13, TDI-14 and TDI-21 (part i) and (part ii) in the 2007 statistical bulletin. 
(48) See Table TDI-10 (part i), (part ii) and (part ix) in the 2007, 2006 and 2005 statistical bulletins.
(49) See Table TDI-18 (part iii) and (part iv) in the 2007 statistical bulletin.
Figure 4: Trends in pattern of use of treatment services (1999–2005) — 
principal drug for which clients ask treatment as a percentage of all 
requests
NB:   Based on data from 21 EU Member States: Bulgaria, the Czech Republic, 
Denmark, Germany, Ireland, Greece, Spain, France, Italy, Cyprus, Lithuania, 
Luxembourg, Hungary, Malta, the Netherlands, Romania, Slovenia, Slovakia, 
Finland, Sweden and the United Kingdom.
   Missing data were interpolated for each country by maintaining the average 
EU trend in the available data for each year.
   For more information and detailed notes see Figure TDI-3 in the 2007 statistical 
bulletin.
Sources:  Reitox national focal points.
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the focus of responses to intensive cannabis use may be on 
prevention rather than treatment, and such differences in 
national practice may affect overall levels of reporting; this 
may in part explain why some high-prevalence countries 
report relatively low cannabis treatment figures. 
Responding to cannabis problems
Data on cannabis treatment has to be seen in the context 
of what constitutes cannabis treatment in Europe, which 
currently covers a broad continuum of measures that range 
from brief interventions to treatment in residential settings. In 
some of the programmes, the orientation is as much towards 
prevention and harm reduction as towards the treatment of 
drug problems. 
Identifying those at risk and intervening early is recognised 
as an important component of all drug programmes, and 
teaching staff may be among the first to identify cannabis 
among their pupils. Germany, Italy and Poland all have 
developed programmes for teachers that help them respond 
to cannabis use and seek specialist help when this is 
appropriate.
No strong evidence base exists to inform cannabis treatment 
practice, and research studies in this area are limited and 
mainly based on American and Australian experiences. 
In Europe, the most common reported approaches to 
cannabis problems include: short-term outpatient services, 
counselling, school-based programmes and outreach 
prevention activities. Generally, interventions appear to be 
based on brief-intervention approaches using a combination 
of motivational interviewing and cognitive-behavioural 
elements. Although no strong consensus exists on what 
constitutes effective practices, some studies have suggested 
this kind of approach can be useful. One European 
initiative in this area is the Incant project, where Belgium, 
France, Germany, the Netherlands and Switzerland have 
cooperated on exploring the value of multidimensional 
family therapy (MDFT) with cannabis users. After receiving 
a positive pilot phase evaluation (Rigter, 2005), this project 
has been expanded into a multi-site, randomised controlled 
trial comparing MDFT to standard treatments for cannabis 
disorders.
Only 13 Member States report the availability of specialised 
treatment facilities for problematic cannabis users, 
suggesting that most cannabis users are seen in general drug 
programmes or generic health or youth services. Concerns 
have been raised that it may be inappropriate to treat young 
cannabis users in general drug services if this leads to clients 
mixing with older, problematic users of other drugs. Although 
the extent to which this is a problem remains unclear, it 
remains an important question for planning services in this 
area.
France provides an example of a specialised service for 
cannabis users where 250 cannabis consultation centres 
have been created in 2005. These centres are now seeing an 
estimated 2 900 clients per month with around a third of the 
clients (31 %) being self-referred, or referred by a third person 
(31 %) and just over a third being referred by court decision 
(38 %). Other examples of specific treatment programmes for 
cannabis users include the Maria Youth Centre in Sweden, 
which provides young problematic cannabis users with a 
counselling programme, followed by support sessions. And 
in Germany, a modular therapy of cannabis-related disorders 
for adolescents (Candis) has been developed at the Research 
Outpatient Department in Dresden since January 2006.
Quasi-compulsory interventions
Despite a general move towards directing cannabis users 
coming into contact with the criminal justice system towards 
treatment and counselling services rather than penal 
sanctions, the availability and structure of these mechanisms 
differ substantially across Europe with few countries 
(Germany, France, Luxembourg, Austria, Sweden) reporting 
offering structured programmes or services.
For cannabis users referred from court services, treatment 
interventions are not the only kind of response noted. 
Occasional users are offered intensive courses in some 
countries, for example Germany, Austria and Luxembourg all 
report courses aimed at changing the beliefs and patterns of 
use of cannabis users (50).
New communication strategies for engaging 
with cannabis users
A number of innovative programmes in Europe attempt to 
exploit new communication tools for engaging with cannabis 
users. In some countries (Germany, the United Kingdom) 
Internet-based brief interventions have been developed that 
allow cannabis consumers to audit their current use and 
self-identify problems. An example of this approach is the 
German ‘quit the shit’ (51), which offers support to users who 
wish to stop using cannabis. An evaluation study found 
that those using this service reported reduced cannabis 
consumption, both in terms of quantity used and number of 
days on which consumption occurred. 
(50) http://www.lwl.org/LWL/Jugend/KS/Projekte_KS1/FreD/FreD-Basics/
(51) http://www.drugcom.de
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In Denmark, SMASH is an anonymous support and 
counselling project for young cannabis users, intended 
to reduce the harmful effects, provide information 
and support to help them stop smoking cannabis (52). 
The project is based around subscription to two SMS 
packages. The first of these (hashfacts) provides factual 
information about cannabis use and the second offers 
support and motivation to those attempting to stop taking 
drugs. Young people can also receive personal coaching 
via text messages to help them stop or reduce their use of 
cannabis. A similar service exists in Ireland, although the 
emphasis is on information dissemination. 
(52) http://www.smash.name
Drug use and related problems among very young people 
(under 15 years old) — EMCDDA 2007 selected issue
The selected issue on the use of drugs by very young Europeans 
(under the age of 15) fi nds that the prevalence of drug use 
among this age group is low and mainly refl ects experimental 
use. Regular use of drugs by very young people is rare, and it 
often concerns a highly problematic section of the population. 
The primary response to drug use among the under-15s 
largely centres on prevention or early intervention strategies. 
Nevertheless, the selected issue estimates that around 4 000 very 
young people receive drug treatment in Europe. Drug treatment 
tailored to the needs of young people is the exception, but most 
of the European countries have identifi ed the need for such 
programmes.
The selected issue also looks at how recognition of the links 
between the consumption of licit and illicit psychoactive 
substances at a young age and substance dependence later in 
life has been worked into European public health policies. 
This selected issue is available in print and on the Internet in 
English only (http://issues07.emcdda.europa.eu).
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Chapter 4
Amphetamines, ecstasy and LSD
In many European countries, the second most commonly used 
illicit substance is some form of synthetically produced drug, 
although on a European scale, there are now more users 
of cocaine. The use of these substances among the general 
population is typically low, but prevalence rates among 
younger age groups are significantly higher, and in some 
social settings or cultural groups the use of these drugs may 
be particularly high. Globally, amphetamines (amphetamine 
and methamphetamine) and ecstasy are among the most 
prevalent synthetic illicit drugs.
Amphetamine and methamphetamine are central nervous 
system stimulants. Of the two drugs, amphetamine is by far 
the more commonly available in Europe whereas significant 
methamphetamine use appears to be restricted to the Czech 
Republic and Slovakia. 
Ecstasy refers to synthetic substances that are chemically 
related to amphetamines but which differ to some extent in 
their effects. The best-known member of the ecstasy group 
of drugs is 3,4-methylenedioxy-methamphetamine (MDMA), 
but other analogues are also occasionally found in ecstasy 
tablets (MDA, MDEA). The prevalence of ecstasy use in the 
EU has been increasing since the 1990s.
Historically, lysergic acid diethylamide (LSD) has been by far 
the best-known hallucinogenic drug, but overall consumption 
levels have been low and somewhat stable for a considerable 
time. Recently, evidence of increased availability and use of 
naturally occurring hallucinogenic substances, hallucinogenic 
mushrooms in particular, has emerged.
Supply and availability (53)
Amphetamine
Global amphetamine production was estimated at 88 tonnes 
in 2005 (UNODC, 2007). Although illicit manufacture has 
extended to other parts of the world, it is still concentrated in 
western and central Europe. Laboratories manufacturing illicit 
amphetamine were dismantled in 2005 in Belgium, Bulgaria, 
Germany, Estonia, Lithuania, the Netherlands and Poland. 
Amphetamine seized in Europe is reported to come mainly 
from Belgium, the Netherlands and Poland, and to a lesser 
extent from Estonia and Lithuania.
Globally, 12.9 tonnes of amphetamine was seized in 2005, 
most of it in two regions: western and central Europe and 
east and south-east Asia.
In 2005, an estimated 40 300 seizures of amphetamine, 
amounting to 6.6 tonnes, were made in Europe. Until 
2004, the United Kingdom has consistently accounted for 
the greatest number of seizures and the largest quantities 
of amphetamine intercepted in Europe. Despite some 
fluctuations, at European level, both the overall number 
of amphetamine seizures and quantities seized have 
increased since 2000 (54). In 2005, however, a majority 
of reporting countries recorded a downward trend in 
the number of amphetamine seizures made. This picture 
Amphetamine and methamphetamine: 
differences and similarities 
On the illicit drugs market, the main representatives 
of the amphetamines group are amphetamine and 
methamphetamine (and their salts) — two closely related 
synthetic substances, members of the phenethylamine family. 
Both substances are central nervous system stimulants, which 
share the same mechanism of action, behavioural effects, 
tolerance, withdrawal and prolonged use (chronic) effects. 
Amphetamine is less potent than methamphetamine, but in 
uncontrolled situations the effects are almost indistinguishable. 
Amphetamine and methamphetamine products mostly consist 
of powders, but ice, the pure crystalline hydrochloride salt 
of methamphetamine is also used. Tablets containing either 
amphetamine or methamphetamine may carry logos similar to 
those seen on MDMA and other ecstasy tablets.
Given the physical forms in which they are available, 
amphetamine and methamphetamine may be ingested, 
snorted, inhaled and, less commonly, injected. Unlike 
the sulphate salt of amphetamine, methamphetamine 
hydrochloride, particularly the crystalline form (ice), is 
suffi ciently volatile to be smoked. 
Source:  EMCDDA drugs profiles (http://www.emcdda.europa.eu/?nnodeid=
25328).
(53) For information on interpreting seizures and other market data see p. 37. Data on seizures and quantities seized of amphetamine, ecstasy and LSD are not 
available for all countries for 2005; see the seizure tables in the 2007 statistical bulletin for more information. 
(54) See Tables SZR-11 and SZR-12 in the 2007 statistical bulletin.
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should be confirmed against 2005 data from the United 
Kingdom when available.
In 2005, the average or typical retail price of amphetamine 
ranged from EUR 7 per gram to EUR 37.5 per gram, with 
most European countries reporting prices of EUR 10–20 per 
gram (55). Over the period 2000–05, mean amphetamine 
prices, corrected for inflation, decreased in most of the 
17 countries providing sufficient data. 
The average or typical retail purity of amphetamine in 2005 
varied considerably, but most European countries reported 
purities between 15 % and 50 % (56).
Methamphetamine
Global methamphetamine production was estimated at 
278 tonnes in 2005. It is mostly manufactured in east and 
south-east Asia and in North America. In Europe, illicit 
manufacture of methamphetamine is still largely limited to the 
Czech Republic (under the local name of ‘pervitin’), although 
production is also reported in Lithuania, Moldova and 
Slovakia (INCB, 2007a; UNODC, 2007). 
In 2005, global seizures of methamphetamine increased 
to an estimated 17.1 tonnes, over half of it being reported 
by east and south-east Asia (China, Thailand), and a third 
by North America (United States). In the same year, an 
estimated 2 200 seizures, amounting to about 104 kg 
of methamphetamine were reported in 15 European 
countries (57). Norway and Sweden accounted for the largest 
numbers of seizures and quantities of methamphetamine 
intercepted.
The average or typical retail price of methamphetamine 
(reported by a few countries only) varied in 2005 between 
EUR 5 and EUR 35 per gram. Most countries reported 
average or typical retail purities of methamphetamine in the 
range 30–65 % (58).
Ecstasy
Global production of ecstasy was estimated at 113 tonnes in 
2005 (UNODC, 2007). Europe remains the main centre of 
ecstasy production, although its relative importance appears 
to be declining as ecstasy manufacture has spread to other 
parts of the world, notably to North America, east and 
south-east Asia and Oceania (CND, 2006; UNODC, 2006). 
In Europe, ecstasy manufacturing takes place mainly in the 
Netherlands (although signs of a decrease in production are 
reported there) followed by Belgium. The ecstasy seized in 
Europe in 2005 is reported to come from these two countries 
and to a lesser extent from Poland and the United Kingdom.
Of the estimated 5.3 tonnes of ecstasy intercepted worldwide 
in 2005, a major share continued to be seized in western 
and central Europe (38 %), followed by Oceania (27 %) and 
North America (20 %). 
International action against the manufacture and 
diversion of drug precursors
Several international initiatives have been set up to prevent 
the diversion of precursor chemicals used in the manufacture 
of illicit drugs: Project Cohesion focuses on potassium 
permanganate (used in the manufacture of cocaine) and 
acetic anhydride (used in the manufacture of heroin), while 
Project Prism addresses synthetic drugs precursors (1). All 
data below come from the INCB report on precursors (INCB, 
2007b).
In 2005, global potassium permanganate seizures were 
the largest ever reported to the INCB with 16 countries 
intercepting 183 tonnes, almost all of which was seized 
outside Europe.
Of the 22 400 litres of acetic anhydride seized worldwide in 
2005, again Europe accounted for only a small proportion.
In 2005, seizures of 41 tonnes of ephedrine and 
pseudo-ephedrine, key precursors of methamphetamine, 
were reported to the INCB, most of them by China, while 
EU Member States (mainly Bulgaria, the Czech Republic, 
Greece and Romania), together with the Russian Federation, 
accounted for 1.7 tonnes.
Global seizures of 1-phenyl-2-propanone (P-2-P), used in the 
illicit manufacture of methamphetamine and amphetamine, 
amounted to 2 900 litres in 2005, with European countries 
contributing 1 700 litres (mostly in Germany and the 
Netherlands). 
Europe’s share of global seizures of 
3,4-methylenedioxyphenyl-2-propanone (3,4-MDP-2-P), 
used to manufacture MDMA, decreased in 2005 to 38 % 
with 5 100 litres being reported (mostly in France and the 
Netherlands). The increasing seizures of 3,4-MDP-2-P in other 
regions seem to indicate that illicit manufacture of MDMA is 
expanding beyond Europe.
(1) All scheduled under Table I of the 1988 United Nations 
Convention.
(55) See Table PPP-4 in the 2007 statistical bulletin.
(56) See Table PPP-8 in the 2007 statistical bulletin. Note that the reported average levels of amphetamine purity may conceal wide variation in the purity of 
samples analysed.
(57) For the United Kingdom, due to the absence of 2005 data, 2004 data were considered for estimating purposes. See Tables SZR-17 and SZR-18 in the 2007 
statistical bulletin.
(58) See Tables PPP-4 and PPP-8 in the 2007 statistical bulletin.
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An estimated 26 500 seizures led to the confiscation of 
about 16.3 million ecstasy tablets in Europe in 2005 (59). 
The largest quantities of ecstasy continue to be seized in the 
United Kingdom, Belgium, the Netherlands and Germany. 
After a peak in 2001, ecstasy seizures made in Europe 
have been on the increase again since 2003. The total 
amount of ecstasy intercepted has been fluctuating at around 
20 million tablets per year between 2000 and 2004. In 
2005, however, the available data show a decrease in the 
quantities of ecstasy seized in a majority of countries. This 
picture should be confirmed against 2005 data from the 
United Kingdom when available.
In 2005, the average or typical retail cost of ecstasy tablets 
ranged from less than EUR 3 per tablet to EUR 15 (60). Over 
2000–05, mean retail prices of ecstasy, corrected for inflation, 
fell in most of the 21 countries providing sufficient data.
In Europe, most ecstasy tablets continued in 2005 to contain 
MDMA or another ecstasy-like substance (MDEA, MDA), 
usually as the only psychoactive substance present. In 
10 Member States, such tablets accounted for more than 
80 % of the total number of tablets analysed. There are some 
exceptions to this finding: in Slovenia MDMA/MDEA/MDA 
are more frequently found in combination with amphetamine 
and/or methamphetamine; while in Poland, amphetamine 
and/or methamphetamine are more frequently found as the 
only psychoactive substances in the tablets analysed. The 
MDMA content of ecstasy tablets varies greatly between 
batches (even between those with the same logo) both 
between and within countries. In 2005, the average or 
typical content of MDMA per ecstasy tablet ranged from 2 to 
130 mg in reporting countries, although in most countries the 
average was between 30 and 80 mg of MDMA.
LSD
After a continuous decrease for several years, both numbers 
of seizures and quantities of LSD intercepted have been on 
the increase since 2003 (61). Although LSD is manufactured 
and trafficked to a much smaller extent than other synthetic 
drugs, an estimated 800 seizures, amounting to 850 000 
LSD units, were made in Europe in 2005, with the 
Netherlands accounting for about 75 % of the total amount 
seized. The average or typical cost to users of a unit of LSD 
ranged from EUR 4 to EUR 30 (62). 
Prevalence and patterns among 
the general population and youth
In terms of measures of recent use, ecstasy is now the most 
commonly used synthetic drug in 17 European countries, 
and amphetamines in nine (63). Ever in lifetime prevalence of 
amphetamines tends to be higher, reflecting the more recent 
emergence of ecstasy on the illicit drug market in Europe. 
Data from school surveys suggest that use by school students 
of ecstasy, amphetamine and psychotropic drugs other than 
cannabis cluster among a few individuals. For example, 
school students who have tried ecstasy also report prevalence 
rates for use of cocaine and hallucinogenic drugs that are 
more than 20 times higher than in the general school student 
population (64) and around five times higher than among 
those who have never used cannabis.
Among EU Member States, use of amphetamines or ecstasy 
appears to be relatively high in only a few countries: the 
Czech Republic, Estonia and the United Kingdom; and, to a 
lesser extent in Latvia and the Netherlands. 
Amphetamines
Recent surveys among the adult population report that lifetime 
prevalence of the use of amphetamines in Europe ranges 
from 0.1 % to 3.6 % of all adults (15–64 years), except in 
Denmark (6.9 %) and the United Kingdom (England and 
Wales), where it reaches 11.5 % (reflecting a higher past 
use, whereas current use is more in line with other countries). 
The countries with the next highest figures are Norway 
(3.6 %), Germany and Spain (3.4 %). On average nearly 
3.5 % of all European adults have used amphetamines 
at least once (65). Last year use is much lower: 0.7 % on 
average (range 0–1.3 %). Data from general population 
surveys suggest that roughly 11 million people will have tried 
amphetamines, and about 2 million Europeans will have 
used the drug in the last year.
Among young adults (15–34 years) ever in lifetime use 
of amphetamines is reported by 0.2–16.8 %, although, if 
the figures from the United Kingdom (England and Wales) 
(16.8 %) and Denmark (12.7 %) are considered separately, 
the range is limited to 0.2–5.9 % (66). Half of the countries 
providing data have prevalence rates below 4 %, with 
the highest rates after the United Kingdom and Denmark 
(59) See Tables SZR-13 and SZR-14 in the 2007 statistical bulletin.
(60) See Table PPP-4 in the 2007 statistical bulletin.
(61) See Tables SZR-15 and SZR-16 in the 2007 statistical bulletin.
(62) See Table PPP-4 in the 2007 statistical bulletin.
(63) Survey data on ‘amphetamine use’ often do not distinguish between amphetamine and methamphetamine, however, typically this will be related to the use of 
amphetamine (sulphate or dexamphetamine), as use of methamphetamine is uncommon.
(64) See Figure EYE-1 (part iv) in the 2007 statistical bulletin.
(65) For the method of computation see footnote (30). 
(66) See Table GPS-9 in the 2007 statistical bulletin.
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reported by Norway (5.9 %), Germany (5.4 %) and Latvia 
(5.3 %). On average, 5.1 % of young European adults have 
tried amphetamines (67). Last year use in this age group 
ranges from 0.1 % to 2.9 %, with Estonia (2.9 %), the United 
Kingdom (2.6 %) and Latvia (2.4 %) reporting the highest 
prevalence rates (Figure 5). It is notable that, when last year 
use is considered, the figures from the United Kingdom and 
Denmark are more in line with those of other countries. It is 
estimated that, on average, 1.5 % of young European adults 
have used amphetamines in the last year.
Only Finland can provide a recent estimate of problem 
amphetamine use (defined as injecting or long duration/
regular use), which in 2002 was estimated to amount to 
between 10 900 and 18 500 problem amphetamine users 
(3.1 to 5.3 cases per 1 000 aged 15–64 years), about three 
times the number of problem opioid users. 
Methamphetamine
Levels of methamphetamine use in Europe appear limited, 
in contrast to the international picture, which has seen a 
growth in the use of this drug in recent years. European 
countries are concerned, however, about the potential of 
the use of this drug to grow in Member States, prompting 
some precautionary measures, for example in the United 
Kingdom where there has been a decision to reclassify 
methamphetamine among the most harmful drugs (Class A).
Historically, methamphetamine use in Europe use has been 
concentrated in the Czech Republic and to some extent 
Slovakia. Recent estimates of problem methamphetamine 
use are reported by two countries (the Czech Republic, 
Slovakia). In 2005, in the Czech Republic there were 
estimated to be 18 400–24 000 methamphetamine 
users (2.5 to 3.2 cases per 1000 aged 15–64 years), 
almost twice the number of problem opioid users, and in 
Slovakia, 6 000–14 000 methamphetamine users (1.5 to 
3.7 cases per 1 000 aged 15–64 years), slightly less than 
the estimated number of opioid users. Methamphetamine 
has become the most frequent primary drug among those 
demanding treatment for the first time in Slovakia, and high 
levels of methamphetamine use have now been reported 
among some subpopulation groups in Hungary. 
In other parts of Europe, significant methamphetamine 
use is not reported. Two important caveats here are: that 
most surveys do not allow the use of methamphetamine 
(67) See Figure GPS-18 (part ii) in the 2007 statistical bulletin.
Figure 5: Last year prevalence of amphetamines use among all adults (aged 15–64) and young adults (aged 15–34 and 15–24)
 (1)   England and Wales.
NB:   Data are from the most recent national surveys available in each country at the time of reporting. Countries are ordered according to the overall (all adults) prevalence. 
See Tables GPS-10, GPS-11 and GPS-18 in the 2007 statistical bulletin for further information.
Sources:  Reitox national reports (2006), taken from population surveys reports or scientific articles.
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to be distinguished from that of amphetamine; and that 
methamphetamine has occasionally been found in tablets 
sold as ecstasy and therefore may have been unknowingly 
consumed (68). 
Ecstasy
Ecstasy has been tried by 0.3–7.2 % of all European adults. 
Half of the countries report lifetime prevalence rates of 2.5 % 
or lower, with the highest prevalence rates being reported 
by the United Kingdom (7.2 %), the Czech Republic (7.1 %), 
Spain (4.4 %) and the Netherlands (4.3 %). The prevalence 
of last year use of ecstasy ranges from 0.2 % to 3.5 % of 
adults, with the highest rates reported by the Czech Republic 
(3.5 %), Estonia (1.7 %) and the United Kingdom (1.6 %), 
although half of the countries report prevalence rates of 0.5 % 
or below. It is estimated that almost 9.5 million Europeans 
(3 % on average) have tried ecstasy, and almost 3 million 
have used it in the last year.
Among young adults (15–34 years), lifetime prevalence of 
ecstasy use ranges from 0.5 % to 14.6 %, with the highest 
figures reported for the Czech Republic (14.6 %), the United 
Kingdom (13.3 %) and the Netherlands (8.1 %) (69). On 
average, over 5 % of young European adults have tried 
ecstasy. 
Among 15- to 24-year-olds, lifetime prevalence of ecstasy 
ranges from 0.4 % to 18.7 %, with the highest figures 
reported by the Czech Republic (18.7 %), the United 
Kingdom (10.4 %), and Hungary (7.9 %) (70). Last year use 
among this age group ranges from 0.3 % to 12 %, with the 
Czech Republic (12.0 %) and Estonia (6.1 %) reporting the 
highest rates (Figure 6). 
Among the 15–24 age group, higher rates of lifetime 
prevalence of ecstasy are found among males (0.3–23.2 %) 
than among females (0.3–13.9 %). In recent school surveys, 
increases in lifetime prevalence of ecstasy use occurred 
largely in parallel among both male and female school 
students, although there is a progressive increase in the 
gender gap with increasing age. Among young people, 
large increases in prevalence levels may occur with 
small increases in age, for example data available from 
16 countries show that, compared to younger students, 
lifetime prevalence of ecstasy use among 17- to 18-year-old 
school students is, in most cases, considerably higher (71).
LSD
Ever in lifetime use of LSD among adults ranges from 0.2 % 
to 5.5 %, with two thirds of countries reporting lifetime 
prevalence rates between 0.4 % and 1.7 %. Among young 
adults (15–34 years), lifetime prevalence of LSD use ranges 
from 0.3 % to 7.6 %, and among the 15–24 age group it 
varies from 0 to 4.2 %. Last year use of this drug is low, 
and in the 15–24 age group exceeds 1 % only in seven 
countries (Bulgaria, the Czech Republic, Estonia, Italy, Latvia, 
Hungary, Poland).
Trends
Overall in Europe, there is continuing evidence of stabilising 
or even decreasing trends in amphetamine and ecstasy 
consumption. Amphetamine use among young adults 
(15–34) has declined substantially in the United Kingdom 
(England and Wales) since 1996, and to a lesser extent in 
Denmark and the Czech Republic, while in other countries 
the prevalence levels appear largely stable, although some 
small increases are reported (72).
A more mixed picture is found for ecstasy use among young 
adults (15–34) (73). After general increases in use during 
the 1990s, in recent years several countries, including two 
high-prevalence countries, Spain and the United Kingdom, 
report some stabilisation or even moderate decreases. In 
some countries, a decrease in prevalence is observed among 
the 15–24 age group, but not among those aged 15–34 (74), 
suggesting a decline in the drug’s popularity among the 
younger age groups. A question arising from the data in 
some countries (Spain, Denmark, the United Kingdom) is 
whether cocaine is replacing amphetamines and ecstasy as 
the stimulant drug of choice (75).
In newly available national or regional school surveys, 
reported in 2006 (Italy, Poland, Sweden; Flanders in 
Belgium), no change or even some decrease is recorded in 
ever in lifetime use of amphetamines and ecstasy (76).
Recreational settings
Studies of drug use in recreational settings such as dance 
events can provide a useful window on the behaviour of 
those using stimulant drugs on a regular and intensive basis. 
Rates of drug use in these settings are typically high, but 
(68) See ‘Amphetamine and methamphetamine: differences and similarities’, p. 48.
(69) See Table GPS-9 in the 2007 statistical bulletin.
(70) See Figure GPS-22 in the 2007 statistical bulletin.
(71) See Figure EYE-1 (part ii) in the 2007 statistical bulletin.
(72) See Figure GPS-8 in the 2007 statistical bulletin.
(73) See Figure GPS-21 in the 2007 statistical bulletin.
(74) See Tables GPS-4  and GPS-15 in the 2007 statistical bulletin.
(75) See Table GPS-20 in the 2007 statistical bulletin.
(76) See Figure EYE-4 in the 2007 statistical bulletin.
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are not generalisable to the wider population. For example, 
studies of people surveyed in selected dance music settings 
report high levels of ecstasy use and lower but still high levels 
of amphetamine use (77). 
An annual reader survey conducted by the United Kingdom 
Mixmag music magazine, whose readership consists of 
regular dance club-goers report that the proportion of those 
defined as heavy ecstasy users (usually consuming more 
than four pills per session) more than doubled between 
1999 and 2003, from 16 % to 36 % (McCambrige et al., 
2005). Although the representativeness of this sample is 
questionable, it does support the general concern that there 
has been an increase in the quantity of ecstasy tablets 
consumed by some groups of users. Increasingly intense 
use of ecstasy and polydrug use by experienced ecstasy 
users is also reported in a United Kingdom Internet study 
(Scholey et al., 2004). However, it is of note that reports 
from Amsterdam suggest that last year and last month 
use of ecstasy decreased by 20 % between 1998 and 
2003 and the average amount of ecstasy used on each 
occasion also declined in this period (2005 Reitox national 
reports). According to a 2005 survey among pub-goers in 
Amsterdam, only 3 % used ecstasy during the night out.
Although data available on the combined use of drugs 
and alcohol remains limited, consumption of alcohol 
in recreational dance music settings, often in quantities 
considered hazardous to health and in combination with 
stimulant drugs, is a growing cause for concern.
Treatment demand data
The number of demands for treatment relating to the use of 
amphetamines and ecstasy is relatively small. In general, this 
form of drug use is rarely the primary reason for attending 
drug treatment in most of the 21 countries for which data 
is available (78). Such treatment demands mostly refer to 
primary amphetamines use, and only a very small proportion 
to ecstasy (79).
There are a limited number of countries with a non-trivial 
proportion of amphetamines and ecstasy users among 
drug clients and they can be divided in three groups. The 
(77) See the 2006 selected issue on drug use in recreational settings. 
(78) See Figure TDI-2 (part ii) and Table TDI-5 in the 2007 statistical bulletin.
(79) See Table TDI-113 in the 2007 statistical bulletin.
Figure 6: Last year prevalence of ecstasy use among all adults (aged 15–64) and young adults (aged 15–34 and 15–24)
(1)   England and Wales.
NB:   Data are from the most recent national surveys available in each country at the time of reporting. Countries are ordered according to the overall (all adults) prevalence. 
See Tables GPS-10, GPS-11 and GPS-18 in the 2007 statistical bulletin for further information.
Sources:  Reitox national reports (2006), taken from population surveys reports or scientific articles.
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Czech Republic and Slovakia report a substantial proportion 
of treatment requests related to primary use of amphetamines 
(correspondingly 58 % and 24 % of all clients), mostly, they 
relate to a primary methamphetamine problem; Sweden, 
Finland and Latvia report around a third of all drug clients 
entering treatment for primary amphetamines use; Ireland, 
the Netherlands, the United Kingdom and France report 
between 1 % and 5 % of patients entering treatment for 
primary ecstasy use (80).
In all countries, except Greece and Sweden, the proportion 
of new clients entering treatment for primary use of 
amphetamines and ecstasy is greater than the proportion of 
all clients receiving treatment for these drugs (81). While this 
may have several explanations, it is in accord with the data 
on trends: from 1999 to 2005 the number of first treatment 
demands for primary amphetamines and ecstasy use 
increased by over 3 000, from 6 500 to 10 000 (82). 
Clients entering treatment for use of stimulants other than 
cocaine are on average around 27 years old (26 if they 
enter treatment for the first time) and used the drug for the 
first time at an average age of 19 (83). Ecstasy clients are, 
along with cannabis users, the youngest group entering 
drug treatment. In the Netherlands the highest proportion 
of women in drug treatment is reported among the ecstasy 
clients. The proportion of women among amphetamines 
clients is higher than that for other drugs, with the highest 
proportion of outpatient female clients reported in the 
youngest age group (84). 
Amphetamines clients usually consume the drug in 
combination with other substances, mainly cannabis and 
alcohol, and in some countries injecting is commonly 
reported (85). In the Czech Republic, an interesting 
geographic variation is reported, with more users reported 
outside the capital; this is similar to reports from the 
United States, where non-metropolitan areas have higher 
admission rates for methamphetamine and amphetamine 
use (Dasis, 2006). 
Responding to drug use in 
recreational settings
Drug prevention activities
In general, there has been shift in approaches to prevention, 
with an increased recognition of the key role that lifestyle 
factors play in shaping attitudes to drug use and in the 
importance of challenging the belief that drug use is a 
normal or acceptable behaviour. This kind of approach is of 
particular relevance to prevention work in settings that are 
culturally associated with drug taking. The high prevalence 
of drug use in some recreational settings, such as clubs, 
bars and dance events means that these locations have 
been identified as appropriate targets for drug demand 
reduction initiatives. The need to further develop prevention 
activities in recreational settings is also noted in the EU drug 
action plan (2005–08).
One approach has been to make information material 
that may have prevention and, sometimes, harm-reduction 
messages available in recreational settings. Material 
is usually developed in a user-friendly style that reflects 
the youth culture of the target group, and is sometimes 
distributed through mobile outreach teams. To engage 
with young people, outreach teams usually take a 
non-judgmental approach and, while stating that the 
safest option is not to take drugs at all, may also provide 
harm-reduction advice (Belgium, the Czech Republic, 
Austria, Portugal).
In addition, to responses that aim at informing and 
persuading individuals not to use drugs, an increasing 
number of Member States are also developing approaches 
to better regulate recreational environments. Some of 
these approaches, including running explicitly drug-free 
events, have attempted to alter the beliefs held by some 
that drug use facilitates their leisure activities. In an 
increasing number of countries (Belgium, Denmark, 
Ireland, Italy, Lithuania, the Netherlands, Sweden, the 
United Kingdom, Norway), there appears to be an interest 
among municipalities in establishing closer contact with 
the leisure industry and developing approaches to limit 
the availability of drugs and reduce the health risks 
in dance music and other settings. For example, safe 
clubbing guidelines, such as those developed in the United 
Kingdom (86), are now being produced in a number of 
countries.
Among the most frequently used responses to the use 
of ecstasy, amphetamines and psychotropic drugs are 
targeted public information campaigns and, increasingly, 
Internet sites. Prevention strategies have made use 
of the Internet to establish low-threshold contact with 
young people who take ecstasy, amphetamines or other 
(80) See Table TDI-5 (part ii) in the 2007 statistical bulletin.
(81) See Table TDI-4 (part ii) and TDI-5 (part ii) in the 2007 statistical bulletin.
(82) See Figure TDI-1 (part ii) in the 2007 statistical bulletin.
(83) See Tables TDI-10, TDI-11 and TDI-102 to TDI-109 in the 2007 statistical bulletin.
(84) See Tables TDI-21 and TDI-25 in the 2007 statistical bulletin.
(85) See Tables TDI-4, TDI-5 (part ii), TDI-24, TDI-116 and TDI-117 in the 2007 statistical bulletin.
(86) See the 2006 selected issue on recreational settings.
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psychotropic drugs or who might be considering taking 
them. In many Member States, information and prevention 
is being provided through Internet sites to promote 
critical reflection among young people about their own 
consumption behaviour. These sites provide advice, 
for example about going out ‘wisely’, safe sex, road 
traffic risks, healthy diets, party tourism and legal issues 
(Belgium) (87).
Drug treatment
Treatment services for users of ecstasy, amphetamines and 
other psychotropic drugs are generally provided through 
drug treatment services that serve problem drug users or more 
specialised services for users of cocaine and other stimulant 
drugs. For further information about drug treatment services 
in the EU see Chapter 2 and Chapter 5.
(87) Links to some of these may be found at http://www.emcdda.europa.eu/?nnodeid=5575
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Chapter 5
Cocaine and crack cocaine
As consumption of cocaine has increased, the use of this 
drug has become a major issue for European drug policy. 
In recognition of the growing importance of this subject, 
patterns of cocaine use are explored in detail in the 2007 
selected issue on cocaine.
Supply and availability (88)
Production and trafficking
Cocaine, after cannabis, is the second most trafficked illicit 
drug in the world. Global seizures of cocaine have continued 
to increase in 2005 to now total 756 tonnes, with the largest 
quantities of the drug intercepted in South America, followed 
by North America. 
Colombia remains by far the largest source of illicit coca 
in the world, followed by Peru and Bolivia (UNODC, 
2007). Most of the cocaine seized in Europe comes from 
South America, either directly or via Central America, the 
Caribbean and West Africa. 
The main point of entry in Europe remains the Iberian 
peninsula, with Portugal appearing to be increasingly 
important. Cocaine is also directly imported into other 
countries, with the Netherlands remaining a key entry point. 
Both Spain and the Netherlands are regarded as main 
distribution centres for the drug. Imports from outside Europe 
are also reported by a number of other countries including 
Belgium, Germany, France and the United Kingdom; 
and distribution may also be diversifying, with reports of 
increased activity through eastern and central Europe and 
both EU and neighbouring countries sometimes now reported 
as secondary transit locations. 
Seizures
In 2005, an estimated 70 000 seizures of cocaine, 
amounting to 107 tonnes, were made in Europe. Most 
seizures of cocaine continue to be reported in western 
European countries, especially Spain, which accounts for 
about half the seizures and amounts of cocaine intercepted 
in Europe (89). Over the period 2000–05, both the number 
of seizures and the quantities of cocaine seized increased 
overall at European level (90). This was principally due to 
marked increases in Spain and Portugal, with Portugal 
overtaking the Netherlands in 2005 as the country 
responsible for the second largest interceptions of cocaine 
after Spain. 
Price and purity
In 2005, the average or typical retail price of cocaine varied 
widely across Europe, from EUR 45 to EUR 120 per gram, 
with most countries reporting prices of EUR 50–80 per 
gram (91). The mean prices of cocaine, corrected for inflation, 
showed an overall downward trend over the period 2000–05 
in most of the 19 countries reporting sufficient data.
The average or typical purity of cocaine at user level varied 
in 2005 from 20 % to 78 %, with most countries reporting 
purities in the 30–60 % range (92). Data available over the 
period 2000–05 indicate an overall decrease in the mean 
purity of cocaine in most of the 21 reporting countries.
Prevalence and patterns of cocaine use
Cocaine is now, after cannabis, the second most commonly 
used illicit drug in many EU Member States and in the EU as 
a whole. Based on recent national population surveys in the 
EU and Norway, it is estimated that cocaine has been used 
at least once (lifetime prevalence) by more than 12 million 
Europeans, representing almost 4 % of all adults (93). National 
figures on reported ever in lifetime use range from 0.2 to 
7.3 %, with three countries reporting values of more than 5 % 
(Spain, Italy, the United Kingdom) (94). 
Use of cocaine in the last year is reported by at least 
4.5 million Europeans (1.3 % on average). Last year use 
of cocaine ranges from 0.1 % in Greece to 3.0 % in Spain, 
(88) See ‘Interpreting seizures and other market data’, p. 37. 
(89) This should be checked against missing 2005 data when available. For estimating purposes, 2005 missing data were replaced by 2004 data.
(90) See Tables SZR-9 and SZR-10 in the 2007 statistical bulletin.
(91) See Table PPP-3 in the 2007 statistical bulletin.
(92) See Table PPP-7 in the 2007 statistical bulletin.
(93) For the method of computation see footnote (30). 
(94) See Table GPS-8 in the 2007 statistical bulletin.
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with Italy and the United Kingdom also reporting prevalence 
levels above 2 % (95). Survey estimates suggest that 2 million 
Europeans (0.6 % on average) have used cocaine in the last 
month (96). 
Prevalence of cocaine use, as it is with other illicit drugs, is 
concentrated among young adults (aged 15–34). Around 
7.5 million young European adults (5.3 % on average) have 
used it at least once in their life, with five countries reporting 
prevalence levels of 5 % or above (Germany, Italy, Denmark, 
Spain, the United Kingdom) (97). Estimates of cocaine use for 
shorter reference periods (98) suggest that in the last year, of 
the 3.5 million (2.4 %) young adults who have used the drug, 
1.5 million (1 %) have used it in the last month. 
Among school students, overall prevalence rates for 
cocaine use are much lower than those for cannabis use. In 
most countries, ever in lifetime prevalence of cocaine use 
among 15- to 16-year-old school students is 2 % or lower, 
rising to 6 % only in Spain and the United Kingdom (99). 
Data on 17- to 18-year-old school students available from 
16 countries show considerably higher lifetime prevalence 
estimates for cocaine use among the older age group in 
Spain, although preliminary data for the country suggest 
a decline has occured recently (100). In most of the other 
15 countries, prevalence is higher among the older students 
but differences are less notable. However, it should be noted 
that last year and last month prevalence levels of cocaine use 
are much lower.
Use of cocaine is not confined to certain social groups, 
but use of the drug by socially integrated young adults in 
recreational settings can reach higher levels than those 
reported in general population surveys. Studies targeting 
dance music settings in several European countries revealed 
lifetime prevalence of cocaine use ranging from 10 % to 
75 % (101). 
Patterns of cocaine use vary greatly between different groups 
of users. Among socially integrated users, the drug is usually 
snorted; many are also using other substances including 
alcohol, tobacco, cannabis, and stimulants other than 
cocaine (102), and this kind of polydrug consumption can lead 
to elevated health risks. 
Overall, the use of crack in Europe remains relatively 
uncommon and is concentrated among marginalised and 
excluded subpopulations in some cities. However, cocaine 
smokers do represent a significant proportion of treatment 
demands, although they remain in the minority. Among those 
not injecting other drugs, the injecting of cocaine does not 
appear to be common, even among treatment clients (see 
below). However, there have been increasing reports of 
heroin injectors also injecting cocaine, or cocaine and heroin 
mixtures. 
Estimations of prevalence of problem cocaine use (103) are 
available for only three countries (Spain, Italy, the United 
Kingdom). The estimates obtained in these countries are 
in the range of three to six problem users of cocaine per 
1 000 adults (aged 15–64) (104).
Trends in cocaine use
Signs of stabilisation in cocaine use among young adults 
noted in the 2006 annual report are not supported by recent 
data. Increases in the last year prevalence of cocaine use 
among the 15–34 age group have been registered in all 
countries reporting recent survey data, although there may be 
some levelling off in Spain and the United Kingdom (England 
and Wales), the Member States with the highest prevalence 
levels. Notable increases were also reported by Italy and 
Denmark (Figure 7).
Analysis of data for countries with longer time series and 
appreciable prevalence rates can allow detection of trends 
within subgroups of the population. In both Spain and the 
United Kingdom, the increase in prevalence was generally 
greater among males than among females. The reported 
increase in last year cocaine prevalence in Spain since 2001 
can be attributed to increased levels of use in the 15–24 age 
group, rather than across 15–34 year olds as a whole. 
It has been suggested that, in some European countries, a 
‘replacement’ of other stimulants by cocaine could have 
taken place (105). Data from surveys conducted with young 
people in dance music club settings need to be treated with 
caution because of the highly selected nature of the sample. 
Nonetheless, they can provide a window on the behaviour 
of regular drug consumers, and studies conducted in the 
(95) See Table GPS-10 in the 2007 statistical bulletin.
(96) See Table GPS-12 in the 2007 statistical bulletin.
(97) See Table GPS-9 in the 2007 statistical bulletin.
(98) See Tables GPS-11 and GPS-13 in the 2007 statistical bulletin.
(99) See Table EYE-3 in the 2007 statistical bulletin.
(100) See Table EYE-2 in the 2007 statistical bulletin.
(101) See the 2006 selected issue on drug use in recreational settings. 
(102) See Figure 15 in the 2006 annual report. 
(103) Defined as long-term and/or regular and/or injecting cocaine use. 
(104) See Table PDU-2 in the 2007 statistical bulletin and the 2007 selected issue on cocaine.
(105) See Chapter 4 in this report.
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Netherlands indicate that, in some municipalities, cocaine 
has outstripped ecstasy among club-goers as the most 
commonly used stimulant, with the drug gaining increased 
acceptability among some groups.
Cocaine: treatment demand data
After opioids and cannabis, cocaine is the drug most 
commonly reported as the reason for entering treatment 
in Europe. In 2005, approximately 48 000 demands for 
treatment for cocaine as the primary drug were reported, 
accounting for about 13 % of all reported treatment demands 
across the EU (106); cocaine is also reported as a secondary 
drug by around 15 % of all outpatient clients (107). The overall 
figure conceals a wide variation between countries, with 
most countries reporting low percentages of cocaine users 
among clients in drug treatment, while high proportions 
of cocaine users among drug clients are reported by the 
Netherlands (35 %) and Spain (42 %, in 2004). Among those 
new to treatment, the proportion of cocaine clients is higher, 
with overall around 22 % of all new treatment demands 
(33 000 individuals, based on 22 countries) reported as 
cocaine-related. 
The increasing trend of clients seeking treatment for cocaine 
use reported in previous years is continuing. From 1999 to 
2005, the proportion of new clients demanding treatment 
for cocaine use grew from 11 % to 24 % of all new drug 
clients and the number of reported cases went from 13 000 
to 33 000 (108). A more detailed analysis of trends in the 
demand for treatment for the drug is presented in the 2007 
selected issue on cocaine. 
European data on drug users entering treatment for primary 
cocaine use are mainly related to cocaine powder (85 %), 
with only 15 % referring to crack cocaine; and almost all 
reported treatment for cocaine dependence takes place in 
outpatient centres (94 %) (109). However, it should be noted 
that the data on cocaine treatment demand provided in 
inpatient centres and general practice settings is incomplete.
Cocaine clients entering outpatient centres are reported to be 
the oldest drug clients after opioid users, with a mean age of 
31 years (110). They are predominantly males, with one of the 
highest male to female ratios among all types of drug clients 
(almost five males for one female in all clients, and six males 
for one female in new clients) (111). Most cocaine users in 
outpatient treatment started to use the drug between the ages 
of 15 and 24 years (112).
Cocaine treatment
The provision of specialised responses for problematic 
cocaine and crack users in Europe remains limited 
and, as noted above, Spain and the Netherlands are 
currently responsible for the majority of reports of cocaine 
treatment. However, among those countries with significant 
cocaine-using populations, there appears to be a growing 
interest in providing specialist services. Unsurprisingly, in 
low-prevalence countries, the provision of specific cocaine 
treatment services is not reported as a policy priority. In 
contrast to opioid treatment, where the target population is 
relatively homogenous, cocaine treatment in Europe faces the 
challenge of providing interventions to a broader spectrum 
of users. Among primary cocaine users, the main route of 
administration reported by outpatient clients is sniffing, 
followed by smoking or inhalation, with relatively few (less 
(106) See Figure TDI-2 in the 2007 statistical bulletin.
(107) See Table TDI-22 (part i) in the 2006 statistical bulletin.
(108) See Figure TDI-1 in the 2007 statistical bulletin.
(109) See Tables TDI-24 and TDI-115 in the 2007 statistical bulletin.
(110) See Table TDI-10 in the 2007 statistical bulletin.
(111) See Table TDI-21 in the 2007 statistical bulletin.
(112) See Table TDI-11 (part i) to (part iv) in the 2007 statistical bulletin.
Figure 7: Trends in last year prevalence of cocaine use among young 
adults (aged 15–34)
(1)   England and Wales.
(2)   In Denmark, the value for 1994 corresponds to ‘hard drugs’.
NB:   Data are from the most recent national surveys available in each country 
at the time of reporting. See Table GPS-4 in the 2007 statistical bulletin for 
further information.
Sources:  Reitox national reports (2006), taken from population surveys reports or 
scientific articles.
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than 10 %) of clients reporting injecting the drug. Among 
those new to treatment, injecting levels are even lower 
(5 %) (113). Around 16 % of cocaine clients report using it 
in combination with opioids and, in some countries, many 
clients being treated for opioid problems will also be using 
cocaine, at least occasionally. 
Treatment services are, therefore, likely to be faced 
with offering care to three populations, which can be 
characterised in simple terms as: first, socially more 
integrated cocaine users who may also have a history 
of regular ‘recreational’ polydrug use including alcohol; 
secondly, cocaine users who may also have opioid 
problems; and thirdly, highly marginalised and problematic 
crack cocaine users. 
The needs of these three groups are likely to be different 
and require different approaches from service providers. 
Most reported cocaine treatment in Europe takes place in 
outpatient settings, which in many cases will be orientated 
to the needs of opioid users. It is questionable how attractive 
such services are to relatively well-integrated cocaine users 
who have developed problems through their recreational use 
of the drug. And it is likely that a proportion of this group will 
seek help either through generic healthcare providers, such 
as general practitioners or counsellors or, if they are able, 
through private specialised clinics. 
In contrast to opioid treatment, pharmacological options for 
cocaine treatment are limited, although prescribing can be 
helpful in providing relief for related symptoms. At present no 
pharmacological agent is available to help users to achieve 
or manage cocaine abstinence — though there may be 
some future options in this direction. The emphasis in Europe 
is put on the provision of psychosocial interventions, which 
are mostly based on cognitive behavioural approaches. An 
in-depth detailed review of options for cocaine treatment can 
be found in the 2007 selected issue on cocaine and in an 
EMCDDA technical review (EMCDDA, 2007b). 
The low prevalence and highly geographically restricted 
nature of crack cocaine problems in Europe means that 
experience of responding to the needs this group of drug 
users is far more limited. There is a large amount of literature 
based on the US experience of crack cocaine problems, 
but the extent to which this can be directly applied to the 
European context remains unclear. The United Kingdom, 
which compared to other European countries reports a 
relatively high level of problematic crack use, has produced 
guidelines for professionals suggesting that crack treatment 
should be provided in the context of a structured programme 
of drug treatment, which includes abstinence and harm 
minimisation measures (NTA, 2002). A recent evaluation of 
service provision in the United Kingdom also reported some 
positive outcomes among crack cocaine clients in residential 
care (Weaver, 2007). 
Risk and harm reduction
Recreational cocaine users are at risk not only of developing 
a dependent drug habit, but also through the interaction 
of cocaine use with other drugs or with coexisting 
cardiovascular problems. Most European countries report 
that cocaine users can access information about cocaine and 
the risks of cocaine use through various information sources 
such as websites, helplines and through other media. It is 
interesting to note that the European Foundation of Drug 
Helplines reports an increase in the number of calls related to 
cocaine during 2005 and 2006 (114). 
Cocaine use may also be associated with high-risk sexual 
activity or with involvement in the sex industry. Studies have 
reported that women using crack cocaine may be particularly 
vulnerable and may engage in high-risk sex behaviours either 
for money or drugs, and in some countries, harm-reduction 
and outreach programmes work specifically with sex workers 
targeting both sexual and drug-taking risk behaviours. 
Although small in number, crack cocaine users are likely 
to be at particularly high risk of experiencing problems 
and may be difficult to engage in treatment and other 
services. In some cities where significant crack cocaine 
problems exist, harm-reduction programmes have attempted 
to intervene by providing outreach, crisis intervention, 
assistance for acute medical problems as well as referral 
to structured services. For example, in Vienna, rooms 
are available through outpatient services to provide a 
safe space for cocaine and crack users who are often 
suffering from anxiety, and basic healthcare and referral to 
other services are offered. In those countries that provide 
consumption rooms for injecting drug users, this kind of 
provision has sometimes been extended to crack cocaine 
users, for example, in Germany, special facilities are 
provided for crack smokers in both Frankfurt and Hamburg.
Harm-reduction approaches to cocaine injectors are, in 
general, no different to those provided to other injectors 
(see Chapter 8), although some studies have suggested 
that stimulant users will inject more and, therefore, be 
potentially at greater risk. In addition, there are specific 
risks related to the injection of crack cocaine if it has been 
incorrectly prepared. 
(113) See Table TDI-17 (part ii) and (part vi) and Table TDI-110 in the 2007 statistical bulletin.
(114) http://www.fesat.org/
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Cocaine and crack cocaine: a growing public health 
issue — EMCDDA 2007 selected issue
In recent years, there have been signs that cocaine use is a 
growing problem in Europe. This selected issue shows that, in 
some European countries, there has been a marked increase 
in the use of cocaine, in treatment demands for cocaine and 
in seizures of the drug. The potential for cocaine use to have a 
major impact on public health is examined. Special attention is 
given to the health consequences of cocaine, which are often not 
well recognised in existing reporting systems. The selected issue 
looks in detail at the challenges to providing effective treatment 
for cocaine and crack cocaine dependence, which has proved to 
be particularly diffi cult, not least because of the very varied types 
of cocaine users and their differing needs. 
This selected issue is available in print and on the Internet in 
English only (http://issues07.emcdda.europa.eu).
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Chapter 6
Opioid use and drug injection
Heroin supply and availability (115)
In Europe, historically, two forms of imported heroin have 
been used: the commonly available brown heroin (its 
chemical base form) mainly from Afghanistan, and the less 
common and more expensive white heroin (a salt form) 
which typically originates from south-east Asia — although 
this form of the drug is now becoming increasingly rare. 
A small amount of opioid drugs are also produced within 
Europe, but manufacture is mainly confined in 2005 to 
small-scale production of home-made poppy products 
(e.g. poppy straw, poppy concentrate from crushed poppy 
stalks or heads) in a number of eastern European countries 
(Latvia, Lithuania, Poland). 
Production and trafficking
Heroin consumed in Europe is predominantly manufactured 
in Afghanistan, which remains the world leader in illicit 
opium supply, followed by Myanmar. It is estimated that 
about 6 610 tonnes of opium was produced in 2006, 92 % 
of which in Afghanistan. This represents a 43 % increase 
compared to the 2005 estimate, due to a substantial 
increase in the area under cultivation. Global potential 
production of heroin was estimated at 606 tonnes in 2006, 
up from 472 tonnes in 2005 (UNODC, 2007). Opioid 
seizures and laboratories dismantled seem to indicate 
that opium produced in Afghanistan is increasingly being 
converted into morphine or heroin before being exported 
(CND, 2007).
Heroin enters Europe by two major trafficking routes. The 
historically important, and shortest, Balkan route continues 
to play a crucial role in heroin smuggling. Following transit 
through Pakistan, Iran and Turkey, the route then diverges 
into a southern branch through Greece, the former Yugoslav 
Republic of Macedonia (FYROM), Albania, Italy, Serbia, 
Montenegro and Bosnia-Herzegovina and a northern branch 
through Bulgaria, Romania, Hungary, Austria, Germany 
and the Netherlands; the latter operating as a secondary 
distribution centre to other western European countries. Since 
the mid-1990s, heroin has been increasingly (but to a lesser 
extent than through the Balkan route) smuggled to Europe 
through the ‘silk route’ via central Asian Republics, the 
Caspian Sea and the Russian Federation, Belarus or Ukraine, 
to Estonia, Latvia, some of the Nordic countries, Germany 
and Bulgaria. Although these routes are the most important, 
countries in the Arabian peninsula (Oman, United Arab 
Emirates) have become transit sites for heroin consignments 
from south-west and south-east Asia (INCB, 2006), with some 
of it being then smuggled through eastern Africa (Ethiopia, 
Kenya, Mauritius), and sometimes through western Africa as 
well (Nigeria), to be shipped to illicit markets in Europe and 
to a lesser extent North America (INCB, 2007a). There are 
also reports of heroin from south-west Asia being smuggled 
to Europe via countries in south and east Asia (India, 
Bangladesh, Sri Lanka, China).
Seizures
In 2005, 342 tonnes of opium, 32 tonnes of morphine and 
58 tonnes of heroin were seized worldwide. Asia (China, 
Afghanistan, Iran, Pakistan) continued to account for the 
greatest quantities of heroin (54 %) seized worldwide, 
followed by Europe (38 %) (UNODC, 2007).
An estimated 52 000 seizures resulted in the interception 
of about 16.8 tonnes of heroin in the EU Member States 
and candidate countries and Norway in 2005. The United 
Kingdom (based on 2004 data) continued to account for 
the highest number of seizures made in Europe, followed by 
Spain, Germany and Greece, while Turkey seized the largest 
quantities (followed by the United Kingdom, Italy and the 
Netherlands), accounting for nearly half of the total amount 
intercepted in 2005 (116). Seizures of heroin show an overall 
decline between 2000 and 2003 and, based on data 
available, have been increasing since then. Over the period 
2000–05, total quantities of heroin seized in EU Member 
States have been fluctuating within a slightly downward 
trend, whereas a large increase is reported in Turkey over the 
same period (117).
(115) See ‘Interpreting seizures and other market data’, p. 37. 
(116) This should be checked against missing 2005 data when available. For estimating purposes, 2005 missing data were replaced by 2004 data.
(117) See Tables SZR-7 and SZR-8 in the 2007 statistical bulletin.
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Price and purity
Detecting trends in both price and purity is hampered by a 
lack of consistent data, and estimates are therefore based 
on only a limited range of countries (118). Most countries 
reported average or typical street price of brown heroin 
in the range EUR 35–80 per gram. Between 2000 and 
2005 mean heroin prices, corrected for inflation, appear 
to have decreased in most of the 18 countries providing 
comparable data. The average or typical purity of brown 
heroin at street level was reported to vary considerably, 
with most countries reporting values between 15 % and 
50 %; figures for white heroin tended to be higher 
(30–70 %), where it was available. The mean purity 
of heroin products has been fluctuating in most of the 
18 reporting countries since 2000.
Prevalence estimates of problem 
opioid use
Data in this section are derived from the EMCDDA 
problem drug use (PDU) indicator, which includes mainly 
estimates of injecting drug use and the use of opioids, 
although in a few countries, users of amphetamines are 
also an important component (119). Estimating the number 
of problem opioid users is difficult, and analyses of a 
sophisticated nature are required to obtain prevalence 
estimates from the available data sources. Moreover, as 
most studies are based on a localised geographical area, 
such as a city or district, extrapolation to generate national 
estimates is difficult. 
Estimation is also complicated as patterns of problem drug 
use in Europe appear to be becoming more diverse. For 
example, polydrug use problems have become progressively 
more important in most countries, and some countries where 
opioid problems (almost exclusively heroin problems) have 
historically predominated now report changes towards other 
drugs, such as cocaine. 
Recent estimates of the prevalence of problem opioid use at 
national level range roughly between one and six cases per 
1 000 population aged 15–64. In comparison, the full PDU 
prevalence is estimated to be between one and eight cases 
per 1 000. Some of the lowest well-documented estimates 
available are from the new countries of the EU, although 
this is not the case for Malta, where a relatively high 
prevalence has been reported (5.8–6.7 cases per 1 000 
aged 15–64) (Figure 8). 
From the limited data available, an average prevalence 
of problem opioid use of between four and five cases per 
1 000 of the population aged 15–64 can be derived. This 
translates into some 1.5 million (1.3–1.7 million) problem 
opioid users in the EU and Norway. However, these 
estimates are far from robust and more extensive data are 
required.
Time trends in problem opioid use
A lack of reliable historical data complicates the assessment 
of trends over time in problem opioid use and trends should 
thus be interpreted with caution. Reports from some countries 
suggest that problem opioid use may, on average, have 
stabilised somewhat in recent years. Data from repeated 
estimates on problem opioid use for the period between 
2001 and 2005 are only available from eight countries 
and provide a relatively stable picture with only one country 
(Austria) showing a clear increase (120). 
Despite the general indication that the overall trend in 
the prevalence of opioid use is relatively stable, there are 
indications of increases in heroin seizures (see above), 
possibly relating to increased availability of heroin on 
the European market, and increasing reports of the use of 
opioids diverted from legitimate uses. In Italy, estimates of 
the incidence of heroin use based on treatment demand 
data suggest a rise since 1998, after a period of decline, 
with an annual incidence in 2005 of around 30 000 new 
heroin users. In Austria, also, the proportion of those under 
age 25 has increased among new substitution treatment 
clients, suggesting a rise in the number of young people 
experiencing problems, associated with the diversion 
and uncontrolled use of prescribed opioids. Similarly, 
after a period of decline, the Czech Republic reports an 
increase in the injecting of a diverted substance (in this case, 
buprenorphine), and information available from Belgium 
suggests that there has been an increase in the illicit use of 
methadone. Recent monitoring of low-threshold services in 
France raises concerns about the illicit use of buprenorphine, 
including injecting use, and use among young people who 
have initiated their problem drug use with buprenorphine 
rather than heroin; concerns about new subgroups of young 
and marginalised injectors have also been reported. In 
Finland, heroin also appears to have been largely replaced 
by buprenorphine among new opioid treatment demands 
and buprenorphine is increasingly mentioned in reports on 
overdose deaths. 
(118) See Tables PPP-2 and PPP-6 in the 2007 statistical bulletin.
(119) Although the technical definition used by the EMCDDA for PDU is ‘injecting drug use or long duration/regular use of opioids, cocaine and/or amphetamines’, 
problem drug use estimates have principally reflected heroin use. In the few countries where problematic use of amphetamines is reported, well-documented 
estimates are available. Estimates of problematic cocaine use are scarce and the PDU indicator is, except in few high-prevalence countries, likely to be less 
reliable for this drug.
(120) See Figure PDU-4 (part ii) in the 2007 statistical bulletin.
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Injecting drug use
Injecting drug users (IDUs) are at high risk of experiencing 
health problems from their drug use, such as blood-borne 
infections (e.g. HIV/AIDS, hepatitis) or drug overdose. 
Despite their importance for public health, few countries are 
currently able to provide estimates of the levels of injecting 
drug use (Figure 9) and, therefore, improving the monitoring 
of this special population is an important challenge for the 
development of health monitoring systems in Europe.
Indirect estimates of injecting drug use prevalence
Most available estimates of injecting drug use are derived 
from either fatal overdose rates or data on infectious diseases 
(such as HIV). Considerable variation is reported between 
countries, with national estimates typically ranging between 
0.5 and six cases per 1 000 population aged 15–64, in the 
period 2001–05. An exception is Estonia, where a much 
higher estimate of 15 cases per 1 000 has been reported. Of 
the other countries able to provide data, the highest estimates 
have been reported from the Czech Republic, Slovakia, 
Finland and the United Kingdom, at between four and five 
cases per 1 000 population aged 15–64, and the lowest 
figures from Cyprus, Hungary and the Netherlands, at under 
one case per 1 000. 
Extrapolation from the limited data available must be done 
with caution, but does suggest an average prevalence of 
IDU (current injectors) of between three and four cases per 
1 000 of the adult population. This would mean there may 
be around 1.1 million (0.9–1.3 million) injectors in the 
EU and Norway today. These are predominantly opioid 
injectors, although they may inject other drugs as well, 
and some countries report a significant amphetamine or 
methamphetamine injecting problem (the Czech Republic, 
Slovakia, Finland, Sweden).
Trends in injecting drug use from treatment demand data
The lack of data makes drawing conclusions on trends in 
injecting difficult, although one window on this behaviour 
is provided by data on drug users entering treatment. 
Treatment demands among opioid users, for example, may 
give an indication of patterns of use in the wider population. 
The proportion of injectors among all primary heroin users 
entering drug treatment (2001–05) shows marked differences 
in levels of injecting between countries. Overall, these data 
suggest that injecting may be becoming less popular, with 
declines observed by Denmark, Ireland, Greece, Hungary, 
the United Kingdom and Turkey. In some countries (Spain, 
the Netherlands, Portugal), a relatively small proportion of 
treated heroin users now inject. However, this picture is not 
Figure 8: Estimates of the prevalence of problem opioid use (rate per 1 000 population aged 15–64), 2001–05
NB:   The symbol indicates a point estimate; a bar indicates an estimation uncertainty interval, which can be either a 95 % confidence interval or an interval based on sensitivity 
analysis (see Table PDU-3 for detailed information). Target groups may vary slightly owing to different estimation methods and data sources; therefore, comparisons 
should be made with caution. Where no method is indicated, the line given represents an interval between the lowest lower bound of all existing estimates and the highest 
upper bound of them. Estimation methods: CR = capture–recapture; TM = treatment multiplier; TP = truncated Poisson; MM = mortality multiplier. For more information, 
see Tables PDU-1, PDU-2 and PDU-3 in the 2007 statistical bulletin.
Sources:  National focal points.
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seen everywhere, for example in several of the new Member 
States, injection appears to remain the predominant mode 
of heroin administration. It should be noted that trends in 
injecting in non-heroin users may be different.
Treatment of opioid dependence
Maintenance treatment
A relatively robust evidence base supported by data from 
treatment outcome studies and controlled trials now exists for 
the effectiveness of drug substitution treatments in treating 
dependence on heroin or other opioids (see Gossop, 2006 
for a review). Positive effects have been shown in reducing 
the use of illicit drugs, health risk behaviours and criminality 
and improved social functioning. Substitution treatment 
programmes usually include, as well as a prescribing 
element, other interventions to support behavioural change. 
Generally, the consensus in this area is that it is good 
practice to integrate programmes into the wider framework 
of medical care and social assistance.
Prescribing practice for substitution treatment in Europe
Over the past 15 years, the provision of treatment for heroin 
dependence has seen large increases in the EU. According 
to available data, this is mainly due to a more than sevenfold 
increase of substitution treatment provision in the EU-15 
Member States, since 1993.
With the exception of five countries (the Czech Republic, 
France, Latvia, Finland, Sweden), methadone is by far 
the most commonly used drug for substitution purposes, 
accounting for around 72 % of all substitution treatments (121). 
In general, methadone treatment is based around specialist 
outpatient centres, but in some countries it may also be 
delivered in general practice settings or, when patients 
have been stabilised, in community-based care settings. 
Methadone dispensing practice varies; sometimes it is 
only available from specialist centres and consumption will 
be supervised, but in some countries, such as the United 
Kingdom, pharmacies also play an important role, and 
take-home prescriptions may be allowed. 
(121) See Tables HSR-7, HSR-9 and HSR-11 in the 2007 statistical bulletin.
Figure 9: Estimates from national and subnational studies of the prevalence of injecting drug use 
(rate per 1 000 population aged 15–64), 2001–05
(1)   English regional estimates for 2004/05.
NB:   Black square = sample with national coverage; blue triangle = sample with subnational coverage. 
   The pattern of subnational prevalence estimates depends much on availability and location of studies within a country. Target groups may vary slightly owing to different 
studies’ methods and data sources; therefore, comparisons should be made with caution. 
   For more details see Tables PDU-1, PDU-2 and PDU-3 in the 2007 statistical bulletin. 
Sources:  National focal points.
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In recent years, there has been interest across the EU 
in additional pharmacological agents for treating drug 
dependence, and the use of buprenorphine, in particular, 
has become more common. In 2005, Slovenia and in 
May 2006, Malta joined the group of European countries 
licensing buprenorphine maintenance treatment at 
specialised units (122), and currently Bulgaria, Hungary, 
Poland and Romania are the only countries where this 
treatment option is not available.
One reason for interest in the use of buprenorphine 
is that it is arguably a more suitable pharmaceutical 
option than methadone for use in community practice. 
This issue is a complex one and is discussed in detail 
in the 2005 selected issue on buprenorphine. In most 
countries buprenorphine can only be prescribed by 
trained, accredited physicians and is subject to regulation 
appropriate to its controlled status under the international 
conventions (Schedule III of the 1971 UN Convention on 
Psychotropic Substances).
Buprenorphine is marketed in the form of sublingual 
tablets, and although it is not considered a particularly 
attractive substance to inject, reports exist that tablets have 
been dissolved and injected. The potential for misuse of 
buprenorphine is supported by reports from some countries 
of the diversion of the drug onto the illicit market. To deter 
illicit use of buprenorphine, a new formulation of the drug, 
in combination with naloxone, has been developed. This 
formulation, Suboxone, received a European marketing 
authorisation in 2006.
In January 2007, the Netherlands introduced heroin 
assisted treatment as a possible option for treating opioid 
dependence, expanding the number of treatment places to 
around 1 000, and therefore joined the United Kingdom 
as one of the two European countries where this option is 
available. Overall, the number of clients receiving heroin 
in Europe is very small, and treatment is usually reserved 
for particularly chronic cases where other therapeutic 
options have proved unsuccessful. The efficacy of 
heroin as a substitution agent has also been explored in 
experimental research in both Spain (March et al., 2006) 
and Germany (Naber and Haasen, 2006). Both studies 
reported positive treatment findings, suggesting that this 
approach may prove an appropriate treatment modality 
for socially excluded opioid users with severe problems 
who have responded poorly to other treatment options. 
Together with earlier work, these studies on heroin 
prescription have stimulated debate about the need for this 
treatment option to be more widely available.
(122) See Figure HSR-1 and Table HSR-8 in the 2007 statistical bulletin.
Quality assurance and substitution treatment
The effectiveness of any service will depend on the quality 
of the care provided. Concerns have been expressed that 
some substitution treatment programmes are of poor quality, 
with the focus of activities too much on prescribing and not 
suffi cient attention paid to providing a more comprehensive 
package of social and medical support. Criticisms made 
also include: the lack of adequate clinical monitoring; poor 
prescribing practices leading to diversion of drugs onto the 
illicit market; and, that low-dose treatment programmes are 
not in line with the clinical evidence on effectiveness (Loth 
et al., 2007; Schifano et al., 2006; Strang et al., 2005).
Many countries have taken these concerns seriously, and 
Denmark, Germany and the United Kingdom all report that 
reviews are under way with the objective of improving the 
quality of care provided. Similarly, Denmark has recently 
completed a three-year project to document the impact of 
wider psychosocial support in substitution treatment and to 
test quality assurance processes. 
In Germany, two recent studies have examined substitution 
therapy practice and looked at possibilities for improving 
care (COBRA) and explored quality assurance issues 
resulting in a new manual for medical practitioners (ASTO). 
In the United Kingdom, an audit was recently undertaken in 
England to analyse prescribing and clinical management 
practices and assess the extent to which they are in line with 
existing clinical guidelines. 
The availability of national clinical guidelines, standards 
and treatment protocols is important in ensuring the quality 
of substitution treatment. National clinical guidelines and 
treatment protocols are reported to be in preparation or being 
revised in Demark, Ireland, Hungary, Portugal, the United 
Kingdom and Norway, and Slovakia published guidance 
on methadone treatment administration in 2004. In the 
Netherlands, maintenance treatment is now increasingly 
realised according to medical treatment standards, and 
administration of methadone is supervised during the fi rst 
phase of treatment. In Austria, two decrees laying down the 
framework of medically assisted treatment were drafted in 
2005, with the aim to improve substitution treatment and 
include measures on supervised consumption as well as 
regulation of physicians operating in this area. 
A national monitoring system for reporting on clients in 
substitution treatment programmes also provides information 
useful for assessing the quality and availability of services. 
Currently, such schemes are reported to exist in 17 Member 
States, and national substitution registers are in preparation in 
Belgium and Luxembourg, while an expansion of the existing 
register to all health centres is being implemented in the 
Czech Republic.
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Treatment data
The EMCDDA collects two types of information to describe 
treatment in Europe. The treatment demand indicator is 
based on the monitoring of characteristics of clients entering 
treatment across Europe. In addition, Member States are 
asked to provide data that describes the overall structure and 
availability of services.
Data from the treatment demand indicator
Data from the monitoring of clients entering drug treatment 
in Europe provides a window not only on the wider 
epidemiological situation in respect to patterns of use and 
trends but also on the relative demand and availability of 
different forms of treatment. This can cause difficulties in 
interpreting the available information, as an increase in those 
being treated for a particular drug problem may indicate 
that demand for services have gone up or that availability of 
a particular kind of service has increased. As an aid to the 
analysis of this sort of data, a distinction is made between 
new and all treatment demands, with the assumption that 
new treatment demands better reflect changes in broader 
patterns of drug taking and all treatments better reflect the 
overall demands made on the treatment sector as whole.
Information available from the treatment demand indicator 
(TDI) does not cover all people in drug treatment, which 
is a considerably greater number; only clients requesting 
treatment during the reported year are recorded, but a pilot 
project is currently being implemented in 2007, aiming to 
extend the European data collection to treatment clients in 
continuous treatment (123) and assess reporting coverage of 
national systems. 
In many countries, opioids, mainly heroin, remain the 
principal drug for which clients seek treatment. Of the total 
326 000 treatment requests reported in 2005 under the 
treatment demand indicator, opioids were recorded as the 
principal drug in about 40 % of cases, with around 46 % of 
these clients reporting injecting the drug (124). 
Some countries report a significant proportion of treatment 
demands relating to opioids other than heroin. In Finland, 
other opioids, especially buprenorphine are reported to be 
a primary drug of use by 41 % of drug clients and in France 
7.5 % of all clients are reported as using buprenorphine. 
In the United Kingdom and the Netherlands, around 
4 % of clients are reported as primary methadone users. 
In Spain, Latvia and Sweden, between 5 % and 7 % of 
drug clients are entering treatment for primary use of 
unspecified opioids other than heroin or methadone (125). 
And in Hungary, where the use of home-made opium 
poppy products has a long history, around 4 % of treatment 
requests are related to opium.
Most opioid users are reported by outpatient treatment 
units; however, in Sweden 71 % of opioid clients are 
reported by inpatient centres, indicating that services are 
differently structured in this country. A small percentage 
(3 %) of inpatient treatment demands for opioid clients 
is also reported by the United Kingdom (126). In the 
few countries reporting data on treatment demand in 
low-threshold agencies, a significant proportion of drug 
clients seek treatment for primary opioid use (127).
The relative proportion of treatment demands made by 
non-opioid clients is increasing in the TDI data set and 
actual numbers of new clients demanding treatment for 
opioid use is also falling in many countries, with the 
absolute number of reported new treatment demands for 
primary heroin use decreasing from 80 000 in 1999 to 
51 000 in 2005 (128).
(123) See http://www.emcdda.europa.eu/?nnodeid=1420 (meeting report 2006).
(124) See Table TDI-5 in the 2007 statistical bulletin.
(125) See Table TDI-114 in the 2007 statistical bulletin.
(126) See Table TDI-24 in the 2007 statistical bulletin.
(127) See Table TDI-119 in the 2007 statistical bulletin.
(128) See Figure TDI-1 in the 2007 statistical bulletin.
Procedure for European marketing authorisation 
for medicinal products
The European Medicines Agency (EMEA) is responsible 
for the scientifi c evaluation of applications for European 
marketing authorisation for medicinal products. Medicines 
approved through the centralised procedure obtain a single 
marketing authorisation which is valid in all Member States of 
the European Union.
All authorised medicinal products are also monitored for 
safety. This is conducted through the EU network of national 
medicines agencies, in close cooperation with healthcare 
professionals and the pharmaceutical companies themselves. 
The EMEA publishes a European public assessment report 
(EPAR) for every centrally authorised product that is granted 
a marketing authorisation; EPARs are published on the EMEA 
website (http://www.emea.europa.eu/) and a summary for 
the public is available in all offi cial languages of the EU. 
The EMEA also works in partnership with the EMCDDA and 
Europol in support of the work to detect new drug threats in 
Europe in the context of the Council decision (see Chapter 7).
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Levels of drug substitution treatment 
In the EU Member States and Norway, in 2005, it is 
estimated that the number of drug substitution treatments 
was at least 585 000. This estimate is based on 
treatment monitoring carried out in most countries and 
provides a general picture of service availability. These 
figures are probably a minimum estimate, as some 
treatment modalities are likely to be under-reported, for 
example treatment provided by general practitioners or 
in prison settings.
The vast majority of treated clients (97 %) are reported by 
the EU-15 Member States, who also contribute the majority 
(80 %) of all treatment demands reported in the TDI data 
set. This represents a more than sevenfold increase since 
1993, when substitution cases were estimated to be 
around 73 000 (Farrell, 1995). Data show a rise of about 
15 % in client numbers in the EU and Norway from 2003 
to 2005, mostly due to increases in Germany (estimated 
increase of 8 300 cases), France (5 706), Italy (6 234), 
Portugal (4 168) and the United Kingdom (41 500) (129). In 
2005, stabilisation in the number of clients in substitution 
treatment was reported in the Netherlands (122 cases per 
100 000 inhabitants) and Luxembourg (355 cases per 
100 000). 
The strongest relative growth during between 2003 
and 2005 was observed in (but not confined to) some 
of the new Member States, with countries reporting 
substantial increases (over 40 %) including Bulgaria, 
Estonia, Greece, Lithuania, Romania and Norway. These 
increases coincided with a geographical expansion of 
the availability of substitution treatment option in many 
of these countries. Provision of substitution treatment did 
not increase in all new Member States: Hungary, Poland 
and Slovakia reported a relatively stable situation, while 
client numbers in the Latvian high-threshold methadone 
programme actually decreased from 67 to 50. In two 
countries with a history of high levels of provision, Spain 
and Malta, provision has recently decreased, possibly 
reflecting overall levels of demand in these countries.
The interrelationship between repeat treatment demands, 
maintenance levels and the prevalence of problem opioid 
use is complex. The levels of clients’ repeat treatment 
demands and the numbers of clients in drug maintenance 
programmes is determined by historical developments in 
opioid use incidence and prevalence, as well as treatment 
service organisation and type. For a few countries, it 
is possible to use estimated levels of opioid drug use 
prevalence to calculate the ratio of clients in maintenance 
treatment to opioid problem users. 
For EU countries where estimates of problem opioid 
use were available for 2005, the extent of substitution 
treatment among problem opioid users was calculated 
(Figure 10). Results show significant differences between 
countries, with rates varying from under 10 % (Slovakia) to 
about 50 % of opioid users (Italy). However, the data does 
suggest the need to review the availability of treatment 
options in all countries in order to ensure that sufficient 
provision is available to meet estimated needs.
Despite some recent increases in substitution treatment in 
the Baltic States and central European countries, levels 
remain low compared to the estimated number of opioid 
users in these Member States, with the exception of 
Slovenia. An estimate from Estonia suggests that only 5 % 
of heroin users in the four major urban centres are covered 
by substitution programmes, and that this rate is as low as 
1 % at national level. 
Opioid treatment demands
The proportion of treatment demands that are for primary 
opioid use reflects, to some extent, the relative prevalence 
of illicit opioids as a problem drug requiring (further) 
treatment, although it is influenced by the organisation of 
the treatment services and the reporting system.
The proportion of clients seeking treatment for opioid use 
varies between countries. Based on the most recent data 
available, opioid users make up 40–70 % of all treatment 
demands in 12 countries, less than 40 % in seven countries 
and more than 70 % in six countries (130).
The percentage of all drug treatment demands accounted 
for by all heroin requests has fallen, decreasing from 
74 % in 1999 to 61 % in 2005. The only countries 
not reporting a decrease are Bulgaria and the 
United Kingdom (131).
The absolute decrease of new opioids treatment demands, 
mainly due to heroin use, is confirmed by looking at 
the trend of new heroin clients: all the countries, except 
Bulgaria and Greece, report a decrease in the proportion 
of new requests for primary heroin use among new drug 
clients in the last seven years. From 1999 to 2005, the 
percentage of new heroin clients among all new drug clients 
fell from 70 % to 37 %.
(129) See Table HSR-7 in the 2007 statistical bulletin.
(130) See Table TDI-5 in the 2007 statistical bulletin.
(131) See Figure TDI-3 in the 2007 statistical bulletin.
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Treatment demand clients
Those seeking treatment for opioid problems tend to be 
relatively old compared with those seeking help for problems 
with other drugs (132) and also tend to report worse social 
conditions. Unemployment levels among opioid clients are 
generally high, education levels low, and between 10 % and 
18 % are reported to be homeless. 
Most clients (60 %) report initiation of opioid use before 
the age of 20; first use of opioids after the age of 25 was 
very uncommon (133). On average, a lag of 7–8 years 
was reported between first use of opioids and first contact 
with drug treatment: the mean age at onset of opioid use 
was 22 years and the mean age at first treatment demand 
29–30 years. Inpatient treatment demands were typically 
a little older than those receiving outpatient care, and the 
data suggest quite a short interval between first contact with 
treatment and subsequent treatment episodes. 
There are three men for every woman among outpatient 
opioid clients and four among inpatient clients; however, 
differences between countries existed, with typically a higher 
proportion of men among the treated population in southern 
European countries. 
Across Europe, among those opioid clients seeking 
treatment for whom the route of administration is known, on 
average, 58 % inject the substance (53 % if they are new to 
treatment). The proportion of injectors is highest in Romania, 
the Czech Republic and Finland and the lowest in the 
Netherlands, Denmark and Spain (134).
Most opioid clients are polydrug users, taking opioids in 
combination with another secondary substance, mainly other 
opioids (35 %), cocaine (23 %) and cannabis (17 %) (135).
Some countries report a high degree of co-occurrence of 
opioid dependence and other psychiatric disorders among 
opioid users. This observation has also been made in many 
clinical studies, which indicate that major depression, anxiety 
disorders, antisocial and borderline personality disorders 
are relatively common disorders among opioid users (Mateu 
et al., 2005).
(132) See Table TDI-10 in the 2007 statistical bulletin.
(133) See Tables TDI-11, TDI-107 and TDI-109 in the 2007 statistical bulletin.
(134) See Tables TDI-4 and TDI-5 in the 2007 statistical bulletin.
(135) See Table TDI-23 in the 2007 statistical bulletin.
Figure 10: Number of opioid maintenance treatment clients as a 
percentage of the estimated number of problem opioid users, 2005
NB:   This information is available for only nine countries.
   The symbol indicates a point estimate; a bar indicates an uncertainty interval 
arising from the estimation procedures; the number of opioid users is estimated 
by various methods: TM = treatment multiplier; PM = police multiplier; 
MI = multivariate indicator. Where no method is indicated, the line given 
represents an interval between the lowest lower bound of all existing estimates 
and the highest upper bound of them. For more information see Figure HSR-3 
in the 2007 statistical bulletin.
Sources:  National focal points.
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Chapter 7
New and emerging drug trends and action on new drugs
Emerging drugs trends often mimic, expand on, or substitute 
previously popular drug trends and raise questions about 
why psychoactive substances are being consumed. 
Therefore, emerging trends in drug and alcohol consumption 
must be understood not only in relation to changes in policy 
by governments, but also in relation to each other and within 
the broader context of current fashions and socio-cultural 
changes in leisure time pursuits.
Developments in information technology and communication 
media, particularly the Internet, provide channels that 
facilitate the diffusion of new trends and allow the expression 
of diverse opinions about drug use and the associated risks.
New or changing patterns of drug use usually emerge at 
local, or city levels and very few Member States have, 
for example, monitoring systems to indicate the extent of 
fatal and non-fatal intoxications from the use of new or 
emerging psychoactive substances. In the context of an 
inevitably partial picture, the accumulated information about 
emerging drug trends in Europe is assessed by triangulating 
information from a wide range of different sources. 
This chapter reports on recent developments in the illicit use 
of psychoactive substances that are not routinely addressed 
by the key drug indicators and have only recently been 
identified as a potential concern by policymakers or have 
attracted attention from the mass media. 
Piperazines: new psychoactive 
substances
The most significant development relating to new 
psychoactive substances in recent years is the spread of 
various novel piperazine derivatives, a number of which 
appeared in Europe between 2004 and 2006.
This group of synthetic substances is derived from the parent 
compound piperazine and includes BZP (1-benzylpiperazine) 
and mCPP (1-(3-chlorophenyl)piperazine). These two 
substances are largely available from chemical suppliers 
and on the Internet, and illicit production is mainly limited to 
producing tablets or capsules. 
BZP
Studies have compared the physiological and subjective 
effects of BZP with those of amphetamine, and suggest 
that BZP has approximately one tenth of the potency of 
dexamphetamine. 
In recent years, products containing BZP started to be 
aggressively marketed as a legal alternative to ecstasy 
by various retailers through the printed media, Internet 
sites, designated shops and stalls at clubs and festivals, 
and may be traded as ‘ecstasy’. BZP is offered in various 
combinations with other piperazines, and some, in particular 
BZP in combination with TFMPP (136), are thought to be 
designed to mimic ecstasy’s effects. These products usually 
are visibly labelled as piperazine-containing, but are often 
misrepresented as ‘natural’ or ‘herbal’. 
The evidence accumulated in the EU about emerging trends 
in drug use suggests that they may parallel consumer trends 
in legal markets — for example the sale of entirely synthetic 
substances such as BZP, with the claim that it is ‘natural’ or 
‘herbal’, may be appealing to a wider consumer interest 
in natural products. Furthermore, perceived safety of BZP 
is fostered by the fact that the products are often sold by 
designated retailers or in specialised shops rather than on the 
street.
BZP has been encountered in 14 EU Member States 
(Belgium, Denmark, Germany, Ireland, Greece, Spain, 
France, Malta, the Netherlands, Austria, Portugal, Finland, 
Sweden, the United Kingdom) and Norway. 
There is some evidence about health risks related to BZP, 
which appears to have a narrow safety margin when 
used recreationally. In the United Kingdom, there have 
been reported incidents where BZP intoxications have 
been clinically observed and BZP has been toxicologically 
confirmed as the only consumed psychoactive substance 
in which users suffered serious side-effects, some resulting 
in medical emergencies. There are, though, no fatal cases 
that can be directly attributed to BZP. In March 2007, the 
EU responded to rising concern over the use of BZP by 
(136) 1-(3-Trifluoromethylphenyl)piperazine.
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formally requesting a risk assessment of the health and 
social risks posed by this substance (137).
mCPP
mCPP has been described as producing stimulant and 
hallucinogenic effects similar to those of ecstasy (MDMA). 
Tablets containing mCPP are often designed to look like 
ecstasy and are almost always traded as such and the drugs 
are sometimes found in combination. It might be assumed 
that the addition of mCPP is intended to potentiate or 
ameliorate the effects of MDMA. 
Since 2004, mCPP has been found in 26 Member States (all 
but Cyprus) and Norway; as such, it is becoming the most 
widely encountered new psychotropic substance in the EU 
ever since the European early-warning system monitoring 
began in 1997.
No serious intoxications or fatal cases related to mCPP have 
been reported in the European Union. There is little evidence 
that it is a particularly dangerous substance in terms of acute 
toxicity, though the chronic (prolonged use) toxicity has not 
been established. 
GHB
Open Internet sales of GHB (138) have been curtailed 
since this substance was added to Schedule IV of the UN 
Convention on Psychotropic Substances in March 2001 
and therefore all EU countries are bound to control it under 
their legislation addressing psychotropic substances. GHB 
has been used therapeutically in anaesthesia in France and 
Germany, and in the treatment of alcohol withdrawal in 
Austria and Italy. In June 2005, the Committee for Medicinal 
Products for Human Use (CHMP) of EMEA recommended 
granting a marketing authorisation for the medicinal product 
Xyrem (GHB being the active substance) for the treatment 
of cataplexy in adult patients with narcolepsy (EMEA, 
2005) (139).
GHB is easily manufactured from its precursors 
gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD), 
solvents widely used in industry and commercially available. 
Some countries, recognising the potential for misuse of 
these precursor substances have chosen to control one or 
both of them under drug control or equivalent legislation 
(Italy, Latvia, Sweden). Because GBL is not controlled in 
most Member States and online chemical suppliers offering 
it provide an easy access, some GHB users appear to 
have switched to consuming GBL. Qualitative analyses of 
online GHB and drug forums based in the United Kingdom, 
Germany and the Netherlands suggest that users obtain 
GBL from chemical suppliers who market GBL for various 
legitimate purposes.
Prevalence and patterns of use
All information sources available suggest that general 
prevalence of GHB use is low, with significant levels of 
use limited to some specific subpopulations. An Internet 
survey conducted in the United Kingdom found that 
GHB was more commonly used within the home (67 %) 
compared with nightlife environments (26 %) (Sumnall 
et al., 2007). A survey of 408 pub-goers in Amsterdam in 
2005 reported lifetime prevalence estimates for GHB which 
were significantly higher among the clientele of gay bars 
and trendy cafes (17.5 % and 19 % respectively) than in 
mainstream and student pubs and cafes (5.7 % and 2.7 % 
respectively) (Nabben et al., 2006).
Trends
A lack of information makes trends in GHB use difficult 
to assess, although the available evidence suggests that 
use of GHB remains limited to some small subpopulation 
groups. Data from dance music surveys from Belgium, the 
Netherlands and the United Kingdom suggest that use of 
GHB may have peaked around 2000–03 and declined 
subsequently. However, the extent to which this finding 
would apply to other subgroups is unclear. It might be noted 
(137) See http://www.emcdda.europa.eu/?nnodeid=1346
(138) The term GHB is used to include the possible use of GBL or 1,4-BD.
(139) See ‘Procedure for European marketing authorisation for medicinal products’, p. 68.
Drug facilitated sexual assault
Cases of sexual assault by means of covertly adding a 
drug to a drink in order to incapacitate a victim have been 
increasingly reported in the media and medical literature 
since the 1980s. However, forensic evidence for this type 
of crime is notoriously diffi cult to obtain. Forensic studies 
do reveal that high concentrations of alcohol and also 
prescription benzodiazepine drugs are commonly identifi ed 
in cases of alleged sexual assault (in over 80 % of French 
cases and 30 % of United Kingdom cases), but the narrow 
window of detection for drugs such as GHB is a limitation in 
establishing evidence in cases of alleged offences that are 
not quickly reported. The forensic evidence that is available 
from studies conducted since 2000 (in the United Kingdom, 
France, United States and Australia) indicate that covert 
administration of drugs for the purpose of sexual assault 
appears uncommon, although true incidence may be higher 
than identifi ed due to non- or delayed reporting.
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that in 2005, drug telephone helplines in Finland reported 
telephone calls about GBL for the first time (FESAT, 2005). 
Health risks
The main health risk associated with the use of GHB appears 
to be the high risk of loss of consciousness, especially when 
the drug is combined with alcohol or other sedative drugs. 
GHB use can also result in other problems including coma, 
decrease in body temperature, hypotonia, hallucinations, 
nausea, vomiting, bradycardia and respiratory depression. 
Physical dependence to GHB has been observed following 
prolonged use, and additional health risks may be posed 
due to the possible presence of solvents or heavy metal 
contaminants. 
Since 1993, five Member States and Norway have reported 
GHB-related deaths to the EMCDDA: Denmark and Italy (one 
case each), Finland and Norway (three cases each) as well 
as Sweden and the United Kingdom (around 40 GHB-related 
deaths).
In Amsterdam, the reported number of non-fatal emergencies 
due to the use of GHB was 76 in 2005, exceeding, as in 
previous years, the medical emergencies attributed to use of 
hallucinogenic mushrooms (70 cases), ecstasy (63 cases), 
amphetamine (three cases) and LSD (one case). Compared 
with other substances, a high proportion of GHB cases (84 %) 
required transportation to a hospital. GHB information requests 
to the National Poisons Information Centre in the Netherlands 
increased by 27 % (constituting 241 of the 1 383 requests 
made) in 2005 compared with 2004.
Risk reduction
Responses to the use of GHB are most commonly provided 
by national or community projects targeting nightlife settings, 
and usually consist of training club staff and disseminating 
information about the risks of using GHB (Germany, France, 
the Netherlands, Austria, the United Kingdom). Advice on 
precautions to be taken in nightlife settings to avoid having 
drinks ‘spiked’ and measures to be taken in the case of a 
potential overdose are central in information disseminated 
about GHB. Teams that provide first aid support for drug and 
alcohol problems are increasingly deployed at large events 
to respond to incidents involving GHB or other drug-related. 
Ketamine
Ketamine has been monitored in the EU since concerns 
first arose in 2000 about its misuse (EMCDDA, 2002). 
At national level, ketamine is subject to controlled drugs 
legislation (as opposed to medicine regulations) in almost 
half of the EU Member States, and in Sweden and the United 
Kingdom, ketamine was listed as a narcotic substance in 
2005 and 2006 respectively. Recently, a critical review 
of ketamine conducted by the WHO concluded that 
international controls would create problems with the 
availability of the substance for use in human medicine 
in remote areas of the world and in veterinary medicine, 
because there is no appropriate replacement (WHO, 2006). 
Following this review, in March 2007, the UN Commission 
on Narcotic Drugs draft resolution on responding to the 
Internet as a source of information on emerging 
drug trends 
In 2004, over a third of young people in the EU stated that 
they would turn to the Internet if they wanted to know more 
about drugs (Eurobarometer, 2004). If young people do 
go online seeking drug information, a real question arises 
as to the extent to which the information they access will 
be unbiased and accurate. Numerous sites cover drug use 
issues, some of them government-sponsored, others run by 
lobby groups, consumer or advocacy networks. In addition 
to acting as a source of information on drugs, the Internet has 
created a marketplace for both licit and illicit drugs, with sites 
offering for sale illicit drugs and legal alternatives. Online 
drug retailers increasingly have the potential to spread new 
drug-taking practices or products by exploiting the marketing 
potential of the Internet by using online marketing strategies 
that are very responsive to users’ demands and to changing 
legal and market situations.
Within the framework of the E-POD (European perspectives 
on drugs) project, the EMCDDA is exploring ways to use the 
Internet as a source of information on emerging drug trends. 
At the EU level there are also developments to provide reliable 
information on public health matters: the new EU public health 
portal provides a gateway into a range of European public 
health resources including drug-related information (1).
(1) http://ec.europa.eu/health-eu
New psychoactive substances 
Council Decision 2005/387/JHA of 10 May 2005 on 
the information exchange, risk assessment and control of 
new psychoactive substances establishes a mechanism for 
the rapid exchange of information on new psychoactive 
substances that may pose public health and social threats. 
The EMCDDA and Europol, in close collaboration with their 
networks — the Reitox national focal points and Europol 
national units respectively — are assigned a central role in 
implementing an early-warning system for detection of new 
psychoactive substances (1).
(1) http://www.emcdda.europa.eu/?nnodeid=1346
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threat posed by the abuse and diversion of ketamine 
encouraged Member States to consider adopting a system of 
precautionary measures for use by their government agencies 
to facilitate the timely detection of the diversion of ketamine.
Little epidemiological data exists on the use of ketamine, 
although a recent school survey in the United Kingdom 
reported lifetime prevalence rates at less than 0.5 %. Some 
data is also available from surveys carried out in dance 
music settings, and among the different studies on this 
high-risk population, rates of ever in lifetime use of ketamine 
were reported to range from 7 % in a Czech study to 21 % in 
a Hungarian sample. 
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Drug-related infectious diseases and drug-related deaths
Drug-related infectious diseases
Data provided to the EMCDDA and the European Centre for 
the Epidemiological Monitoring of AIDS (EuroHIV, 2006) 
suggest that, by the end of 2005, the transmission of HIV 
among injecting drug users (IDUs) was low in most countries 
of the European Union. This may at least partly follow from 
the increased availability of prevention, treatment and 
harm-reduction measures including substitution treatment 
and needle and syringe programmes, although other factors, 
such as the declines in injecting drug use observed in several 
countries, may also have played an important role. In several 
EU countries and regions, however, it is likely that IDU-related 
HIV transmission still continued at relatively high rates in 
2005 (140), underlining the need to ensure the coverage and 
effectiveness of local prevention practice.
Surveillance of drug-related infectious diseases among 
IDUs in Europe is currently focused on HIV/AIDS and viral 
hepatitis (B and C). It consists of two complementary systems, 
case reporting (or ‘notifications’: absolute counts of newly 
reported/notified cases) and ‘seroprevalence monitoring’ 
(or ‘sentinel surveillance’: percentage testing positive in 
samples of IDUs) (Figure 11) (141). Both systems are likely 
to be imperfect, and countries differ in the availability of 
data. However, while the data provided by either of these 
two systems should be interpreted with caution, taken 
together, they provide a more complete picture of recent 
epidemiological trends. 
Indicators of HIV incidence and prevalence
HIV case reporting
An important indicator of the number (incidence) of new 
infections among injecting drug users is provided by case 
reports of newly diagnosed HIV infections. In interpreting this 
data, a number of considerations should be borne in mind: 
infected IDUs may not be diagnosed if they are not in contact 
with health services; new infections may not necessarily 
be attributed to drug injection; and, the number of cases 
identified may be influenced by differences in testing and 
reporting rates between countries or over time. 
The available data suggests that, by 2005, in most countries, 
rates of new infection related to IDUs were low. A caveat 
to this analysis is that in several high-prevalence countries, 
recent case reporting data is not available (Estonia, Spain, 
Italy, Austria). In 19 Member States, most of which have 
never experienced large HIV epidemics among IDUs, rates 
of reported IDU-related cases remained under five cases per 
million population in 2005. Higher figures were reported 
by Ireland and Luxembourg, with 16 and 15 new cases 
per million respectively. In Portugal, which reported the 
highest rate among the countries where IDU-specific data 
are available (85 new cases per million of the general 
population in 2005), the current situation appears to have 
stabilised after a decline between 2000 and 2003 (142). 
In Latvia, Lithuania and probably also in Estonia, rates of 
reported new IDU-related infections have strongly declined 
since the epidemic peaks in 2001–02, although they are still 
high in comparison with most other countries. In Latvia, the 
rate has dropped from 283 new cases per million in 2001 
to 49 per million in 2005. In Lithuania, after an outbreak 
among prisoners, a peak observed in 2002 (109 per million) 
has been followed by a decrease to 25 new cases per million 
in 2005. Although there has been a strong decline in HIV 
infection in Estonia, the country still reports the highest rate 
of new HIV infections in the EU. And, while IDU-specific data 
are not available for Estonia, drug injecting is likely to remain 
a major transmission route for HIV in this country. 
HIV prevalence among young and new IDUs
Support for the conclusions drawn from the available case 
reporting data can be found by analysing levels of HIV 
infection in samples of new IDUs (those injecting less than two 
years) and young IDUs (those under age 25). As infections 
in these groups are likely to be recently acquired, these 
data provide proxy indicators of HIV incidence. In these 
subgroups (found in the prevalence studies reported below), 
a high level of HIV infection (over 5 % in 2004–05) supports 
(140) See Figure INF-2 in the 2007 statistical bulletin.
(141) Some prevalence studies in this area are small-scale: only samples of more than 50 people and statistically significant (p < 0.05) time trends are reported in 
this section.
(142) The rises in 2004 (HIV cases) and 2005 (AIDS cases) in Portugal may be due to increased attention and reporting by professionals following discussions 
regarding the change to mandatory HIV reporting in 2005.
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indications of recent high incidence among IDUs in Portugal 
(data are national), Lithuania and Estonia (data are regional 
or city level), and suggests this has also been the case in one 
city out of the three reporting in Poland (143). It should be kept 
in mind that the size of these subsamples is, in general, small 
and that HIV seroprevalence data on young and new IDUs is 
not available from some countries. 
Trends in HIV prevalence
Increasing HIV prevalences in repeated samples of IDUs 
may also indicate ongoing infections — although declines 
in mortality of infected IDUs or decreasing numbers of 
uninfected IDUs can be important confounders. Most 
available time series for the EU show stable prevalence, 
suggesting that the numbers of infected IDUs dying are 
balanced by the numbers of IDUs contracting HIV infection. 
Nonetheless, geographically scattered increases in 
prevalence across nine countries are observed since 2001 
in some time series studies, although often alongside stable 
or declining trends in other regions making overall trends 
difficult to detect. These countries include again Latvia 
(national increase) and Lithuania (increase in one city), 
but also Austria (national increase), the United Kingdom 
(increase in England and Wales, but still at a low level) as 
well as some countries where prevalence is still very low (less 
than 1 %). Overall, these local or national level increases in 
HIV prevalence suggest that complacency concerning the 
provision of prevention measures to IDUs should be avoided.
In contrast, declining prevalence is reported from Greece 
(both at national level and in one region), Spain (both at 
national level and in one region) and Finland (national). 
Moreover, consistently low prevalence since 2001 (less 
than 1 % in all available data) is reported in four countries, 
all of which are new Member States: Bulgaria (Sofia, but 
prevalence is increasing), Hungary (national), Slovenia (two 
cities, but increasing) and Slovakia (two cities).
Overall, among the more than 90 time series of repeated 
HIV prevalence measurements in IDU samples covering 
22 EU Member States plus Norway in 2001–05, more 
regions show a declining than an increasing trend. The 
Figure 11: Estimates from national and subnational studies of HIV prevalence among injecting drug users, 2004/05
NB:   Black square = sample with national coverage; blue triangle = sample with subnational (including local or regional) coverage. 
   Estimates for Spain and Sweden include 2006 data; data for Ireland and Latvia are from 2003; data for Slovakia are from 2003/04.
   Countries are presented by order of increasing prevalence, based on the average of national data or, if not available, of subnational data. 
   Comparisons between countries have to be interpreted with caution owing to different types of settings and study methods; national sampling strategies vary — see Figure 
INF-3 in the 2007 statistical bulletin for further information. All reported sample sizes are larger than 50.
Sources:  Reitox national focal points. For primary sources, study details and data before 2004, see Table INF-8 (part i) and (part ii) and Table INF-0 (part i) in the 2007 
statistical bulletin.
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(143) See Tables INF-9 and INF-10 in the 2007 statistical bulletin. In the annual report, only samples of size 50 and larger are reported.
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data suggest that, especially in areas where prevalence has 
been high, the burden of infection in IDUs is likely to be now 
decreasing and possibly that prevention and harm-reduction 
policies are showing effect (144).
EU estimate
From the available case reporting and seroprevalence data 
and estimates of the number of IDUs and problem drug users 
(see Chapter 6), it is estimated that, in the EU, there may 
be some 100 000 to 200 000 people living with HIV who 
have ever in their lives been drug injectors. The number of 
newly diagnosed cases of HIV among injecting drug users is 
estimated to be currently around 3 500 per annum in the EU. 
AIDS incidence and access to HAART
As highly active antiretroviral treatment (HAART), available 
since 1996, effectively stops progression of HIV infection 
to AIDS, AIDS incidence data have therefore become less 
helpful as an indicator for HIV transmission. Levels of HAART 
coverage are estimated by the WHO to be high in the EU 
Member States, candidate countries and Norway, with all 
reporting at least 75 % coverage (145), although specific data 
for IDUs are not available. AIDS incidence data remains 
important as it indicates the level of symptomatic disease and 
the introduction and availability of HAART.
Portugal remains the country with the highest incidence 
of IDU-related AIDS and it is the only country recording a 
recent increase, with an estimated 36 new cases per million 
population in 2005, up from 30 cases per million in 2004. 
In addition, total AIDS mortality (most likely largely related 
to injecting drug use) has not declined between 1997 and 
2002, suggesting that access to HAART may have been 
low during this period (146). Of the Baltic countries, Latvia 
records a decrease in AIDS incidence, at 23 new cases per 
million in 2005, down from a peak of 26 new cases per 
million in 2004, while Estonia has not provided IDU-specific 
data in 2005 but reported an increase between 2003 and 
2004 (from four to 13 cases per million) (147).
Hepatitis B and C infections
While HIV infection in IDUs in the EU is mainly concentrated 
in few high-prevalence countries, viral hepatitis and, in 
particular, infection caused by the hepatitis C virus (HCV), is 
much more evenly distributed and more highly prevalent. 
HCV antibody levels of over 60 % among the IDU samples 
tested in 2004–05 are reported in 60 studies from 
17 countries (six countries out of 28 report no data) (148). 
Among young IDUs (under age 25) in these samples, a high 
prevalence (over 40 % in at least one sample) was found in 
seven countries and among new IDUs, for whom data are 
not available for many countries, in Poland and the United 
Kingdom (149). Only five countries reported studies where 
prevalence was less than 25 %.
From the available data and estimates of the number of IDUs 
and problem drug users (see Chapter 6), it can be calculated 
that there may be around one million people living with an 
HCV infection in the EU who have ever in their lives been 
drug injectors.
The prevalence of markers for HBV infection varies to a 
greater extent than that of HCV markers, possibly due to 
differences in vaccination levels. The most complete data 
set available is that for the antibody to the hepatitis core 
antigen (anti-HBc), which indicates a history of infection. 
In 2004–05, prevalence rates of over 40 % were reported 
from six countries.
Time trends in notified cases of hepatitis B and C show 
different pictures. In the case of hepatitis B, the proportion 
of IDUs among all notified cases appears generally to 
have declined, possibly reflecting the increasing impact of 
vaccination programmes. No general trend is visible for 
the proportion of IDUs among notified cases of hepatitis 
C infection (150); however, this proportion differs strongly 
between countries, suggesting that differences exist in the 
transmission of hepatitis C. Understanding the factors that are 
responsible for inter-country differences in infection rates is 
likely to be important for the design of better prevention and 
harm-reduction strategies in this area.
Preventing infectious diseases
The last decade has seen a consensus emerging at EU level 
on the key elements necessary for an effective response to 
infectious diseases among injecting drug users. In Europe, 
multi-component prevention responses are well established 
— they may include: access to adequate drug treatment, 
especially substitution treatment; needle and syringe 
programmes; information and distribution of prevention 
material; education, including peer education, on how to 
(144) See Tables INF-8, INF-9 and INF-10 in the 2007 statistical bulletin.
(145) See Figure INF-14 in the 2006 statistical bulletin.
(146) Portugal National Coordination for HIV/AIDS Infection, Ministry of Health, 2006.
(147) See Figure INF-1 in the 2007 statistical bulletin. Data for the two most recent years are estimates adjusted for reporting delays therefore subject to changes 
over time (source EuroHIV).
(148) See Tables INF-11, INF-12 and INF-13 in the 2007 statistical bulletin. In the annual report only samples of size 50 and larger are reported.
(149) See Figure INF-6 (part vii) in the 2007 statistical bulletin.
(150) See Figures INF-8 and INF-11 in the 2007 statistical bulletin.
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reduce risks; voluntary counselling and testing of infectious 
diseases; vaccination and treatment of infectious diseases.
Regardless of the balance of these elements in different 
national policies, there is clear agreement that a coordinated 
and comprehensive public health approach is vital to reduce 
the spread of infectious diseases among drug users. 
To address the problem of undiagnosed HIV infection, new 
guidance has been published this year (WHO/UNAIDS, 
2007). A more proactive approach of healthcare providers 
to recommending HIV testing and counselling, especially at 
facilities targeting most-at-risk populations, such as injecting 
drug users, is suggested in order to achieve increased 
voluntary uptake of HIV testing. A message emerging 
from the work of the EMCDDA on this topic is that regular 
voluntary medical examination, including testing and 
counselling for HIV and other infections, is a particularly 
appropriate service to offer to injecting drug users.
For the prevention of hepatitis A and B, vaccination has an 
important role to play. Some countries provide vaccination 
for hepatitis B at the population level, while others target 
those considered to be at particular risk. In Norway, hepatitis 
A and B vaccinations were stepped up after epidemic 
outbreaks of these liver infections showed that injecting drug 
use had spread to smaller municipalities. 
The high prevalence of hepatitis C infection among injectors 
points strongly for the need to develop more effective 
responses to this disease, for which vaccination is not an 
option. A number of countries have specific programmes 
aimed at hepatitis C prevention and some interesting work 
is developing in this area, for example the ‘stop hepC’ 
campaign, which has run in Oslo since 2003, aims at 
reaching drug users before they have started injecting or 
while they are still new to the practice. 
Drug treatment and harm-reduction services also need to 
develop responses to the risks posed by the sexual behaviour 
of their clients. In addition to drug injecting, drug users may 
also be exposed to an elevated risk of HIV infection due to 
their sexual behaviour — either because of impaired decision- 
making, the association of some drugs with high-risk sexual 
behaviours, or through their involvement in sex work or sex 
for drug exchanges. Women drug users may be particularly 
vulnerable, though concerns also exist about the interaction 
between drug use and high-risk sexual behaviour among 
some groups of men who have sex with men. In addition to 
HIV, drug users may also be at higher risk of acquiring other 
sexually transmitted diseases (STDs), and drug treatment 
services may be able to play an important role in diagnosing 
undetected STDs. For example, a recent Maltese study 
reported undetected human papilloma virus infections among 
women screened at an outpatient treatment unit. 
Needle and syringe programmes
The integration of needle and syringe exchange or 
distribution schemes within services provided by drugs 
agencies and the combined offer of risk counselling and 
advice services, as well as of referral of drug users to 
treatment are common in the EU. Needle and syringe 
Good prison health is good public health
Among the greatest challenges in public health in the last 
two decades are: the resurgence of communicable diseases 
such as TB; the rise and rapid spread of HIV/AIDS; and 
the seemingly uncontrollable pandemic of problematic use 
of psychotropic drugs. The most vulnerable sections of the 
population suffer disproportionately from these conditions. 
Among prison populations, in particular, drug problems are 
often common and levels of infectious diseases relatively 
high. Moreover, drug use often continues or, sometimes, is 
initiated in prison; and in this setting, high-risk behaviours 
can be common. Prisons, therefore, have the potential to 
lead to elevated levels of infection of potential life-threatening 
diseases but may also provide an opportunity to intervene 
with a particularly important target group. 
With a few exceptions (France, the United Kingdom (England 
and Wales), Norway) prison health is generally an integral 
part of the judicial or security system rather than of the 
health system, thus risking isolating health in prisons from 
mainstream public health approaches and raising questions 
about the independence, quality, accessibility and level of 
health services provided.
The poor health status of prisoners can have implications 
for wider public health, when drug users are released and 
resume contact with their family and others in the community. 
Therefore, the detection of serious communicable diseases 
such as HIV infection and tuberculosis, accompanied by 
adequate treatment and harm-reduction measures can 
contribute signifi cantly to the health status of the communities 
from which the prisoners come and to which they will return. 
For those who are drug-dependent, treatment programmes in 
prison can provide an opportunity that may benefi t not only 
the individual’s health, but may also reduce the likelihood of 
future offending.
In order to increase our knowledge of the prison health 
situation and of the specifi c responses, the public health 
programme of the European Commission supports the Health 
in Prisons Project, World Health Organisation Regional Offi ce 
for Europe, to establish a database for the collection of relevant 
prison health indicators and other health determinants. The 
EMCDDA is involved in the joint development of the database 
together with WHO Europe and the European Network on 
Drugs and Infections Prevention in Prison (Endipp) (1). 
(1) http://data.euro.who.int/hip/
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programmes (NSPs) were identified as a priority measure 
for addressing the spread of infectious disease among 
drug injectors in three out of four EU countries and 
Norway (151). Provision of clean needles and syringes 
is reported by all countries except Cyprus, where this 
measure has, in 2006, been recommended by an expert 
group to curb a possible increase in injecting-related 
infections. The distribution of other sterile equipment such 
as alcohol pads and dry wipes, water, filters and cookers 
together with clean syringes is becoming a general 
approach among service providers. While the distribution 
of sterile injecting material through NSPs is generally no 
longer regarded as a controversial issue, not all countries 
prioritise these programmes, and some consider pharmacy 
sales as largely sufficient. 
The nature and range of provision of sterile injecting 
material vary between countries. In general, syringe 
provision outlets are located in specialised drugs agencies, 
and in all but three countries this type of provision is 
complemented by mobile services that can reach out to 
groups of drug injectors in marginalised neighbourhoods. 
Syringe vending machines complement the available NSP 
services in 10 countries (152), but data on turnover are 
scarce and research about the effectiveness of this type of 
provision is lacking. Luxembourg has now joined Spain 
and Germany among the few countries offering needle 
and syringe exchange in prisons; although provision in 
Germany is limited to one prison in Berlin. 
The widespread availability of community-based 
pharmacies means that syringe exchange schemes 
operated through pharmacies can considerably improve 
the geographical availability of syringes and, therefore, 
complement provision by specialist agencies. For example, 
in Scotland, 1.7 million syringes were distributed through 
a network of 116 participating pharmacies in 2004, 
and in Portugal more than 1 300 pharmacies took part 
in the scheme and distributed 1.4 million syringes (153). 
Formally organised pharmacy-based syringe exchange 
or distribution schemes are reported in eight European 
countries (Belgium, Denmark, Spain, France, the 
Netherlands, Portugal, Slovenia, the United Kingdom).
In countries where pharmacies represent a common 
source for drug users to obtain their injecting equipment, 
they could play a more important role in delivering other 
health-promoting measures to drug users, including 
the dissemination of information about sexual and 
injecting-related risks of infectious diseases, testing and 
counselling services, and referral to treatment. Currently, 
work to motivate pharmacists to get involved in syringe 
programmes and to support those who are is only reported 
by France, Portugal and the United Kingdom.
The geographic coverage of NSPs and the provision of 
injecting material through them vary greatly between 
countries. However, a growing number of countries 
have nationwide networks of NSPs. Countries reporting 
good national coverage of NSPs include: Luxembourg 
and Malta, two small countries; Italy, where NSPs 
are commonly or often implemented in about 70 % of 
all local health districts; the Czech Republic, where 
they are available in all 77 districts and in the capital 
city of Prague; and Finland, where legislation obliges 
municipalities to provide relevant services to prevent 
infectious diseases, including NSPs. Portugal estimates that 
its pharmacy-based and outreach NSPs cover about 50 % 
of the territory, and in Denmark, 10 of the 13 counties 
run NSPs. All Austrian cities with a significant injecting 
drug scene have at least one needle and syringe outlet, 
and in Bulgaria, services are available in 10 cities with 
relatively high levels of problem drug use. In Estonia, it 
was estimated in 2005 that 37 % of IDUs were in contact 
with NSPs, while the coverage of the target groups in 
Slovakia and Romania was estimated to be considerably 
lower (20 % and 10–15 %, respectively). 
Between 2003 and 2005, increases in the total number 
of syringes exchanged or distributed through specialised 
NSPs were reported by several countries (Bulgaria, the 
Czech Republic, Estonia, Hungary, Austria, Slovakia, 
Finland) (154).
Specialised agencies that provide needle and syringe 
programmes can have other important public health 
roles, for example, assessing and raising the awareness 
for risk behaviour among clients, motivating them to get 
tested and vaccinated, as well as providing a conduit to 
primary healthcare and drug treatment. While the extent 
to which these agencies deliver these services is unclear, 
the need for this type of service development is underlined 
by the findings of a national audit recently conducted in 
England. This audit report found that levels of awareness 
of infectious diseases among clients were relatively low, 
and that agencies could be more proactive in offering 
counselling, testing and vaccination. 
(151) See Figure 11 in the 2006 annual report.
(152) See Table HSR-2 in the 2007 statistical bulletin.
(153) See Table HSR-4 in the 2007 statistical bulletin.
(154) See Table HSR-3 in the 2007 statistical bulletin.
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Drug-related deaths and mortality
Drug-related deaths
The EMCDDA definition of drug-related deaths refers to 
those that are caused directly by the consumption of one or 
more drugs. In general, drug-related deaths occur shortly 
after the consumption of the substance(s). Other terms used 
to describe these deaths include ‘overdoses’, ‘poisonings’, 
‘drug-induced deaths’ and ‘acute drug deaths’ (155). The 
number of drug-related deaths in a community will depend 
on the number of people using drugs associated with 
overdose (particularly opioids). Other factors that will also 
be important include: the proportion of injectors, prevalence 
of polydrug use, availability and policy of treatment services 
and emergency services. 
Although the comparability of European data has improved 
in recent years, differences in the quality of reporting 
between countries still mean that direct comparisons should 
be made with caution. The extent of drug-related deaths 
can be expressed in terms of the number of cases reported, 
by population rates or by proportional mortality. While 
differences in the quality of reporting exist between countries, 
if methods are unchanged over time, trends in numbers and 
characteristics of overdose cases may be observed. 
Between 1990 and 2004, from 6 500 to over 9 000 deaths 
were reported each year by EU Member States, adding up to 
more than 122 000 deaths during this period. These figures 
should be considered as a minimum estimate (156). 
Population mortality due to drug-related death varies widely 
between countries, ranging from 3–5 (157) to over 50 deaths 
per million inhabitants (average 18.3), with rates of over 
20 per million being found in 11 European countries. Among 
males aged 15–39 years, mortality rates are typically three 
times higher (averaging 61 deaths per million). In 2004–05, 
drug-related deaths accounted for 4 % of all deaths among 
Europeans aged 15–39 years, and for more than 7 % in nine 
countries (158). 
In addition to overdoses, drug users die from causes 
indirectly related to drug use. For instance, AIDS deaths 
related to injecting drug use accounted for almost 
1 400 deaths in 2003 (EuroHIV, 2006) (159), although this is 
possibly an underestimate. The number of deaths from other 
causes indirectly related to drug use (e.g. hepatitis, violence, 
suicide or accidents) is more difficult to assess. It has been 
estimated that, in at least some European cities, 10–20 % of 
mortality among young adults could be attributed to opioid 
use, directly or indirectly (Bargagli et al., 2006) (see below). 
Mortality related to other forms of drug use (e.g. cocaine) 
would add to this figure, but is more difficult to quantify. 
Determining the overall level of mortality resulting from 
problem drug use at a national or European level will require 
advances in data collection and analysis. An attempt at 
such an exercise on a national scale is reported in the Dutch 
national report. By extrapolating data from a local study, the 
mortality rate due, directly and indirectly, to problem drug 
use was estimated, taking into account regional differences. 
Although further methodological work is needed, this type of 
study, in addition to measuring the extent of deaths indirectly 
related to drug use, has the potential to overcome possible 
under-reporting of overdose deaths.
Acute deaths related to opioids
Heroin deaths (160)
Opioid overdose is one of the leading causes of death 
among young people in Europe, particularly among males 
in urban areas. Opioids are present in most cases of acute 
drug-related deaths due to illegal substances reported in 
the EU, accounting for 46 % to 100 % (Figure 12), mainly 
heroin or its metabolites. In Europe, most opioid deaths 
are related to heroin, but often other substances are also 
identified as having possibly played a role, in particular 
alcohol, benzodiazepines, or other opioids and, in some 
countries, cocaine. A voluntary data collection on substances 
involved in drug deaths in which nine countries participated 
in 2006 (161) has confirmed that in opioid overdoses, more 
than one drug is usually mentioned (60–90 % of cases) and 
they could be considered ‘polydrug deaths’. 
Men account for the majority of opioid overdose deaths 
(59–100 %), with the highest proportions of females 
occurring in the Czech Republic, Poland and Slovakia and 
the lowest in Italy, Lithuania and Luxembourg. Most overdose 
(155) Most national case definitions are the same as the EMCDDA definition or very similar, although some countries still include cases due to psychoactive 
medicines or non-overdose deaths, generally as a limited proportion (see the 2007 statistical bulletin methodological note ‘Drug-related deaths summary: 
definitions and methodological issues’ and ‘DRD Standard Protocol, version 3.1’).
(156) See Tables DRD-2 (part i), DRD-3 and DRD-4 in the 2007 statistical bulletin.
(157) In France, the rate was 0.9 per million in 2005, which may imply some under-reporting, but it should be noted that it was about 10 times higher in 1994, 
when overdose deaths started to decline.
(158) See Table DRD-5 in the 2007 statistical bulletin.
(159) Note that figure refers to the west and centre area of WHO Europe, which includes some non-EU countries, and the total deaths for Estonia, Latvia and 
Lithuania (east area).
(160) As most cases reported to the EMCDDA are opioid overdoses, general characteristics of acute drug-related deaths are used for description of opioid cases.
(161) The Czech Republic, Denmark, Germany, Latvia, Malta, the Netherlands, Austria, Portugal and the United Kingdom.
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fatalities concern those aged between 20 and 40 years old, 
with the mean age in most countries in the mid-30s (162). The 
mean age at overdose death is lowest in Bulgaria, Estonia, 
Latvia, and Romania and highest in Poland, Finland and 
the United Kingdom. There are very few reported overdose 
deaths among people aged less than 15 years, although 
drug deaths in this age group could be under-reported. 
While some drug-related deaths are recorded among those 
aged over 65 years, only seven countries report more than 
5 % of cases in this age group. In several of the Member 
States that joined the EU since 2004, the comparatively 
low mean age at death and the high proportion of fatal 
overdoses among those aged less than 25 years may signal 
a younger heroin-using population in these countries (163). 
In many Member States, the age of overdose fatalities is 
increasing, suggesting a decrease in the incidence of heroin 
use among young people. This trend is common among the 
EU-15 Member States, although in Austria and Luxembourg 
decreases have been observed in recent years. In the other 
Member States, the trend is less clear, and the small numbers 
of cases makes it difficult to interpret the figures (164).
Methadone and buprenorphine deaths
Although research shows that substitution treatment reduces 
the risk of fatal overdose, each year some deaths are 
reported associated with the misuse of substitution medicines. 
Monitoring the number of deaths related to methadone 
and to buprenorphine and the circumstances surrounding 
the deaths can provide important information for the 
quality assurance of substitution programmes and to inform 
prevention and harm-reduction initiatives.
The presence of methadone in a substantial proportion 
of drug-related deaths is reported by several countries, 
although the role played by methadone in the death 
is not always clear and other substances may also be 
present. Denmark reported that methadone was the 
cause of poisoning (alone or in combination) in 43 % of 
drug-related deaths (89 out of 206, in 2005); Germany 
reported that 255 cases (out of 1 477) were attributed 
to ‘substitution substances’ (75 alone and 180 with other 
narcotics) in 2005, compared with 345 cases in 2004; 
the United Kingdom reported 280 cases (out of 1 972, 
drug strategy definition) with ‘mention’ of methadone 
Figure 12: Proportion of acute drug-related deaths that show presence of opioids
(1)   For the Czech Republic, the EMCDDA Selection D definition of acute drug-related death was used instead of the national definition. The national definition includes 
poisoning by psychoactive medicines, which accounts for most cases (156 cases out of 218). 
(2)   Office of National Statistics definition.
NB:   In some countries, the ‘National definitions’ of drug-related death include a limited number of cases of deaths indirectly related to drug use.
   Data for 2005 or last year for which information is available. For further information, see Table DRD-1 in the 2007 statistical bulletin.
Sources:  Reitox national reports (2006), taken from national mortality registries or special registries.
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(162) See Table DRD-1 (part i) in the 2007 statistical bulletin.
(163) See Figure DRD-2 in the 2007 statistical bulletin.
(164) See Figures DRD-3 and DRD-4 in the 2007 statistical bulletin.
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(2004); and, in Norway, 55 autopsies revealed traces 
of methadone. Spain reported (Reitox national reports, 
2005) that there were few fatal overdoses involving only 
methadone (2 % of total), but that it was frequently present 
in combination in opioid deaths (42 %) and cocaine 
deaths (20 %). Other countries did not report methadone 
deaths or the numbers were very small.
Deaths due to buprenorphine poisoning appear to 
be rare, which is attributed to the agonist–antagonist 
pharmacological characteristics of this drug. However, 
some deaths have been reported by European countries. 
In the 2006 and 2005 national reports, only France and 
Finland recorded deaths related to this substance. In 
Finland, buprenorphine was found in 83 cases in 2005 
(73 in 2004), generally combined with benzodiazepines, 
sedatives or alcohol, or injected. In France, only two 
fatal overdoses involving buprenorphine were reported in 
2005 (four in 2004). Buprenorphine is the main opioid 
substitution drug in these two countries, but the estimated 
70 000 to 85 000 people receiving the substance in 
France is much greater than the numbers treated in 
Finland. In addition to France and Finland, in 2004, three 
other countries reported deaths mentioning buprenorphine 
(two or three in each case). A study searching exhaustively 
for deaths with mentions of buprenorphine in the United 
Kingdom between 1980 and 2002 found only 43 cases, 
often in combination with benzodiazepines or other 
opioids (Schifano et al., 2005).
Acute deaths related to non-opioid drugs
Deaths related to ecstasy and amphetamines
Deaths mentioning ecstasy are infrequent, but caused 
considerable concern when they started to be reported 
some years ago, as they often occur unexpectedly among 
socially integrated young people. The limited data 
available in the 2006 Reitox national reports suggests that 
ecstasy deaths remain at similar levels to those reported 
in previous years. In Europe as a whole, there were 
references to 78 deaths involving ecstasy (165).
Amphetamine deaths are also infrequently reported, 
although in the Czech Republic 16 deaths were attributed 
to pervitin (methamphetamine) in 2004 and 14 in 2005, 
correlating with an increase in the estimated number of 
problem pervitin users and treatment demands. In Finland, 
65 deaths were reported involving amphetamines, 
although the role of the drug in these deaths was not 
specified. 
Deaths related to cocaine
Overdose deaths due to cocaine are more difficult to identify 
than those caused by opioids, and are often considered to 
be the result of a combination of causes, rather than from 
cocaine toxicity itself (166). Studies have found that most 
cocaine deaths are related to chronic use of the drug and 
are often the result of cardiovascular and neurological 
problems brought on by the use of cocaine over a long time, 
particularly in users with predisposing conditions or risk 
factors. In Europe, reports of deaths with cocaine involved 
usually also mention the presence of other substances 
(including alcohol and opioids), reflecting the use of cocaine 
in combination with other drugs.
Among the countries supplying data, over 400 cocaine 
deaths were identified in both the 2006 and 2005 national 
reports. There is a clear need to investigate further the health 
consequences and mortality related to cocaine use.
Trends in acute drug-related deaths
National trends in drug-related deaths can provide insights 
both into developments in patterns of problematic drug 
use in each country and into developments in responses. 
Data available for the EU reveal some general trends in 
drug-related deaths. From a longer term perspective, the 
EU-15 Member States and Norway experienced a sharp 
increase in drug-related deaths during the 1980s and early 
1990s, possibly paralleling the expansion of heroin use and 
injection (167). Drug deaths continued to increase between 
1990 and 2000, although less sharply.
Since 2000, many EU countries have reported decreases 
in the numbers of drug-related deaths, possibly related 
to increases in treatment availability and harm-reduction 
initiatives, although possible moves away from injection or 
a reduction in heroin availability may also be important. At 
European level, drug-related deaths fell by 6 % in 2001, by 
14 % in 2002 and by 5 % in 2003 (Figure 13). However, 
reports for 2004 and provisional data for 2005 indicate 
that the decrease in drug-related deaths has not continued 
beyond 2003. 
A worrying trend has begun to emerge in reports of 
drug-related deaths in some countries. After marked peaks 
in drug-related deaths in 1999–2001, followed by a clear 
decrease for two to three years, an increase in reported 
deaths has been observed in 2004 and 2005 (168). This 
pattern generally describes the trends in drug-related deaths 
observed in recent years in Ireland, Greece, Portugal, 
Finland and Norway and, to a lesser extent, those observed 
(165) Depending on country, figures refer to 2004 or 2005, for ecstasy and cocaine.
(166) See the 2007 selected issue on cocaine for a more detailed report on deaths related to this drug. 
(167) See Figure DRD-8 in the 2007 statistical bulletin.
(168) See Table DRD-2 in the 2007 statistical bulletin.
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in the Netherlands, Austria and the United Kingdom. 
In Italy, after several years of decreasing numbers of 
drug-related deaths, some increase has been recorded in 
the past two years (169). Several possible causes have been 
suggested to account for this recent increase, among which 
are polydrug use by opioid users, or a possible increase in 
the availability of heroin.
There is a marked discrepancy in trends in drug-related 
deaths between the EU-15 Member States and those who 
have joined since 2004. Among the EU-15 Member States, 
there has been an overall decrease since 1996, very marked 
between 2000 and 2002, suggesting a long-term decrease 
in the number of young opioid injectors. However, recent 
trends in these countries are mixed. In the new Member 
States, a sharp increase was observed until 2002, but 
decreasing in 2003–04.
Increases in the proportion of drug-related deaths in 
drug users aged under 30 years have been observed in 
Greece and among those aged under 25 years in Estonia, 
Luxembourg and Austria, and to a lesser extent in Latvia and 
the Netherlands, although in most countries young drug users 
account for a decreasing proportion of overdoses (170). 
Gender differences are also observable in trends in 
drug-related deaths (171). For more details see the 2006 
selected issue on gender and drug use.
Overall mortality among problem drug users 
Information on the overall mortality (directly and indirectly 
caused by drugs) among problem drug users mostly refers 
to opioid users whereas information on mortality related 
to other forms of drug use is generally lacking, but it will 
be increasingly important for public health purposes, for 
instance among regular but socially integrated cocaine users.
Research studies among opioid users in various European 
settings have found that mortality among this group is high 
compared to that of the general population. A collaborative 
study that started within an EMCDDA project found that 
opioid users recruited in treatment in eight European 
locations had a very high mortality compared to their peers 
of the same age (see EMCDDA, 2006). A mortality cohort 
study carried out in the Czech Republic found that the 
standardised mortality ratio of stimulant users was 4–6 times 
higher than that of the general population, while that of 
opioid users was 9–12 times higher (Reitox national reports, 
2005). A French cohort study that followed individuals 
arrested for heroin, cocaine or crack use found that male 
mortality was five times higher and female mortality 9.5 times 
than in the general population, but with a decreasing 
trend (Reitox national reports, 2005). Further information 
on mortality among drug users is expected from cohort 
studies in progress in several European countries (Bulgaria, 
Spain, Malta, Austria, Poland, Romania, Sweden, the 
United Kingdom, Norway). 
Recent studies from the Netherlands and Norway did not find 
any relationship between age and risk of overdose death 
(Cruts et al., in press; Ødegård et al., 2006 cited in the 
Norwegian national report), however, as opioid users age, 
mortality due to chronic conditions may add progressively to 
mortality due to external causes such as suicide and violence. 
Poor living conditions of drug users as well as their mental 
health problems may also contribute substantially to the high 
mortality of this group. 
Suicide is identified as a cause of drug overdose deaths in 
some studies among drug users. Known suicides, added 
together with undetermined intent deaths constituted 30 % 
of all drug-related deaths reported in Scotland in 2005. 
In 2003, 13 % of all drug-related deaths were suicides 
(169) See Figure DRD-11 in the 2007 statistical bulletin.
(170) See Figure DRD-9 in the 2007 statistical bulletin.
(171) See Figure DRD-6 in the 2007 statistical bulletin.
Figure 13: Overall trend in acute drug-related deaths, 1996–2005 
for all Member States with available data
(1)   For 2005 the figure is provisional, based on comparing 2004 and 2005 
only for those countries with data for both years.
NB:   The indexed change is calculated based on countries with information for the 
stated year and the preceding. 
   See Table DRD-2 in the 2007 statistical bulletin for numbers of deaths in each 
country and notes on methodology.
Sources:  Reitox national reports (2006), taken from general mortality registries or 
special registries (forensic or police).
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(Scottish Executive, 2005). Substance misuse problems are 
thought to contribute to suicidal behaviour in several ways: 
common risk factors, substance misuse among people prone 
to high-risk behaviours. 
Reducing drug-related deaths
The attention given to overdose prevention measures has 
grown in recognition of the relative importance of drug 
overdose as a public health issue. While engagement 
with treatment and other services may reduce drug-related 
deaths, there remains considerable potential for developing 
interventions targeted specifically on overdose risks, and 
overall, Europe still lacks a comprehensive approach to 
overdose prevention.
Member States, especially those with older heroin epidemics, 
have increasingly stepped up their availability of drug 
treatment over the past years and are now reaching an 
increasing number of hard-to-reach problem drug users 
(see also Chapter 2 and Chapter 6). Easier accessibility 
of treatment and greater variety of approaches, including 
substitution treatment, improve rates of retention in treatment, 
which makes an important contribution to reducing 
drug-related deaths and mortality. Several countries have 
lowered accessibility thresholds to drug maintenance 
treatment, and changes in philosophy towards expediting 
entry and re-enrolling in methadone maintenance treatment 
(measures which have been shown to increase survival) 
are evident. Furthermore, studies from high-threshold 
programmes, suggest that strict admission criteria and 
treatment rules lead to more disciplinary discharges, 
increasing the risk of death to those discharged, compared 
to those remaining in treatment (Fugelstad et al., 2007). 
A longitudinal study on the effectiveness of treatments 
for heroin addiction, which will examine the association 
between retention in treatment and mortality, is currently 
underway in Italy (Bargagli et al., 2006).
In the first few weeks after leaving prison or treatment those 
who have withdrawn from opioid drugs are at an elevated 
risk of an overdose, if they relapse back into drug use — as 
their previous tolerance will be reduced. It is, therefore, an 
important harm-reduction measure to inform those leaving 
such settings of the risks that resuming drug use can pose and 
discuss with them risk reduction strategies. Continuity of care 
with social support and treatment services can play an import 
role here, especially for those leaving prison.
Other overdose prevention approaches include teaching 
drug users the recovery position and how to respond better 
to emergency situations, as well as working with the police, 
ambulance service and drug users themselves to encourage 
the calling of emergency medical services at an early stage 
in an overdose event. Research suggests that concurrent use 
of other drugs, particularly alcohol and sedative drugs, may 
increase the risk of fatal opioid overdose and, therefore, 
polydrug use is an important issue for services to address. 
Some experimental work has looked at the possibility of 
providing drug users with opioid antagonists, an example 
being a Scottish pilot scheme to distribute Naloxone to 
drug users, their families and friends. This approach has 
not been widely developed in Europe to date, but may 
have potential. The availability of opioid antagonists in 
ambulances, treatment facilities or other settings where 
opioid drug overdose is likely to be encountered is a 
more common approach, though not universal. Given 
the effectiveness of these drugs, if quickly administered, 
a need clearly exists to review the availability of this sort 
of response within any review of overdose prevention 
measures.
An approach that has generated some controversy is the 
provision of drug consumption rooms, whereby drug users 
may consume their drugs in a designated space where 
Co-morbidity and Isadora project
Psychiatric disorders are commonly related to problematic 
drug use. Although no systematic collection of information 
on co-morbidity exists at European level, fi ndings from local 
research conducted in several European countries suggest 
that between 30 % and 90 % of clients in drug treatment 
may have co-morbid psychiatric conditions. The most 
common disorders diagnosed among those dependent on 
drugs include personality disorders, depression, antisocial 
personality, anxiety, and mood and eating disorders. 
Schizophrenia and suicidal tendencies are also mentioned. 
Co-morbidity is reported to be more common among heroin 
users, especially those who have a long history of drug 
use and who have experienced several interruptions in 
methadone treatment and whose social and living conditions 
have deteriorated. Similarly, drug dependence is common 
among people with serious mental illness.
The European project Isadora (‘integrated services aimed 
at dual diagnosis and optimal recovery from addiction’) 
was concluded in 2005 after a three-year research 
period (1). The project, aiming to identify major institutional 
and individual risk factors for co-morbidity, involved 
seven sites across Europe and 352 patients recruited 
from acute psychiatric wards. According to the results, 
poor prognosis and chaotic dual diagnosis pathways 
are not due to client characteristics alone, but also to 
fragmented service provision, often resulting in an ineffi cient 
compartmentalisation of care. Among the outputs of Isadora 
is a comprehensive dual diagnosis training manual. 
(1) http://isadora.advsh.net/
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medical and other services may also be available. Drug 
consumption rooms have been criticised by the INCB in 
their recent annual reports, but are viewed by some EU 
Member States as a useful component of their responses to 
some forms of highly problematic drug use. The arguments 
made in favour of drug consumption rooms include that they 
can provide an overdose prevention measure, reduce other 
risks associated with injecting, provide an opportunity for 
disseminating information and act as a conduit to primary 
healthcare, treatment and other drug services. Consumption 
rooms are sometimes also viewed as an opportunity to limit 
public nuisance caused by the use of drugs. There are now 
in excess of 70 consumption rooms in the EU and Norway: 
about 40 in the Netherlands, 25 in Germany, six in Spain 
and one each in Luxembourg and Norway. 
Information, education and communication (IEC) techniques 
are used throughout Europe in initiatives that aim to reduce 
drug-related deaths. Several countries report that specifically 
developed information materials are distributed among drug 
users, their peers and families, or police. However, besides 
first aid courses for staff at drugs agencies or for drug users 
themselves, overdose risk assessment and counselling about 
risk management seems to be becoming more common in 
Europe and is mentioned, for example, in the reports from 
Romania, the Netherlands and Malta. In 2005, an action 
plan to reduce drug-related deaths was launched in Scotland, 
and consists of an overdose awareness DVD, new research 
to look at the delays in calling for help and a national forum 
to look at trends and identify areas where further action 
needs to be taken.
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The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information 
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable 
and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide 
range of audiences including policymakers and their advisers; professionals 
and researchers working in the field of drugs; and, more broadly, 
the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug 
phenomenon in the EU and is an essential reference book for those seeking 
the latest findings on drugs in Europe. 
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